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Abstract 
Feline chronic gingivostomatitis (FCGS) is an inflammatory disease of the oral cavity 
that causes severe pain and distress. No specific treatment methods are available and 
little is known about its aetiology. The aims of this study were:- 1) to identify the 
bacterial flora, including uncultivable and potentially novel species, in healthy cats and 
those with FCGS, using 16S rRNA gene sequencing in combination with conventional 
culture methods; 2) to investigate the viral status of cats with and without FCGS; 3) to 
assess the immune response by investigating the expression of cytokine and Toll-like 
receptor (TLR) genes in tissue biopsies from normal cats and those with FCGS; 4) to 
investigate the histopathological changes in tissue biopsies from normal cats and those 
with FCGS, 5) to assess putative risk factors for FCGS by the use of a questionnaire-
based study. 
Oral swabs, mucosal biopsies and blood were collected and the location of the oral 
lesions was recorded. A total of 32 cats with FCGS and 16 normal cats were included in 
the study. Bacteria were identified from swabs by use of 16S rRNA gene sequencing and 
by conventional culture methods. Blood samples and swabs were used for diagnosis of 
infection with feline leukaemia virus (FeLV), feline immunodeficiency virus (FIV), feline 
herpes virus 1 (FHV-1), feline calicivirus (FCV) and for blood biochemistry and 
haematology. Gene expression levels for TLR2, TLR3, TLR4, TLR7 and TLR9, and 
cytokines IL-1β, IL-4, IL-6, IL-10, TNF-α and IFN-γ mRNA were determined using 
quantitative PCR in biopsy samples from healthy cats and cats with FCGS. 
Histopathological examination of the tissue biopsies was done using hematoxylin and 
eosin (H&E) staining.  
In the healthy group, 16S rRNA gene sequencing demonstrated that the most prevalent 
bacteria were part of the Proteobacteria and Bacteroidetes phyla, plus a group of 
uncultured bacteria. The most prevalent species in the healthy group were 
Xanthomonadaceae bacterium (6.2 % of clones analysed), Capnocytophaga canimorsus 
(5.4%), Capnocytophaga cynodegmi (4.8%), Bergeyella species (4.5%) and Pasteurella 
multocida subspecies septica (4.4%). Uncultured bacteria accounted for 29% of the 
clones analysed. In the FCGS group most of the identified species were part of the 
phylum Proteobacteria. The most prevalent species in the FCGS group were 
P. multocida subsp. multocida (14.1%) P. multocida subsp. septica (11.5%), 
Pseudomonas sp. (7.3%), Tannerella forsythia (6.6%) and Porphyromonas circumdentaria 
(5.6%). A variety of uncultured bacteria represented 7.7% of all analysed FCGS clones. 
The culture data showed the most prevalent bacteria in the healthy group were 
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P. multocida subsp. septica (9.9%), and uncultured bacteria (30.5%). In the FCGS group 
the most prevalent isolates were P. multocida subsp septica and P. multocida subsp. 
multocida (both 9.9%). Uncultured bacteria accounted for 21.7% of all isolates. 
FCV was detected in 71% of cats with FCGS and in 13.3% of normal cats. FeLV antigen 
was detected in 33.3% of normal cats but not in any cats with FCGS. FIV antibodies were 
detected in 3.4% of cats with FCGS and in 33.3% of normal cats. FHV-1 was detected in 
6.9% of cats with FCGS, but was not detected any of the normal cats. 
In the FCGS group a significant increase was seen in the expression of TLR2 and TLR7 
genes as well as TNF-α, IFN-γ, IL-1β and IL-6 cytokine genes. The healthy cats and cats 
with FCGS in the study that were found to harbour T. forsythia and P. circumdentaria 
showed an increase in the expression of several TLR and cytokine genes when compared 
to the group of cats in which these bacterial species were absent. 
The most severely inflamed sites in the oral cavity of cats with FCGS included the tissue 
lateral to the palatoglossal folds and the maxillary attached gingiva. Histopathological 
analysis of the tissue from the palatoglossal folds showed two types of infiltrates:- 1) a 
combination of lymphocytes and plasma cells, most often seen in the milder inflamed 
tissue samples; 2) a predominantly plasmacytic infiltration, most often seen in the 
severely inflamed tissue samples. 
Preliminary data from a questionnaire-based epidemiological study showed that the 
presence of potential environmental stress factors such as no ability to roam outdoors 
and the presence of more than one cat in the household is significantly higher in cats 
with FCGS when compared to normal cats. 
This study highlights the possibility of a multifactorial aetiology for FCGS in which FCV, 
specific bacteria and stress factors may play an important role. Although species from 
the Bacteroidetes phylum appeared to be capable of eliciting an immune response, 
these were not the most prevalent species in the FCGS group. A shift could be seen in 
the composition of the bacterial flora when healthy cats and those with FCGS were 
compared. 
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Chapter 1 General introduction  1 
Chapter 1 General introduction 
1.1 Preface 
Feline chronic gingivostomatitis (FCGS) is a severe inflammatory disease of the feline 
oral cavity that causes pain and distress and can be serious enough to lead to euthanasia 
of affected cats. More insight into the aetiopathogenesis is needed to make progress in 
the development of treatments for this disease. Many different bacterial species 
associated with human periodontal disease have been implicated in the feline disease 
and there is a strong suggestion that viruses play an important role. FCGS is the most 
challenging of all the oral inflammatory diseases to treat. No standard treatment or 
preventive measures showing consistent results are available in first opinion practice. 
Previous research in FCGS has been relatively limited and focused on three main 
aspects: bacterial culture, determination of the viral status of cats and nature of the 
immune response to infection. To fully understand the complex aetiopathogenesis of 
this disease there is a need to study all three aspects together and try to identify links 
between them. This study was based on this approach. Molecular microbiological 
methods were combined with conventional microbiological culture for bacterial 
identification. The cellular immune response to infection was investigated by 
determining Toll-like receptor (TLR) and cytokine gene expression. The prevalence of 
feline viruses in affected cats was determined and a questionnaire based 
epidemiological study was included to explore the putative risk factors in FCGS. 
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1.2 Feline chronic gingivostomatitis 
1.2.1 Definition of FCGS 
1.2.1.1 Nomenclature 
FCGS is a severe inflammation of the oral cavity. The syndrome is referred to in the 
literature by various names including feline gingivitis-stomatitis pharyngitis, 
lymphocytic plasmacytic gingivitis stomatitis, plasma cell stomatitis pharyngitis and 
chronic stomatitis. These names either refer to location of the lesions in the oral cavity 
or reflect the type of inflammation found in the histopathological evaluation of biopsies 
from the oral cavity (Knowles et al., 1991; White et al., 1992; Diehl and Rosychuk, 
1993; Lommer and Verstraete, 2003; Healey et al., 2007). FCGS is the name that is 
commonly referred to in the recent literature but the described clinical signs may vary 
(Table 1.1). 
1.2.1.2 Clinical appearance 
The different names used for FCGS in the literature often refer to a variety of clinical 
signs (Table 1.1) and the terms used, have generally been defined differently as far as 
the location of the lesions within the oral cavity is concerned. The research carried out 
to date is difficult to compare because of such inconsistencies. FCGS is described as a 
proliferative and ulcerative inflammation of the oral cavity that can affect a variety of 
sites (White et al., 1992). The most severe presentation, that is most challenging to 
treat, involves inflammation at two main sites; the tissue lateral to the palatoglossal 
folds, often referred to as the fauces (Figure 1.1, site 9) and the mucosa overlying the 
premolar/molar area extending to the buccal mucosa (Figure 1.1, sites 2 and 3) 
(Southerden, 2010; Hennet et al., 2011). Other areas that can be affected are the 
pharynx, tongue and lips. Inflammation of the palate can also be seen and periodontal 
disease is often identified (Hennet, 1997). The pain that is caused by the inflammatory 
changes is the main cause of the variety of symptoms seen in affected animals. 
Symptoms include dysphagia, weight loss, loss of grooming behaviour, excessive saliva, 
pawing at the mouth and halitosis. Additionally these severe symptoms can cause a 
change the cats’ demeanour. Affected animals may seek seclusion and can become 
more aggressive when handled (Bonello, 2007; Southerden and Gorrel, 2007; Bellei et 
al., 2008). 
 
Table 1.1: Nomenclature for feline chronic gingivostomatitis 
Described location of lesions 
 
Name given to syndrome Reference 
Premolar/molar gingiva with or without palatoglossal arches, pharynx, hard 
palate, tongue, periodontal disease 
Gingivitis stomatitis Frost and Williams (1986) 
Gingiva with or without palatoglossal folds, pharynx, hard palate, tongue Plasma cell gingivitis-pharyngitis Sims et al. (1990) 
Gingiva or palatoglossal folds, pharyngeal walls, tongue, palate, lips, buccal 
mucosa 
Plasma cell stomatitis pharyngitis White et al. (1992) 
Gingiva or adjacent mucosa or palatoglossal folds with or without cheeks, 
tongue, lips 
Feline gingivitis stomatitis pharyngitis complex Diehl and Rosychuk (1993) 
Fauces with or without gingiva and tongue Gingivostomatitis Hawkins (1999) 
Isolated or a combination of gingivitis, stomatitis, periontal disease, glossitis, 
palatitis, buccostomatitis, faucitis, ostitis, osteomyelitis 
Gingivitis-stomatitis-oropharyngitis (GSO) Mihaljevic (2003) 
Gingivitis-stomatitis: premolar/molar gingiva/bucca with or without 
palatoglossal folds and lingual area 
Stomatitis-gingivitis: Palatoglossal folds and gingival/buccal mucosa with or 
without hard palate, tongue 
FCGS Gorrel (2004) 
Gingiva, caudal parts, lips, ventral tongue Lymphoplasmacytic gingivitis Baird (2005) 
Caudal parts extending to buccal and gingival mucosa with or without pharynx, 
palate, tongue 
FCGS Healey et al. (2007) 
Palatoglossal folds or gums or palate or buccal mucosa or tongue FCGS Bellei et al. (2008) 
Palatoglossal folds, premolar/molar gingival and buccal mucosa FCGS Southerden and Gorrel (2007) 
Southerden (2010) 
Arzi et al. (2010b) 
Hennet et al. (2011) 
A selection of names for FCGS taken from the literature and the described location of the lesions 
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Figure 1.1: Anatomy of the feline oral cavity 
 
Reproduced from Arzi et. al. (2010a) 
1. Attached gingiva 6. Floor of the mouth 
2. Alveolar mucosa 7. Hard palate 
3. Buccal mucosa 8. Soft palate 
4. Ventral surface of the tongue 9. Palatoglossal folds 
5. Dorsal surface of the tongue 10. Molar lingual salivary gland 
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1.2.1.3 Histopathological appearance 
Histopathologically, two patterns can be seen in the inflammatory cell infiltrates 
(Barker et al., 1992). The first pattern (Group 1) is described as either feline 
ulcerative stomatitis and glossitis or lymphocytic plasmacytic stomatitis. This is 
described as an ulcerative chronic active inflammation of the mucosa and 
palatoglossal folds. The predominant cells in mucosa and submucosa are lymphocytes 
and plasma cells. The second pattern (Group 2) is feline plasma cell gingivitis-
pharyngitis or FCGS, which is described as proliferative lesions, mainly at the 
glossopalatine arches. The inflammatory reaction in the submucosa consists 
predominantly of plasma cells with smaller numbers of lymphocytes, neutrophils and 
histiocytes. Mott cells, which are plasma cells containing immunoglobulin (Ig), also 
named Russell bodies, and multi-nuclear plasma cells are also seen (Johnessee and 
Hurvitz, 1983; Barker et al., 1992; White et al., 1992; Diehl and Rosychuk, 1993; 
Lyon, 2005; Wiggs, 2007). Approximately 70% of cases demonstrate a lympho-
plasmacytic infiltrate (Group 1) and 30% of cases show a predominant plasmacytic 
infiltrate (Group 2) (White et al., 1992; Diehl and Rosychuk, 1993). 
1.2.2 Prevalence 
Feline oral diseases that are most commonly seen in practice include periodontal 
disease and feline tooth resorption (TR) lesions, previously referred to by other 
names such as feline odontoclastic resorption lesions (FORL) and neck lesions (Ingham 
et al., 2001; Girard et al., 2009). In the United States a study showed that 13% of 
cats visiting veterinary practices were diagnosed with gingivitis (Lund et al., 1999) 
but no record was made of FCGS despite the fact that it is a well known disease in 
veterinary practice. A survey from the American Dental Society found that 62% of 
veterinarians were seeing at least one case of gingivostomatitis per week (Frost and 
Williams, 1986). In a study from the north-west of England a FCGS prevalence of 0.7% 
was seen in a population of 4858 cats visiting veterinary practices. Forty-four percent 
of these were new cases (Healey et al., 2007). 
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1.3 Treatment and management of FCGS 
1.3.1 Preventive measures 
The unknown aetiology of FCGS makes preventive measures difficult. Any oral 
preventive medicine starts with hygiene. The focus should therefore be a reduction 
of plaque accumulation and mechanical disruption of the bacterial biofilm to reduce 
the risk of periodontal disease that often accompanies the caudal stomatitis. 
1.3.1.1 Dietary management 
A variety of dental care diets is available. These diets are designed to reduce plaque 
accumulation and consequently are used as an oral hygiene product. The diet is 
presented as kibbles that are larger than ordinary cat food and have a tougher 
structure to mechanically clean the teeth during eating. This is based on the 
observation that dried foods have a positive effect on periodontal health when 
compared with moist food (Studer and Stapley, 1973). Ordinary moist cat food does 
not represent the natural diet of felids, where natural diets would normally involve 
considerable chewing. A different pattern of dental disease is seen in wild felidae 
with more tooth fractures than infection. This is possibly related to the diet and the 
greater chance of trauma during hunting (Longley et al., 2007; Longley, 2010). One 
study on the prevalence of TR showed a lower prevalence in wild cats when 
compared to domestic cats (Roux et al., 2009; Longley, 2010). In addition to dental 
care ‘main’ diets for domestic cats, there are chew treats available with the same 
purpose of removing plaque during mastication. Research on the effect of these diets 
and treats on oral status has shown a decrease in calculus and plaque accumulation 
when used regularly (Ingham et al., 2002; Vrieling et al., 2005). Changing the shape 
of the kibble and increasing the surface area and volume results in a reduction in 
plaque accumulation (Clarke et al., 2010). 
As well as presentation of the diet, the ingredients may also play a role in oral 
health. In a single case study of FCGS, the cat was given symptomatic treatment and 
the diet was changed to a natural cat diet without artificial ingredients (Addie et al., 
2003). The cat showed improvement after the change in diet. In human dentistry, 
food additives are seen as a possible factor in the aetiology of stomatitis. In a 
retrospective study of 1252 patients with stomatitis and 100 healthy controls, the 
stomatitis patients were significantly more likely to have hypersensitivity towards 
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food additives (Wray et al., 2000). No large scale research has been done in cats to 
support this suggestion. 
1.3.1.2 Dental hygiene 
The modern cat diets, which are soft and easy to consume, have created the need 
for home dental hygiene measures in cats. A wide range of products is available from 
pet shops and veterinary practices and include toothpaste, mouthwash, toothbrushes 
and hygienic wipes. Dedication by the owner is mandatory for this form of preventive 
medicine to be effective but calculus formation is decreased significantly when cats 
teeth are brushed once or twice weekly (Richardson, 1965). 
1.3.2 Symptomatic treatment 
1.3.2.1 Hygienic treatment and surgical measurements 
Initial treatment in cats diagnosed with FCGS is professional oral hygiene treatment 
including dental scaling, periodontal debridement and polishing. TR lesions require 
restoration or removal (Wiggs, 2007). Studies recording TR lesions in combination 
with FCGS showed the presence of minimal one TR lesion in 41% (Bellei et al., 2008) 
and 66% (Hennet, 1997) of the cases. Antibiotic treatment and advice on home 
hygienic measurements, including brushing and chlorhexidine gel are important 
(Frost and Williams, 1986; Harvey, 1991). When the response to initial treatment is 
unsatisfactory, further treatment is likely to include extracting the teeth most 
closely located to the mucosal inflammation or removing all premolars and molars 
(Gorrel, 2004; Baird, 2005; Bellei et al., 2008). In areas with hyperplasia of the 
gingiva, gingivoplasty may be indicated (Wiggs, 2007). Dental extraction requires a 
thorough approach since any retained roots or parts of roots can cause persistence of 
the clinical signs. Studies on the success rate of elective surgical extraction 
(removing all premolars and molars), show that approximately 50-60% of cases will 
require no further treatment, 20-40% of cases show improvement and 10-20% of the 
cats will show no improvement after the procedure (Hennet, 1997; Girard and 
Hennet, 2005; Bellei et al., 2008). In the study by Hennet (1997) these results were 
shown after removing all teeth in 6.6% of cases, leaving one to five premolar teeth in 
13.4% of cases and all premolar and molar teeth were removed in the remaining 
cases. 
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1.3.2.2 Antibiotic drug therapy 
Antibiotic therapy alone provides only temporary improvement in FCGS cases 
(Harvey, 1991; Lyon, 2005). No standardised clinical trials of antibiotic therapy have 
been reported. In a small study, improvement was noted in 30% of cats treated with 
different antibiotic regimes (White et al., 1992). No treatment period was recorded 
and no details of the scale of improvement or of any additional treatments were 
provided. Antibiotics that are often recommended in combination with surgical 
methods include clindamycin, amoxicillin, amoxicillin/clavulanic acid, metronidazole 
and doxycycline (Frost and Williams, 1986; Harvey, 1991; Harvey, 1994; Lyon, 2005; 
Wiggs, 2007). Administration of antibiotic treatment ranging from a week to months 
is suggested and a combination of topical and systemic treatment is sometimes 
advised. 
1.3.2.3 Anti-inflammatory and immunosuppressive drug therapy 
Corticosteroid use in FCGS cases is advocated for its immunosuppressive and anti-
inflammatory actions (Frost and Williams, 1986; Diehl and Rosychuk, 1993; Lyon, 
2005; Wiggs, 2007). In a study where a number of corticosteroids was tested, 
improvement was seen in 50% to 80% of the cases (White et al., 1992). In many cases, 
the effect of the drug became less reliable over a period of months. The co-
administration of other drugs was not recorded in this study and there was no 
standardised treatment period. A more recent study evaluated the use of a tapering 
anti-inflammatory dose of prednisolone for three weeks in cats with persistent 
clinical signs at least two months after dental extractions and antibiotic therapy 
(Hennet et al., 2011). The cats were treated for three weeks. Eight percent of cats 
were completely cured, improvement was seen in 46% of cases and no response or 
worsening of symptoms was seen in 46% of cases. Pain scores decreased during the 
first 30 days, although not significantly, and increased subsequently from day 30 to 
90. A scoring system was used to score the caudal stomatitis intensity and area 
affected and the presence of alveolar and buccal mucositis; these scores decreased 
over a 90 day period although not significantly past 30 days. 
Other immunosuppressive drugs that have been used are azathioprine, chlorambucil 
and cyclophosphamide (Diehl and Rosychuk, 1993; Wiggs, 2007). Non-steroidal anti-
inflammatory drugs (NSAIDs) are also prescribed in FCGS often in combination with 
antibiotic therapy (Mihaljevic, 2003; Hennet et al., 2011). However, no studies have 
shown effectiveness of these treatment methods. 
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1.3.2.4 Interferon treatment 
Type I recombinant interferons (IFNs) have been used for their action against viruses 
in cats (Jameson and Essex, 1983). Human recombinant INF-α was the first to be 
commercially available and has been used against feline retrovirus infections (Kociba 
et al., 1995; Domenech et al., 2011). To overcome problems with the production of 
neutralising antibodies, species-specific feline recombinant IFN (rFeINF) α has been 
produced (Ueda et al., 1993). rFeIFN-α has been described as having in vitro anti-
viral effects (Wonderling et al., 2002) and rFeIFN-ω has been described as having 
antiviral effects against feline and canine viruses, including feline calicivirus (FCV) 
and feline herpesvirus-1 (FHV-1) (Truyen et al., 2002). rFeIFN-ω is now commercially 
available and registered for veterinary use in the UK. In the past few years several 
studies have been conducted on the effect of rFeIFN-ω on FCV-positive cats with 
FCGS (Mihaljevic, 2003; Southerden and Gorrel, 2007; Hennet et al., 2011). Cats that 
do not respond to the initial surgical treatment as described previously (Section 
1.3.2.1) have been treated with positive results. A non-controlled clinical study on 20 
cats showed an improvement in all cats and seven of these were described as 
clinically cured according to veterinary evaluation after a treatment period of three 
to six months (Mihaljevic, 2003). A single case report described a successful result 
after six weeks of treatment (Southerden and Gorrel, 2007). A double-blind study on 
39 cats compared the results of rFeIFN-ω with prednisolone treatment (Hennet et 
al., 2011). A statistically significant improvement was seen in the scores for clinical 
lesions and pain after 90 days of treatment with rFeIFN-ω. A significant difference 
between the groups was found with the pain scores at day 60 and day 90, the group 
treated with rFeIFN-ω having lower pain scores. 
1.3.2.5 Other treatments 
Oral administration of bovine lactoferrin, an antimicrobial peptide, provided 
improvement in pain, salivation, appetite and oral inflammation scores of cats with 
FCGS (Sato et al., 1996). None of the cats was totally cleared of signs and some cats 
showed no improvement. It has been proposed that treatment with bovine lactoferrin 
should be in combination with antibiotics and glucocorticoids. 
A paramunity inducer containing an inactivated parapox ovis virus (PIND-ORF) 
(Buttner, 1993), has been tested as a treatment for FCGS. Thirty-three cats with 
FCGS were treated with PIND-ORF and compared to 39 cats with FCGS treated with 
conventional methods. According to this study 42% of the cats did not need other 
treatment after PIND-ORF, compared to 13% in the conventionally treated group 
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(Mayr et al., 1991). When tested on 17 cats with FCGS, of which 15 were FCV 
positive, a significant improvement was seen in all the clinical scores of the treated 
cats (Zetner et al., 2006). 
Administration of megoestrol acetate is also reported to have positive results in cats 
with FCGS (Johnessee and Hurvitz, 1983; White et al., 1992). Of a total of five cats 
that were treated with megoestrol acetate four showed improvement but due to 
side-effects the drug was discontinued in two of these four cats (White et al., 1992). 
Due to the high risk of side effects this treatment is not recommended. 
Anti-inflammatory chrysotherapy, or ‘gold salts’, has been utilised in human 
medicine for years (Forestier, 1932; Stuhlmeier, 2007). One study has been published 
on the use of weekly injections with aurothioglucose in 17 cats with FCGS. 82% of 
these cats showed improvement but no information on improvement scales was given 
(White et al., 1992). 
Laser therapy has been used in FCGS to reduce proliferative tissue and create fibrous 
tissue to reduce the inflammatory reaction (Harvey, 1991; Lyon, 2005; Lewis et al., 
2007). No studies have shown any effectiveness of the treatment on its own, 
although one single case study showed a cat free of caudal stomatitis after treatment 
with CO2-laser therapy in combination with other treatment methods including a full 
dental extraction (Lewis et al., 2007).  
Other approaches that have been advised but not supported by clinical trials are food 
supplements such as vitamins A, B and C and shark cartilage (Gaskell and Gruffydd-
Jones, 1976; Wiggs, 2007) and chemical cautery (Gaskell and Gruffydd-Jones, 1976). 
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1.4 Bacteriology 
1.4.1 The healthy bacterial oral flora in cats 
From studies on the bacteria of the human oral cavity we have learnt that there is a 
diverse microbiome with thousands of different species growing in complex biofilms. 
Initial colonisers of oral bacterial biofilms are predominantly gram-positive aerobes 
such as Actinomyces species and Streptococcus species. Secondary colonisers of the 
biofilm are mostly gram-negative bacteria including pathogenic bacteria like 
Tannerella species (Kolenbrander, 2000; Li et al., 2004). 
The healthy oral flora of the cat has been poorly studied. Most studies to date have 
used cultivable methods and from studies on the human oral microflora it is 
estimated that approximately 50% of the bacteria are uncultivable (Socransky et al., 
1963); a similar situation could be expected in the feline oral cavity. A summary of 
the oral bacteria that have been identified in cats is shown in Table 1.2  
In a microbiological study on plaque bacteria in five healthy cats and five cats with 
gingivitis, Bacteroides species, Fusobacterium nucleatum, and Actinomyces species 
were isolated from both healthy cats and cats with periodontal disease (Tannock et 
al., 1988). Gram staining showed a combination of gram-positive and gram-negative 
bacteria and spiral-shaped forms (spirochaetes) in both healthy cats and cats with 
gingivitis. 
In another study the gingival margin of 14 healthy cats between six and 12 month of 
age which were free of gingivitis or tartar build up was investigated (Love et al., 
1990). From these cats 150 isolates were obtained. The most common obligate 
anaerobes identified belonged to the genera Bacteroides (presently partly classified 
as Porphyromonas or Prevotella) and Fusobacterium. The most common facultative 
anaerobe species were Actinomyces, Pasteurella multocida and Propionibacterium. 
P. multocida subsp. multocida and P. multocida subsp. septica are common 
organisms in the oral cavity of the cat and are often isolated (Baldrias et al., 1988; 
Ganiere et al., 1993).  
Studies on Bacteroides sp. showed that Bacteroides tectum was the most prevalent 
Bacteroides species in the feline oral cavity (Love et al., 1987; 1989). 
 
Table 1.2: Bacteria found in the healthy feline oral cavity.  
Gram-positive Gram-negative 
Aerobes/facultative anaerobes Anaerobes Aerobes/facultative anaerobes Anaerobes 
Actinomyces sp. Bifidobacterium sp. Actinobaccilus sp. Campylobacter sp. 
Lactobacillus sp. Clostridium sp. Branhamella sp. Bacteroides sp. 
Micrococcus sp Peptostreptococcus sp. Campylobacter sp. Fusobacterium sp. 
Nocardia sp. Propionibacterium sp. Capnocytophaga sp. Porphyromonas sp. 
Streptococcus sp.  Coliforms Prevotella sp. 
  Eikenella sp. Spirochaetes sp. 
  Haemophilus sp. Veilonella sp. 
  Neisseria sp. Wolinella sp. 
  Pasteurella sp.  
Adapted from Bonello (2007) 
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Studies on the oral microflora of cats are often focused on potential human pathogens. 
Bacteria such as P. multocida and Capnocythophaga canimorsus are of particular 
interest in human medicine and can cause local abscessation or severe illness, 
respectively, following cat bites (Blanche et al., 1998; Love et al., 2000; Gaastra and 
Lipman, 2009). Studies on cat bite infections have shown that a variety of bacteria can 
be transferred during cat bites which implies their presence in the oral cavity (Talan et 
al., 1999; Love et al., 2000). A summary of the types of bacteria identified from cat 
bite infections is shown in Table 1.3 (Talan et al., 1999). 
1.4.2 The oral flora in the inflamed feline oral cavity 
Studies of the bacterial oral flora in diseased cats have mostly focused on periodontal 
disease and therefore isolated bacteria are often from plaque samples (Mallonee et al., 
1988; Norris and Love, 1999a). 
Culture-dependent methods in cats with gingivitis showed that the prevalence of 
Bacteroides, Provetella and Porphyromonas species is higher when compared to the 
healthy gingival margin and increased with severity of disease (Mallonee et al., 1988; 
Love et al., 1989). Porphyromonas species are known to be of importance in human 
periodontal disease and are often described in combination with Actinobacillus 
actinomycetemcomitans and Tannerella forsythia (Slots et al., 1986; Bragd et al., 1987; 
Socransky et al., 1998). In cats a positive correlation between the presence of 
Porphyromonas species and the grade of periodontal disease has been observed (Norris 
and Love, 1999a). T. forsythia has been identified in plaque samples from cats with and 
without periodontal disease. The proportion of T. forsythia was higher in cats with 
periodontitis (Booij-Vrieling et al., 2010). 
Peptostreptococcus species were found to be more predominant in cats with 
increasingly severe periodontal disease (Mallonee et al., 1988). P. multocida was often 
isolated but numbers seemed to decrease with increasing severity of periodontal 
disease (Mallonee et al., 1988). Another study demonstrated the presence of 
significantly higher numbers of P. multocida in cats with inflamed gingiva compared to 
normal gingiva and with mildly inflamed gingiva showing the largest increase (Mihaljevic 
and Klein, 1998). In a study on gingivitis P. multocida could be isolated and accounted 
for 5% of all isolates (Harvey et al., 1995). Fusobacterium nucleatum is detected more 
frequently in plaque from cats with gingivitis when compared to healthy cats (Tannock 
et al., 1988). 
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When investigating the oral cavity of the cat, several sources of bacteria must be taken 
into account. Grooming and hunting are natural habits and consequently will be adding 
to the bacterial diversity in the oral cavity. The possibility of not only colonisation of a 
variety of bacteria but also the presence of bacterial DNA from other sources needs to 
be considered. 
 
 Table 1.3: Bacteria isolated from cat bite infections.  
Gram-positive Gram-negative 
Aerobes/facultative anaerobes Anaerobes Aerobes/facultative anaerobes Anaerobes 
Actinomyces sp. Clostridium sordelli Acinetobacter sp. Bacteroides sp. 
Bacillus sp. Eubacterium sp. Actinobaccilus sp. Fusobacterium sp. 
Brevibacterium sp. Filifactor Villosus Aeromonas hydrophila Porphyromonas sp. 
Corynebacterium sp. Peptostreptococcus sp. Alcaligenes sp. Prevotella sp. 
Enterococcus sp. Propionibacterium sp. Capnocytophaga sp. Veilonella sp. 
Erysipelothrix rhusiopathiae  EF4B bacteria  
Gemella morbillorum  Eikenella corrodens  
Lactobacillus sp.  Enterobacter cloacae  
Rhodococcus sp.  Klebsiella oxytoca  
Rothia dentocariosa  Moraxella sp.  
Staphylococcus sp.  Neisseria sp.  
Streptococcus sp.  Pantoea agglomerans  
Streptomyces sp.  Pasteurella sp.  
  Pseudomonas sp.  
  Reimerella anatipestifer  
  Weeksella sp.  
Adapted from Talan et al. (1999) 
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In a study on periodontal disease, Bacteroides sp. Porphyromonas sp. and Gram 
negative bacillus were found to be the most predominant anaerobes and Neisseria and 
Staphylococcus epidermidis were the main aerobic bacteria in calculus samples (Samsar 
et al., 2003) 
Studies that report bacteria relating to FCGS specifically are relatively rare. In a study 
of affected and normal cats where serum antibodies against a variety of human and cat 
gram-negative anaerobes and lipopolysaccharide (LPS) from these bacteria were 
analysed, cats with FCGS had significantly increased titres when compared to control 
cats for all bacteria and most of the LPS tested (Sims et al., 1990). The bacteria tested 
included A. Actinomycetemcomitans and P. gingivalis. Two single FCGS case studies 
showed large numbers P. multocida in both cats (Reindel et al., 1987; Addie et al., 
2003). 
1.4.3 Bartonella henselae 
Bartonella species are intracellular gram-negative bacteria that can cause a persistent 
intra-erythrocytic bacteraemia in the host. Transfer of Bartonella species can be 
mediated by bloodsucking arthropodes (Chomel et al., 2009; Breitschwerdt, 2011). The 
precise pathogenesis of Bartonella sp. still needs to be unravelled. So far two important 
pathogenicity factors of B. henselae have been described: Bartonella adhesion A which 
allows binding to the host cells and the VirB/VirD4 type IV secretion system which 
modulates the host cell function, for example, by inhibion of apoptosis of infected cells 
(Franz and Kempf, 2011). The first authors researching the possible connection between 
the presence of Bartonella sp. in cats and clinical disease showed a higher prevalence 
of gingivitis in cats coinfected with FIV and B. henselae (Ueno et al., 1996). Several 
studies have been done on the possible relationship between Bartonella henselae and 
other feline oral diseases but without any consistent results. A study compared illness 
and health in cats seropositive and seronegative for B. henselae (Glaus et al., 1997). 
There was no higher prevalence of disease in seropositive cats but a higher frequency of 
stomatitis was seen in the seropositive group. When a study combined blood culture, 
polymerase chain reaction (PCR) on oral swabs and antibody tests and compared these 
results to the presence of oral lesions, no correlation was found between cats with a 
bacteraemia and having oral lesions (Namekata et al., 2010). A higher but not 
significant prevalence of oral lesions was seen in cats where PCR showed the presence 
of Bartonella sp. However cats with antibodies against both, B. clarridgelae and B. 
henselae were 3-4 times more likely to suffer from oral lesions. Another study found 
opposing results when blood culture and serological tests were used to assess any 
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correlation with a number of clinical illnesses (Sykes et al., 2010). In that study an 
association between the presence of FCGS and isolation of Bartonella sp. was seen, but 
not between FCGS and seropositivity for Bartonella sp. Some studies have found no 
correlation at all between FCGS and Bartonella sp (Quimby et al., 2008). In a group of 
nine cats with FCGS and 39 healthy cats, enzyme linked immunosorbent assay (ELISA) 
and Western blot immunoassays on blood samples showed no correlation between 
seropositivity for Bartonella sp. and FCGS. Also, a study on 52 cats with FCGS and 50 
healthy controls failed to show a correlation between FCGS and B. henselae (Belgard et 
al., 2010). When blood from a total of 70 FCGS and 61 healthy cats was tested for 
deoxyribonucleic acid (DNA) of Bartonella species by PCR and for antibodies by ELISA 
and Western blot, the prevalence of Bartonella sp. did not differ between the two 
groups (Dowers et al., 2010). Additionally, PCR on oral biopsies from 42 cats with FCGS 
and 19 healthy cats did not show a correlation between FCGS and Bartonella species. At 
this point no evidence of a correlation between the presence of Bartonella species and 
FCGS can be found in any large scale studies that have investigated the aetiology of 
FCGS. 
  
Chapter 1 General introduction  18 
1.5 Feline viruses and FCGS 
1.5.1 Feline leukaemia virus 
Feline leukaemia virus (FeLV) is a retrovirus first discovered in 1964 (Jarrett et al., 
1964; Kawakami et al., 1967) Between 1-5% of healthy cats in European countries are 
believed to be infected with FeLV (Hosie et al., 1989; Levy, 2005; de Lange, 2008; 
Gleich et al., 2009). Young cats that spend time outdoors are more likely to be infected 
than older cats that remain mostly indoors (Hosie et al., 1989). The most common 
transmission route is oro-nasal spread through saliva from viraemic cats (Hardy et al., 
1973; Francis et al., 1977). Infection with FeLV can have several outcomes. The acute 
infection can follow one of three courses: it can develop into a persistent viraemia, an 
inactive latent form or, if the immune system eliminates the virus, the cat can become 
immune (Hardy et al., 1976; Rezanka et al., 1992). It is difficult to differentiate 
between an inactive latent form and an infection that has been eliminated. The path 
that is followed differs and depends on factors such as age, dose and duration of 
exposure. In 60% of cases the immune system eliminates the virus and approximately 
30% of the cats develop a persistent viraemia (Dunham and Graham, 2008). In case of a 
persistent viraemia most cats develop signs including lymphoma and leukaemia, within 
three years. Clinical symptoms that are often observed are weight loss, fever, 
conjunctivitis, dehydration and rhinitis. In 15% of cases, oral inflammation is seen 
(Sparkes, 1997; Levy, 2005).  
Often commercial immunochromatography (IC) tests in the veterinary practice or 
laboratory ELISAs are used to screen for FeLV. Both tests detect the FeLV p27 capsid 
protein. The positive predictive value (PPV; the proportion of correctly diagnosed 
positives in a population) for these tests is variable and a positive screening, especially 
in healthy, low risk cats, needs to be confirmed with viral isolation, PCR or 
immunofluorescence (Hartmann et al., 2007; Dunham and Graham, 2008). Whole virus, 
viral nucleic acids and protein p27 respectively are detected in these tests (Levy, 2005). 
A possible relationship between FeLV and FCGS has been described in the literature 
based on the fact that oral inflammation is sometimes seen with FeLV infection (Cotter 
et al., 1975; Frost and Williams, 1986). It has not been possible to show a consistent 
relationship between the presence of FeLV and FCGS. In three small case studies all cats 
with FCGS tested negative for FeLV (Johnessee and Hurvitz, 1983; Thompson et al., 
1984; Quimby et al., 2008). In a study that tested 36 cats suffering from plasma cell 
stomatitis pharyngitis, 16.6% tested positive for FeLV (White et al., 1992). In a study of 
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23 cats with FCGS, none were found positive for the virus (Hennet, 1997). Several single 
case reports have shown that cats with FCGS were negative for FeLV (Addie et al., 2003; 
Baird, 2005; Southerden and Gorrel, 2007). 
1.5.2 Feline immunodeficiency virus 
Feline immunodeficiency virus (FIV) is a T-lymphotropic lentivirus that was first isolated 
in a cattery in California (Pedersen et al., 1987). Its prevalence varies around the world 
and depends on age, lifestyle, health status and gender. Adult cats that spend time 
outdoors are more likely to be infected than younger and indoor cats (Crawford and 
Levy, 2007; Dunham and Graham, 2008; Gleich et al., 2009). The most common way of 
transmission is through bite-wounds. Vertical transmission and infection through sexual 
contact has been shown in experimental studies (Ueland and Nesse, 1992; O'Neil et al., 
1995; Jordan et al., 1998). FIV infection occurs in several phases. The acute infection, 
which is associated with clinical signs such as anorexia, depression and pyrexia, is 
followed by a persistent viraemic stage in which the cat appears healthy (Callanan et 
al., 1992; Dunham and Graham, 2008). The length of the viraemic stage is variable and 
may last for years. The outcome of the viraemic stage is variable and in most cats this is 
followed by the terminal phase. In this phase the immune system is not able to prevent 
the plasma viral load from increasing and this leads to immunodeficiency. The most 
common clinical signs of infection are secondary bacterial infections of the upper 
respiratory tract and oral cavity (Hartmann, 2005). Other symptoms include chronic 
enteritis, neurologic disease and neoplasia.  
For diagnosis of FIV, commercial ELISA based screening tests that test the presence of 
anti-FIV antibodies are available (Crawford and Levy, 2007; Dunham and Graham, 2008). 
Due to a higher prevalence of FIV when compared to FeLV, the PPV for the screening 
tests is also higher; however confirmation by another method is recommended after 
initial screening (Hartmann et al., 2007; Dunham and Graham, 2008). Methods that can 
be used to confirm an initial screening test are Western blot, immunofluorescence 
assays, virus isolation and PCR. Western blot and the immunofluorescence assay detect 
anti-FIV antibodies, virus isolation detects whole virus and viral or proviral DNA will be 
detected with the PCR assay. However, the PCR assays currently available do give 
varying results (Bienzle et al., 2004; Hartmann, 2005; Crawford and Levy, 2007; Dunham 
and Graham, 2008). 
FIV is often seen in cats with chronic forms of oral ulceration. The severity of oral 
lesions can increase in cats positive for FIV, especially when co-infections with other 
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viruses such as FCV and FeLV occur (Dawson et al., 1991; Tenorio et al., 1991; Waters et 
al., 1993). In a UK and USA study, 75% and 81% of cats with FCGS in the UK tested 
positive for FIV compared to only 16% in the control group. 54% of the cats with FCGS in 
the USA tested positive for FIV compared to 50% in the control group (Knowles et al., 
1989). Other studies have shown lower levels of FIV infection (13-28%) in FCGS cases 
(White et al., 1992; Hennet, 1997; Bellei et al., 2008; Quimby et al., 2008). Several 
single case reports have shown cats with FCGS that were negative for FIV (Addie et al., 
2003; Baird, 2005; Southerden and Gorrel, 2007) 
1.5.3 Feline calicivirus 
FCV is a non-enveloped Ribonucleic acid (RNA) virus that causes upper respiratory tract 
disease in cats. FCV belongs to the family of Caliciviridae. The prevalence of the virus is 
variable, and is considered to be approximately 10% in the UK for cats that live in small 
groups or alone (Wardley et al., 1974; Gaskell, 2005; Radford et al., 2007). Larger 
groups such as shelter cats or catteries have a much higher prevalence of up to 40%. 
FCV is transmitted via nasal, oral or conjunctival mucous membranes (Poulet et al., 
2000). Clinical signs that are associated with FCV infection are variable but oral 
ulceration is the most common sign. Signs typical of acute upper respiratory tract 
disease (URTD) caused by FCV include serous or mucopurulent nasal and ocular 
discharge, sneezing, conjunctivitis, depression, anorexia and pyrexia. Occasionally 
pneumonia and coughing develop and some strains of the virus can induce lameness 
(Dawson et al., 1994; Poulet et al., 2000). In 1998, a very highly contagious strain was 
described for the first time (Pedersen et al., 2000). This strain causes in addition to the 
typical URTD symptoms, ulcerative facial dermatitis, cutaneous oedema, severe 
pyrexia, vomiting and diarrhoea. Mortality in this strain is high at around 50%. Diagnosis 
of FCV is by viral isolation from nasal, conjunctival or oropharyngeal swabs (Hurley and 
Sykes, 2003; Gaskell, 2005). Immunofluorescence antibody test (IFA) has been used but 
is considered less sensitive than viral isolation, as is PCR. 
FCV and FCGS have been linked in many studies (Gaskell and Gruffydd-Jones, 1976; 
Povey, 1976). A high percentage of cats have been found to be positive for FCV 
especially when cats with caudal stomatitis are examined (Reubel et al., 1992). In one 
of the first studies in which ten cats with chronic stomatitis were tested for FCV, eight 
tested positive (Thompson et al., 1984). In 78 British cats tested in three different 
locations 79 to 92% of cats with chronic stomatitis were positive for FCV compared with 
19% for control cats (Knowles et al., 1989). In the same study, in cats from the USA, 50% 
of cats with chronic stomatitis tested positive for FCV, compared to 0% for controls. A 
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study on co-infection with FCV and FHV-1 showed that in 25 cats with FCGS, 88% shed 
both viruses compared to a control group of 24 cats with periodontal disease where only 
21% shed these viruses (Lommer and Verstraete, 2003). Only two out of 25 cats were 
positive for FCV alone and one for FHV-1 alone. When a group of 32 cats with FCGS were 
tested, 66.6% were positive for FCV (Bellei et al., 2008). In one study all of the cats 
were negative for FCV by PCR, serological tests showed 100% positive for both, control 
and FCGS groups (Quimby et al., 2008). A later study from the same research group 
showed that 40.5% of cats in the FCGS group were positive for FCV compared to 0% in 
the control group (Dowers et al., 2010).  
Most studies have demonstrated a significantly higher prevalence of FCV in cats with 
FCGS when compared to a control group but in almost every study a proportion of the 
cats with FCGS tested negative for the presence of FCV. Cats that were infected with 
FCV did not show a higher prevalence or a greater severity of oral lesions compared to 
virus-free cats (Tenorio et al., 1991). Also, infection of specific pathogen-free (SPF) cats 
with FCV induced signs of acute faucitis and oral ulceration but no signs of chronic oral 
inflammation were observed (Knowles et al., 1991; Reubel et al., 1992). When FCV was 
introduced into a colony of cats some of which had been infected with FIV, chronic 
gingivitis was observed in nine cats, six positive for FCV and FIV, one only positive for 
FIV and two positive only for FCV. Gingivitis was more severe in cats positive for both 
viruses (Waters et al., 1993). 
1.5.4 Feline herpes virus 1 
FHV-1 is a member of the subfamily of alphaherpesvirinae (Davison et al., 2009). FHV-1 
is a common virus among cats with respiratory problems and is also known as feline 
rhinotracheitis virus. Studies have been conducted to investigate the prevalence of the 
disease. A study in the UK of 622 cats showed that 11% of cats with respiratory problems 
were positive for the virus and 1% of clinically healthy cats were also positive (Binns et 
al., 2000). In Korea the prevalence in clinically healthy cats in an animal shelter was 
found to be as high as 63% (Kang and Park, 2008). The virus is transmitted by direct 
contact through nasal, oral and conjunctival mucous membranes (Binns et al., 2000; 
Gaskell, 2005; Gaskell et al., 2007). The most important sources of viral spread are 
acutely infected cats but carrier cats can also spread the virus. An infection with FHV-1 
is most common in young cats and cats from multi-cat households. Following an 
incubation period of two to six days, clinical signs start to develop. Sneezing, pyrexia 
and depression are the most common changes in the early stages of the disease (Povey, 
1976; Gaskell et al., 2007). The signs quickly worsen to include ocular and nasal 
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discharge and sometimes severe mucopurulent conjunctivitis, dyspnoea and coughing 
will occur. Oral ulceration can also occur but is not as common as in other viral 
infections (Povey, 1979; Gaskell, 2005; Gaskell et al., 2007). After recovery most cats 
will become latently infected. Reactivation of the virus is likely in times of stress, after 
corticosteroid therapy and during lactation. At such times the cat can develop mild 
signs and will shed virus. Diagnosis of FHV-1 is usually done by viral isolation from saliva 
(Gaskell, 2005; Maggs, 2005; Gaskell et al., 2007). Another technique is 
immunofluorescence from conjunctival smears (Maggs, 2005; Gaskell et al., 2007). PCR 
to detect viral DNA is now used in many laboratories and is significantly more sensitive 
than viral isolation, although variation in sensitivity between different assays is 
significant (Hara et al., 1996; Gaskell, 2005; Maggs, 2005; Maggs and Clarke, 2005; 
Gaskell et al., 2007). 
FHV-1 in combination with FCV, was present in 88% of cats with FCGS compared to 21% 
in cats with periodontal disease (Lommer and Verstraete, 2003). Other studies have 
failed to show a correlation between FHV-1 and FCGS (Quimby et al., 2008; Dowers et 
al., 2010). 
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1.6 The immune response 
1.6.1 Defence mechanism in the oral cavity 
1.6.1.1 Mucous membrane 
The first defence mechanism in the oral cavity is the mucous membrane. The oral cavity 
is exposed to a variety of antigens and the epithelium needs to protect the host against 
mechanical trauma and micro-organisms, either commensal or pathogenic (Orsini and 
Hennet, 1992). The mucosa consists of a stratified squamous epithelium and connective 
tissue divided into lamina propria and submucosa (Garant, 2003a; Eubanks, 2007). Three 
different types of mucosa are seen in the in the oral cavity: 1) Lining mucosa which is 
elastic and loosely bound to the connective tissue that is rich in elastin. Lining mucosa 
covers the moving structures in the mouth such as the bucca, floor of the mouth and 
soft palate. 2) Masticatory mucosa which lines the gingivae and hard palate; it consists 
of tough keratinised epithelium with dense connective tissue. 3) Specialised mucosa 
found on the dorsum of the tongue that comprises cornified, stratified squamous 
epithelium (Orsini and Hennet, 1992; Garant, 2003a) 
1.6.1.2 Saliva 
Saliva has several functions in the oral cavity including digestion, lubrication and 
protection against microorganisms (Lehner, 1992; Amerongen and Veerman, 2002; 
Garant, 2003b). The protective function of saliva is provided by a variety of proteins 
and peptides secreted in the saliva. Both innate and adaptive responses play a role in 
the defence mechanisms of saliva. 
The nature of the immunoglobulins in the cat saliva, has been studied. The levels of 
IgM, IgG and IgA were determined and IgA was the most predominant class in the saliva 
from healthy cats (Harley et al., 1998). When cats with FCGS were tested, salivary 
immunoglobulins changed from predominantly IgA to predominantly IgG and IgM (Harley 
et al., 2003b).  
1.6.1.3 Mucosal cellular immune response 
The immune cell population of the oral cavity includes aggregates of, as well as 
individual lymphocytes and dendritic cells (DC), macrophages and mast cells (Arzi et al., 
2010a). The immune cell population has been investigated in a variety of locations 
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within the healthy oral cavity of the cat. T-lymphocytes, oral mucosal Langerhans cells, 
mast cells and macrophages are present in the different tissues (Arzi et al., 2010a). In 
the epithelium of the palatoglossal folds, Cluster of differentiation (CD) 3+ cells were 
observed with CD8+ cells being detected in higher numbers than CD4+ cells (Harley et 
al., 2003a). The tissue from the palatoglossal folds contained mostly mast cells in the 
lamina propria and submucosa and also included CD3+ T-lymphocytes and an equal 
division of CD4+/CD8+ cells. Least often detected were CD79+ cells and leucocyte 
antigen 1 (L1+) cells. The plasma cells that were detected were either IgG+ or IgA+. 
Aggregation of T-lymphocytes and antigen presenting cells (APCs) were seen in the 
lamina propria and may represent lymphoid follicles (Harley et al., 2003a; Arzi et al., 
2010a). No B-lymphocytes were detected in the oral mucosa of the SPF cats tested (Arzi 
et al., 2010a). 
The immune cells in the oral mucosa of cats with FCGS has also been assessed and the 
most prevalent cells in the mucosa were CD79a+, IgG+ and L1+ (Harley et al., 2011). CD3+ 
cells were also detected with CD8+ cells being more prevalent than CD4+ cells. Mast 
cells accounted for a small proportion of the cells but were higher when compared to 
previous studies in the healthy cat (Harley et al., 2003a). Another study showed an 
increase in the numbers of mast cells in the oral mucosa of cats with FCGS when 
compared to SPF cats (Arzi et al., 2010b). 
1.6.2 Toll-like receptors 
When pathogens invade through the anatomical barrier, the immune system reacts 
through the leucocytes of the innate immune system. Phagocytes (macrophages, 
dendritic cells and neutrophils) recognise pathogens and initiate phagocytosis, cytokine 
excretion and present antigen (Paltrinieri, 2008). Inflammation is the response that 
follows the excretion of the pro-inflammatory cytokines Interleukin (IL)-1, IL-6 and 
tumor necrosis factor (TNF)-α by activated macrophages. These cytokines organise the 
acute phase reaction in which fever, acute phase proteins, phagocytosis and the first 
stimulation of the adaptive immune system play a role (Gabay, 1999; Paltrinieri, 2008). 
On the surface of the leucocytes and of some epithelial cells, Toll-like receptors (TLRs) 
are found (Akira and Hoshino, 2003). They recognise different pathogens and when 
activated will stimulate the production of cytokines (Janeway and Medzhitov, 2002). 
TLRs activate the innate and the adaptive immune response. 
TLRs are pattern recognition receptors that recognise pathogens and differentiate them 
from the host by the pathogen-associated molecular patterns (PAMPs) that are found on 
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the microorganisms. The process of TLR signalling is reviewed by Akira and Takeda 
(2004) and Kawai and Akira (2006). TLRs are found on the cell surface or in the cell 
compartment of a variety of leucocytes and epithelial cells. TLRs are part of a 
superfamily that includes interleukin-1 receptors (IL-1R) based on the similarity found in 
the cytoplasmatic region designated the Toll/IL-1R (TIR) domain (Akira and Takeda, 
2004). This domain is essential for the signalling pathway. After binding to the ligand, 
the TLRs activate different adapter molecules. These adapter molecules are the start of 
the intracellular pathway that ultimately releases nuclear factor kappa B (NF-κB) to 
induce expression of genes within the nucleus. Myeloid differentiation primary response 
protein 88 (MyD88) is the adapter that is shared by almost all TLRs. The MyD88-
dependent pathway controls inflammatory responses by inflammatory cytokine 
production. TLR2 and TLR4 require an additional adapter namely the TIR domain-
containing adapter protein (TIRAP)/MyD88-adaptor-like protein (MAL), to induce the 
inflammatory response through MyD88-dependent signalling (Kawai and Akira, 2006). 
TIR-domain-containing adaptor protein inducing IFN-β (TRIF) is the adaptor that is 
activated after ligand binding to TLR3 and, in some cases, TLR4. This is known as the 
MyD88-independent pathway. TRIF-related adaptor molecule (TRAM) is another adapter. 
TRAM plays a role in the TLR4 MyD88-independent pathway in combination with TRIF. 
TRAM is not found in the TLR3 MyD88-independent pathway (Figure 1.2). 
1.6.2.1 Feline TLR mRNA sequences 
References which provide the cloned sequences of feline TLR messenger RNA (mRNA) 
are summarised in Table 1.4. 
1.6.2.2 Toll like receptor 1, Toll like receptor 2 and Toll like receptor 6 
TLR1, TLR2 and TLR6 are found on the cell surface. They combine together as a TLR1/2 
dimer and as a combination of TLR2 and TLR6 (Figure 1.2). Each TLR in the dimer has 
different ligands but as a dimer they can discriminate between triacyl (TLR1/2) and 
diacyl (TLR2/6) lipopeptide. The adapter molecules that are activated after binding 
those combinations are TIRAP and MyD88, which mediate the production of 
inflammatory cytokines (Akira and Takeda, 2004; Ignacio et al., 2005; Kawai and Akira, 
2006). 
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Figure 1.2: TLR-mediated immune responses 
 
 
Reproduced from Kawai and Akira (2006) 
 
Table 1.4: References which provide the cloned sequences of feline TLRs and cytokines 
Gene Reference 
TLR1 Ignacio et al. (2005) 
TLR2 Ignacio et al. (2005) 
TLR3 Ignacio et al. (2005); Astakhova et al. (2009) 
TLR4 Asahina et al. (2003) 
TLR5 Ignacio et al. (2005) 
TLR6 Ignacio et al. (2005) 
TLR7 Ignacio et al. (2005); Astakhova et al. (2009) 
TLR8 Ignacio et al. (2005); Astakhova et al. (2009) 
TLR9 Griebel et al. (2009) 
IL-1β Daniel et al. (1992) 
IL-4 Genbank accession number X87408 
IL-6 Bradley et al. (1993); Ohashi et al. (1993) 
IL-10 Genbank accession number U39569 
IL-12 P35 Fehr et al. (1997) 
IL-12 P40 Schijns et al. (1997) 
IFN-γ Argyle et al. (1995); Schijns et al. (1995) 
TNF-α McGraw et al. (1990) 
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1.6.2.3 Toll like receptor 3 
TLR3 is found in the cell compartment and recognises double stranded RNA. TRIF is 
activated in a MyD88 independent pathway and leads to the production of inflammatory 
cytokines and type 1 IFN in particular IFN-β (Figure 1.2) (Ignacio et al., 2005; Kawai and 
Akira, 2006; Astakhova et al., 2009). 
1.6.2.4 Toll like receptor 4 
TLR4 is found on the cell surface, recognises bacterial LPS and stimulates production of 
inflammatory cytokines and type 1 IFN, IFN-β in particular (Figure 1.2). TLR4 utilises 
adapters TRAM, TRIF, TIRAP/MAL and MyD88 (Asahina et al., 2003; Kawai and Akira, 
2006). 
1.6.2.5 Toll like receptor 5 
TLR5 is found on the cell surface and recognises bacterial flagellin. The MyD88 pathway 
is then activated which stimulates production of inflammatory cytokines (Figure 1.2) 
(Ignacio et al., 2005; Kawai and Akira, 2006). 
1.6.2.6 Toll like receptor 7 and Toll like receptor 8 
Both TLR7 and TLR8 recognise small synthetic compounds and single stranded RNA. They 
are found in the cell compartment. Binding of the ligand to these TLRs activates MyD88 
and inflammatory cytokines and type 1 IFN are produced (Figure 1.2) (Ignacio et al., 
2005; Kawai and Akira, 2006; Astakhova et al., 2009). 
1.6.2.7 Toll like receptor 9 
Cytosine-guanine bond (CpG) DNA of viruses and bacteria is recognised by TLR9. It is 
situated in the cell compartment and activates MyD88 after binding to the ligand. 
Inflammatory cytokines and type 1 IFN are produced after activation (Figure 1.2) 
(Griebel et al., 2005; Kawai and Akira, 2006). 
1.6.2.8 TLR10 and TLR11 
TLR10 and TLR11 have been discovered but the pathways in which they are involved are 
not yet fully understood. TLR11 recognises uropathogenic bacteria and activates MyD88 
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but the exact ligand is unknown (Akira and Hoshino, 2003; Akira and Takeda, 2004; 
Hasan et al., 2005; Kawai and Akira, 2006) 
1.6.2.9 Feline Toll-like receptors in infection 
Little research has been conducted on the function of feline TLRs. Full length cDNA 
cloning of the sequences for feline TLR3, TLR4, TLR7, TLR8 and TLR9 has been carried 
out (Asahina et al., 2003; Griebel et al., 2005; Astakhova et al., 2009). Feline TLR 
expression was determined in lymphoid tissue of the cat by Ignacio et al. (2005). TLR 
expression was tested in the spleen, thymus, intestinal intra-epithelial lymphocytes, 
lymphocytes from the lamina propria and retropharyngeal and mesenteric lymph nodes. 
TLR1 was only detected in the spleen. TLR6 expression was not detectable in any 
lymphoid tissue. All other TLRs were detected in the different lymphoid tissues 
investigated. Infection of a macrophage cell line with FIV resulted in an increase in 
TLR3 and TLR6 expression, whereas TLR9 expression was increased when an epithelial 
cell line was similarly infected. A down-regulation in TLRs was found in infected T-cell 
lines (Ignacio et al., 2005). When TLR expression was investigated in bone marrow 
dendritic cells during FIV infection, no significant changes were detected in the 
expression of TLR2, TLR3, TLR4, TLR7 and TLR9 (Lehman et al., 2009). 
1.6.3 Cytokines 
Cytokines are small proteins with a range of regulating functions in the immune system. 
They are released from various cells after a stimulus and activate cells of the immune 
system in an autocrine, paracrine or endocrine manner (Janeway et al., 2001). The 
different cytokines evaluated in this study are described. The references for the cloned 
feline cytokines are summarised in Table 1.4. 
1.6.3.1 Interleukin-1 
IL-1 consists of two proteins, IL-1-α and IL-1-β. Il-1 is synthesised by macrophages, 
monocytes and dendritic cells and is a mediator of inflammation. Together with IL-6 and 
TNF-α, IL-1 induces inflammatory responses during the initiation of an infection. IL-1 
plays a part in activating B lymphocyte growth and differentiation and CD4+ T cell 
proliferation (Daniel et al., 1992; Paltrinieri, 2008; Cruse and Lewis, 2010). 
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1.6.3.2 Interleukin-4 
IL-4 is produced by Th2 and mast cells. IL-4 function has mostly been studied in mice 
and includes the activation of B-cells, B-cell class switching to IgE, up-regulation of MHC 
class II production and differentiation of naive helper T cells (Th0 cells) into Th2 cells 
(Cruse and Lewis, 2010).  
1.6.3.3 Interleukin-6 
IL-6 is a pro-inflammatory cytokine produced by fibroblasts, mononuclear phagocytes, 
activated-lymphocytes and vascular endothelial cells. A variety of neoplasms are known 
to produce IL-6. IL-6 activates immune responses after tissue damage and is secreted in 
response to IL-1 and TNF-α stimulation. Hepatocytes are induced to form acute-phase 
proteins and B-lymphocytes are activated (Bradley et al., 1993; Ohashi et al., 1993; 
Cruse and Lewis, 2010). 
1.6.3.4 Interleukin-10 
IL-10 is expressed by CD4+ and CD8+ T lymphocytes, B lymphocytes, keratinocytes, 
monocytes and macrophages. IL-10 down regulates Th1 cytokine expression, blocks 
antigen presentation and IFN-γ formation. IL-10 inhibits macrophage production of IL-1, 
IL-6 and TNF-α and macrophage presentation of antigen. IL-10 is likely to contribute to 
the regulation and proliferation of B cells and mast cells and is known to stimulate B 
cells in vitro (Moore et al., 1993; Cruse and Lewis, 2010). 
1.6.3.5 Interleukin-12 
IL-12 stimulates natural killer (NK) cells and is a growth factor for CD4+ and CD8+ T 
lymphocytes. IL-12 stimulates the production of IFN-γ by NK cells and T cells. IL-12 is a 
heterodimeric molecule and consists of two subunits of 35-kDa (P35 or IL-12A) and 40-
kDa (P40 or IL-12B) (Fehr et al., 1997; Schijns et al., 1997; Cruse and Lewis, 2010). 
1.6.3.6 Interferon-γ 
IFN-γ is produced by activated CD4 Th1 cells, CD8 T cells and NK cells. IFN-γ-stimulated 
NK cells activate mononuclear phagocytes and can stimulate expression of class I and 
class II MHC and the differentiation of both B- and T-lymphocytes. IFN-γ is known to 
decrease in several diseases such as chronic lymphocytic leukemia, lymphoma and 
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infections with rubella, Epstein-Barr virus and cytomegalovirus (Argyle et al., 1995; 
Schijns et al., 1995; Schroder et al., 2004; Cruse and Lewis, 2010). 
1.6.3.7 Tumor necrosis factor-α 
TNF-α is produced by cells such as macrophages, monocytes, T and B lymphocytes and 
NK cells once stimulated by pathogens. TNF-α facilitates wound healing. Vascular 
endothelial cells are stimulated to express adhesion molecules and secretion of 
chemokines by macrophages and endothelial cells is induced by TNF-α (McGraw et al., 
1990; Cruse and Lewis, 2010).  
1.6.3.8 T helper 1/T helper 2/T helper 17 subgroups 
Helper T lymphocytes (Th cells) are subsets of CD4 cells that can be separated into 
functional groups. Naive T cells (Th0 cells) are differentiated into certain groups to 
facilitate the immune system by producing a distinct pattern of cytokines (Cruse and 
Lewis, 2010). Th1 cells are known to produce IFN-γ, IL-2 and TNF-β and are responsible 
for activation of NK cells, macrophages and CD8+ cells and for the delayed type 
hypersensitivity responses. Th2 cells produce a combination of IL-4, IL-5, IL-6, IL-9, IL-
10 and IL-13. Their main function is stimulation of B-cell, IgE and IgG humoral responses 
(Cruse and Lewis, 2010). The recently identified Th17 subgroup consists of cells that 
produce IL-17, which is an important cytokine in inflammatory and autoimmune 
diseases. IL-23, transforming growth factor (TGF) β, IL-6 and IL-7 appear to play an 
important role in Th17 production (Gaffen and Hajishengallis, 2008; Cruse and Lewis, 
2010). 
In cats with FCGS, the expression of IL-2, IL-4, IL-6, IL-10, IL-12 and IFN-γ was shown to 
be increased when compared to healthy cats (Harley et al., 1999). The profile in 
healthy cats is of a Th-1 type and in cats with FCGS there is a combined Th1/Th2 
profile. 
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1.7 Risk factors in FCGS 
Few studies have investigated the epidemiology of FCGS. Possible risk factors such as 
breed and age have been suggested (Frost and Williams, 1986; Tenorio et al., 1991; 
Diehl and Rosychuk, 1993). 
1.7.1 Age 
Gingivitis stomatitis pharyngitis has been described as most commonly seen in cats 
under the age of two and is gradually progressive (Diehl and Rosychuk, 1993). Age 
distribution among cats with FCGS has been assessed in a study in the UK (Healey et al., 
2007). In this study of 4858 cats visiting the veterinary practice, 34 were suffering from 
FCGS and two age peaks were seen in the cats with FCGS - one to five years and 10 to 
13 years. Also, the mean age of the cats with FCGS was higher (9 years) than the mean 
age of the non-FCGS cats (6.7 years) but this difference was not significant. In numerous 
studies a mean age of 6.9-8.3 years with a minimal age of 0.8 years and a maximum of 
15 years has been reported (Johnessee and Hurvitz, 1983; Hennet, 1997; Hennet et al., 
2011). 
1.7.2 Breed 
The proportion of different cat breeds suffering with FCGS has been described. Breeds 
that have been cited are Siamese, Himalayan, Burmese, Abyssinian and Persian (Frost 
and Williams, 1986; Diehl and Rosychuk, 1993). In the study of 4858 cats by Healey et 
al. (2007), no breed could be identified that appeared predisposed to FCGS. Of 34 cats, 
two were pedigree animals, a Siamese and a Persian. Out of the total population of cats 
the two most common pedigrees were also Siamese and Persian.  
1.7.3 Sex 
Sex has never been a suggested risk factor in FCGS and studies demonstrate an 
approximately equal distribution of male and female in cats with FCGS. In the 4858 cat 
population studied in the UK, 50% were female, 49% male and 1% unknown (Healey et 
al., 2007). Within the FCGS population 47% were female, 50% were male and 3% were 
unknown. This concurs with other studies which show a similar distribution (Johnessee 
and Hurvitz, 1983; White et al., 1992). 
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1.8 Aims 
The aims and objectives of the study were as follows: 
1. Identify the bacteria associated with a healthy oral cavity and FCGS in cats using 
conventional aerobic and anaerobic microbiological culture 
2. Identify the bacteria associated with a healthy oral cavity and FCGS in cats using 
16S ribosomal RNA (rRNA) gene sequencing and determine if fastidious 
3. Determine the prevalence of FCV, FIV, FHV and FeLV in each cohort 
4. Quantify the expression patterns of TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9 and 
cytokines IL-1β, TNF-α, IFN-γ, IL-2, IL-4, IL-6, IL-10 and IL-12 in oral tissue using 
quantitative PCR (qPCR) 
5. Using matched data arising from Aims 2 and 4, establish if associations exist 
between the presence and quantity of bacterial species and TLR expression 
6. Elucidate if bacterial/viral load and TLR expression levels correlate with the 
pattern of cytokine expression 
7. Explore the association of putative risk factors for FCGS in cats 
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Chapter 2 Materials and methods 
2.1 Ethical approval 
Ethical approval was obtained from the Local Research Ethics Committee to collect 
biopsies, swabs and blood samples from cats suffering from FCGS. For the healthy 
control samples, approval was given to collect saliva swabs. Biopsies and blood samples 
were collected from cats euthanatised for reasons unrelated to the oral cavity but that 
presented with a healthy oral cavity. 
2.2 Sample collection 
Samples were collected from cats with a clinical appearance and history of FCGS as 
described in Section 1.2.1.2. To exclude other oral diseases such as juvenile stomatitis 
and non-chronic forms of stomatitis (Williams and Aller, 1992), all cats were over 12 
months of age and the time since onset of the disease was at least two months. FCGS 
samples (32) were collected by two veterinary dentistry specialists from cats brought to 
the following veterinary clinics: Dental Vets in North Berwick (F2-F19) and Mulberry 
Court Veterinary Surgery in Sudbury (F20-F32) between March 2009 and December 2011. 
Sample F1 was collected at the School of Veterinary Medicine, University of Glasgow. 
Healthy control samples (16) were collected from cats at the School of Veterinary 
Medicine, University of Glasgow. Control swabs from healthy cats were also collected at 
a local veterinary practice. 
From each cat, three swab samples were collected; one sterile swab was placed into 
viral transport medium (VTM) (University of Glasgow, School of Veterinary Medicine, 
Glasgow, UK) and two sterile swabs were placed into anaerobic transport medium (ATM) 
(Barloworld Scientific, Staffs, UK). Each swab was taken from the palatoglossal folds of 
the oral cavity (Figure 1.1). Blood samples were collected from the cats following a 
standard protocol. A total of 3 ml blood was collected, from which 1 ml was transferred 
into a tube containing ethylenediaminetetra-acetic acid (EDTA) (Teklab, Durham, UK) 
and 2 ml into a tube containing heparin (Teklab). 
Tissue samples were collected from the caudal mucosa of the cats’ oral cavity. Two 
biopsies with a minimum size of 2 x 2 mm were collected. One of the biopsies was 
placed into RNAlater (Sigma-Aldrich, Irvine, UK) and one into 4% buffered 
paraformaldehyde. 
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From 18 cats with FCGS (F2–F19), swab, blood and tissue samples were obtained; from 
three cats (F20-22) blood and tissue samples were collected, one VTM and one ATM 
swab were obtained; from one cat with FCGS (F1) one ATM swab sample was collected; 
from seven cats with FCGS (F23-F28) complete blood samples, tissue biopsies and viral 
swabs were collected; from one cat (F29) VTM swabs, heparin blood and tissue biopsies 
were collected; from two cats with FCGS (F30, F31) tissue biopsies and VTM swabs were 
collected; from one cat (F32) complete blood samples and tissue biopsies were 
collected (Table 2.1). 
From one healthy cat (H1) one ATM swab sample was collected; from two healthy cats 
(H2, H5) blood and tissue samples were collected, one VTM and one ATM swab were 
obtained; from two healthy cats (H3, H15) one VTM swab, one ATM swab, tissue biopsies 
and heparin blood were collected; from three healthy cats (H4, H6, H14) one VTM swab, 
one ATM swab and tissue biopsies were collected; from seven healthy cats (H7-H13) two 
swabs, one ATM and one VTM were collected; from one healthy cat (H16), one VTM 
swab, tissue biopsies and blood samples were collected (Table 2.1). 
2.3 Sample processing 
The blood, one formalin sample, one ATM swab and the VTM swab were sent for 
diagnostic evaluation to the School of Veterinary Medicine, University of Glasgow. One 
ATM swab and the biopsy stored in RNAlater were sent to Glasgow Dental Hospital and 
School for laboratory analysis. 
Each ATM swab was immersed in 2 ml Fastidious Anaerobe Broth (FAB) (Bioconnections, 
Leeds, UK) and mixed for 30 s to remove bacteria. 1 ml of the mixed material was 
plated immediately, as described in Section 5.2.1.1, and 1 ml was stored at -20ºC until 
needed for DNA extraction. Each biopsy sample in RNAlater was stored at 4ºC until 
required for RNA extraction. 
2.4 Statistical analysis 
Throughout the thesis statistical analysis was performed using GraphPad Prism for 
Windows, version 5 (GraphPad Software Inc., San Diego, California, USA). For the 
comparison of two unpaired samples, continuous data with a normal distribution was 
analysed with a 2-sample t-test, the Mann-Whitney U test was used as a non-parametric 
test for continues data. All ordered data was analysed by a Mann-Whitney U test. For 
nominal data, a X2 test was used and binary data was also analysed by a X2 test, 
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however, when category numbers were below 5 in binary data, a Fisher’s exact test was 
used. In a few occasions, when more than 2 groups were compared, the non-parametric 
Kruskal-Wallis test was used with the Dunn’s comparison test as the post-hoc analysis. 
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Table 2.1: Sample collection from 32 cats with FCGS (A) and 16 healthy cats (B) 
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F1       H1      
F2       H2      
F3       H3      
F4       H4      
F5       H5      
F6       H6      
F7       H7      
F8       H8      
F9       H9      
F10       H10      
F11       H11      
F12       H12      
F13       H13      
F14       H14      
F15       H15      
F16       F16      
F17       
F18       
F19       
F20       
F21       
F22       
F23       
F24       
F25       
F26       
F27       
F28       
F29       
F30       
F31       
F32       
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2.5 List of suppliers 
Suppliers Product 
Affymetrix/USB, High Wycombe, UK Rapid Gel-XL-40% concentrate 
 
Agilent technologies, Cheshire, UK StrataClone™ PCR cloning kit  
 
BioConnections, Leeds, UK Fastidious anaerobe broth 
 
Cambio ltd, Cambridge, UK SequiTherm EXCEL™ II DNA  
 
E&O laboratories ltd, Bonnybridge, UK Defibrinated horse blood 
 
Fermentas Life Sciences, York, UK RsaI, MnlI restriction enzymes 
 
Fisher Scientific, Loughborough, UK Dimethyl sulfoxide (DMSO)  
Ethanol  
Sodium hydroxide (NaOH) 
Phosphate buffered saline (PBS) 
 
Invitrogen, Paisley, UK SuperScript™ first-Strand Synthesis 
System 
QPCR primers 
SYBR-Green Mastermix 
 
Lab M limited, Bury, UK Fastidious anaerobe agar 
 
MWG biotech, Milton Keynes, UK 357f IRD800 labelled primer 
 
New England Biolabs, Hitchin, UK 100 bp DNA marker 
dNTPs 
 
Promega, Southampton, UK 1 x GoTaq® PCR buffer 
1.5mM MgCl2  
GoTaq® polymerase 
 
Qiagen, Crawley, UK Qiaquick PCR Purification Kit 
RNeasy® RNA extraction kit 
 
Roche, Burgess Hill, UK Agarose 
 
Sigma Genosys, Cambridge, UK Primers 63F/1387R  
 
Sigma-Aldrich, Irvine, UK Ammonium persulphate  
Ampicillin  
Colombia agar 
Ethidium bromide  
Glycerol  
L-agar 
L-broth 
N,N,N’,N’ tetramethylethyl enediamine 
(TEMED) 
Urea 
 
Technical Service Consultants LTD, Heywood, UK PROTECT cryopreservation vials 
 
Thermoscientific, Epsom , UK Reddymix  
 
VWR, Lutterworth, UK 0.5 M Hydrogen chloride (HCl) 
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2.6 General stock solutions and buffers 
Columbia Blood Agar: 42 g powder dissolved in 1 litre dH2O. Sterilise by 
autoclaving. Cool to 50°C and add 7.5% defibrinated 
horse blood. 
 
Ethidium bromide (10 mg/ml): 10 g ethidium bromide, dH2O to 1 litre. 
Store away from light. 
 
Fastidious anaerobe blood agar: 46 g powder dissolved in 1 litre dH2O by swirling and 
mixing. Sterilise by autoclaving. Cool to 50°C and add 
7.5% defibrinated horse blood. 
 
Fastidious anaerobe broth : 29.7 g powder dissolved in 1 litre dH2O. Sterilise by 
autoclaving. 
 
L agar:  35 g powder dissolved in 1 litre dH2O. Sterilise by 
autoclaving. 
 
L Broth Medium : 25 g powder dissolved in 1 litre dH2O. Sterilise by 
autoclaving. 
 
4% Paraformaldehyde: 4 g paraformaldehyde dissolved at 70-80°C in 100 ml 1 
x PBS. Add 1 ml of 1M NaOH 
pH 7.2-7.4 
 
5M NaOH: 
 
200g NaOH, dH2O to 1 litre sterilise by filtration. 
Phosphate buffered saline (PBS): Dissolve one tablet in 100 ml dH2O. Sterilise by 
autoclaving 
 
Proteinase-K: Dissolve 100 mg powder in 5 ml nuclease-free water. 
Aliquot and store at -20°C. 
 
10x Tris/Borate/EDTA (TBE): 108 g Tris base 
55 g Boric Acid 
50 ml 0.2M EDTA (pH 8.0) 
dH2O to 1 litre 
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Chapter 3 Clinical signs and laboratory diagnostic 
evaluation 
3.1 Introduction 
FCGS is a poorly described disease. The clinical signs that are seen in cats with FCGS are 
mostly a direct result of the pain caused by the oral inflammation and include a poor 
appetite, dysphagia, weight loss, loss of grooming behaviour, excessive salivation, 
halitosis and pawing at the mouth (Southerden and Gorrel, 2007). Other oral pathologies 
are often seen in combination with FCGS, these include periodontal disease with 
calculus accumulation and feline odontoclastic resorption lesions (Hennet, 1997). The 
signalment of cats with FCGS has been sparsely studied with no evidence of sex, age or 
breed predisposition (Healey et al., 2007). 
The description of the oral lesions in FCGS has not been standardised and a variety of 
lesions can be seen. As described in Section 1.2.1.2, the most recent literature refers to 
the most severe and hard to treat chronic form of FCGS as having inflammation at two 
main sites; the tissue lateral to the palatoglossal folds and the attached mucosa at the 
premolar and molar area, extending to the buccal mucosa (Southerden, 2010; Hennet et 
al., 2011). Other sites in the oral cavity, such as the tongue and pharynx, can be 
affected but lesions in these areas are seen in less than a quarter of the patients 
(Johnessee and Hurvitz, 1983; White et al., 1992; Hennet, 1997; Healey et al., 2007; 
Bellei et al., 2008). 
The blood biochemistry and haematology data that has been described in cats with 
FCGS show features that can be expected in cases of chronic inflammation. Increases in 
the total protein and globulin concentration in the blood of cats with FCGS have been 
demonstrated (Johnessee and Hurvitz, 1983; White et al., 1992; Mihaljevic, 2003). 
Haematology often shows an elevated white blood cell count (WBCC) (Johnessee and 
Hurvitz, 1983; White et al., 1992). The differential WBCC in FCGS generally show an 
absolute lymphopenia and a neutrophilia with a mild left shift (Johnessee and Hurvitz, 
1983). 
In this chapter the signalment and the clinical signs of the cats with FCGS are described. 
The distribution of the inflammatory lesions in the oral cavity of the cats is reported 
and all biochemistry and haematology results of the cats with FCGS are evaluated. 
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3.2 Materials and methods 
3.2.1 History and clinical signs 
For each cat, where possible, detailed records were collected in the form of a 
questionnaire (Appendix). Signalment (age, sex and breed) and vaccination status were 
recorded and the cats’ owner together with the veterinarian and/or veterinary nurse 
completed the questionnaire. 
3.2.2 Oral examination 
An oral examination was performed under general anaesthesia. Concurrent oral diseases 
were recorded and full mouth radiographs were taken. The severity of plaque and 
calculus accumulation was recorded and the grade of periodontal disease assessed. 
Plaque accumulation was assessed according to the plaque index by Loë (1967): 
- Grade 0: No plaque in the gingival area. 
- Grade 1: Mild; a film of plaque adhering to the free gingival margin and adjacent 
area of the tooth. The plaque may only be recognized by running a probe across 
the tooth surface. 
- Grade 2: Moderate accumulation of soft deposits within the gingival pocket, on 
the gingival margin and/or adjacent tooth surface, which can be seen by the 
naked eye. 
- Grade 3: Severe; abundance of soft matter within the gingival pocket and/or on 
the gingival margin and adjacent tooth surface. 
Dental calculus was scored according to the following categories: 
- Grade 0: No dental calculus. 
- Grade 1: Supragingival with slight subgingival calculus accumulation. 
- Grade 2: Moderate subgingival calculus accumulation. 
- Grade 3: Abundant supragingival and/or subgingival calculus accumulation. 
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The scoring used for periodontal disease was as advised by the American Veterinary 
Dental College (AVDC) Nomenclature committee (http://avdc.org/nomenclature.html) 
(Wolf et al., 2005) and divided as follows: 
- Grade 0: Clinically normal. 
- Grade 1: Gingivitis only, without attachment loss. 
- Grade 2: Initial periodontitis, less than 25% attachment loss. 
- Grade 3: Moderate periodontitis, 25-50% attachment loss. 
- Grade 4: Severe periodontitis, more than 50% attachment loss. 
Tonsillitis was scored using the range of none, mild, moderate and severe tonsillitis 
according to visual signs of inflammation, ranging from mild swelling and redness to 
exudate and necrotic foci. The degree of mucosal inflammation in the oral cavity was 
scored according to a modified version of the gingival index (Loe, 1967): 
- Grade 0: No inflammation; pale pink to pink mucosal tissue. 
- Grade 1: Mild inflammation; reddened, may include slight oedema. 
- Grade 2: Moderate inflammation; severe redness, oedema. 
- Grade 3: Severe inflammation; severe redness and oedema, ulceration and 
hypertrophy. 
The degree of mucosal inflammation was scored for each of the following anatomical 
sites in the feline oral cavity (Figure 1.1): 
- Maxillary buccal mucosa. 
- Mandibular buccal mucosa. 
- Maxillary attached gingiva. 
- Mandibular attached gingiva. 
- Mucosa lateral to the palatoglossal folds. 
- Molar salivary gland. 
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- Oropharynx. 
- Lingual/sublingual mucosa. 
3.2.3 Blood biochemistry and haematology 
Blood biochemistry values and haematology results, including blood smears, were 
assessed by the Veterinary Diagnostics Service, School of Veterinary Medicine, 
University of Glasgow. The tested profiles and the reference range can be found in 
Tables 3.1 and 3.2. 
3.2.4 Statistics 
Graphical representations and statistics of clinical signs and signalment were prepared 
in GraphPad Prism for Windows, version 5 (GraphPad Software Inc., San Diego, 
California, USA). 
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Table 3.1: Biochemistry profile used by the Veterinary Diagnostic Service 
 
Biochemistry Abbreviation 
Reference 
range 
Unit 
Sodium  145-160  mmol/l 
Potassium  2.6-5.2  mmol/l 
Sodium:Potassium ratio  27-  
Chloride  94-120  mmol/l 
Calcium  1.6-2.65  mmol/l 
Phosphate  1.29-2.84  mmol/l 
Urea  2.7-9.2  mmol/l 
Creatinine  91-180  µmol/l 
Cholesterol  1.8-5.2  mmol/l 
Triglyceride  -0.6  mmol/l 
Total Bilirubin  -10  µmol/l 
Alkaline Phosphatase ALK phos -100  U/l 
Aspertate aminotransferase AST -30  U/l 
Alanine aminotransferase ALT -35  U/l 
Gamma-glutamyl transferase GGT -15  U.l 
Total Protein  60-85  g/l 
Albumin  26-36  g/l 
Globulin  27-45  g/l 
Albumin:Globulin ratio  0.6-1.5  
 
Table 3.2: Haematology profile used by the Veterinary Diagnostic Service 
 
Heamatology Abbreviation 
Reference 
range 
Unit 
Red blood cell count RBCC 5.0-10.0 x10 E12/l 
Haemoglobin Hb 10.0-15.0 g/dl 
Haematocrit HCT 30-45 % 
Mean corpuscular volume MCV 39.0-55.0 fl 
Mean corpuscular haemoglobin MCH 12.5-17.5 pg 
Mean corpuscular haemoglobin concentration MCHC 30.0-36.0 g/dl 
White blood cell count WBCC 5.5-15.5 x10 E9/l 
Band Neutrophils  0.00-0.3 x10 E9/l 
Neutrophils  2.5-12.5 x10 E9/l 
Lymphocytes  1.5-7.0 x10 E9/l 
Monocytes  0.00-0.85 x10 E9/l 
Eosinophils  0.00-1.50 x10 E9/l 
Basophils  0.00-0.1 x10 E9/l 
Normoblasts   x10 E9/l 
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3.3 Results 
3.3.1 Signalment 
A total of 32 cats with FCGS and 16 healthy cats were included in the study. The mean 
age of the cats with FCGS was 7.6 years, standard deviation (SD) 4.5 years with a 
minimum age of 1 year and a maximum of 17 years. Most cats fell into the age category 
of 5-10 years old (61-119 months). The mean age of the healthy cats was 6.7 (SD 3.6) 
with a minimum age of 1.2 years and a maximum age of 13 years (Table 3.3 and 3.4, 
Figure 3.1). Nineteen cats from the FCGS group were male (17 neutered) and 12 cats 
were female (10 neutered). The sex of one cat was unknown. Six of the healthy cats 
were male (four neutered) and seven were female (five neutered). The sex of two 
healthy cats was unknown (Table 3.3, Figure 3.2). The majority of cats were domestic 
shorthair (DSH). In the FCGS group 77.4% were DSH and 19.4% were pedigree cats. In the 
healthy group 93.3% of the cats were DSH and one cat (6.7%) was pedigree (Table 3.3). 
3.3.2 Vaccination status 
The vaccination status was recorded for 22 of the cats from the FCGS group. Sixty-eight 
percent of these cats were vaccinated every 12-18 months. All vaccinated cats received 
vaccines for FCV, FHV-1 and feline panleukopenia virus (FPV). A total of 45.5% of the 
cats were vaccinated against FeLV and 9.1% of the cats were vaccinated against 
Chlamydophila felis. 27.3% of the cats were not regularly vaccinated and the 
vaccination status of one cat was unknown (Table 3.5). 
3.3.3 Clinical signs 
The clinical signs of 22 cats with FCGS were recorded. The signs that were most often 
recorded when the cats were presented to the veterinarian included halitosis in 54.6% 
of the cats, excessive salivation in 40.9%, dysphagia in 40.9%, weight-loss in 40.9% and a 
change in grooming behaviour in 40.9%. Thirty-two percent of the cats did not exhibit 
any of these features. The maximum number of clinical signs seen together was nine out 
of the eleven described signs (in cat F18) (Tables 3.6 and 3.7). 
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3.3.4  Previous medication 
All cats in the current study received previous medication. Treatment of 20 cats with 
known history is shown in Table 3.8 and 3.9. Time since last treatment for antibiotics is 
shown on the date of the last tablet or two weeks after cefavecin injection, when 
action of the injection ends. Cats receiving treatment within two weeks prior to 
sampling were; 9 cats treated with antibiotics, 8 cats treated with NSAID’s, one cat 
treated with corticosteroids and one cat treated with Interferon-ω. 
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Figure 3.1: Age distribution in 31 cats with FCGS and 14 healthy cats 
 
 
Table 3.3: Signalment of sampled cats 
FCGS Healthy 
Cat ID Age 
(months) 
Breed Sex Cat ID Age 
(months) 
Breed Sex 
F1 - - - H1 - - - 
F2 164 Siamese cross FN H2 96 Domestic shorthair M 
F3 104 Domestic shorthair MN H3 35 Domestic shorthair MN 
F4 164 Siamese MN H4 156 Domestic shorthair FN 
F5 90 Domestic shorthair MN H5 88 Domestic shorthair FN 
F6 47 Norwegian forest MN H6 32 Domestic shorthair MN 
F7 113 Domestic shorthair MN H7 51 Domestic shorthair F 
F8 14 Maine Coon MN H8 85 Domestic shorthair FN 
F9 66 Domestic shorthair FN H9 75 Domestic shorthair F 
F10 48 Domestic shorthair F H10 35 Domestic shorthair FN 
F11 80 Domestic shorthair MN H11 14 Maine Coon F 
F12 12 Domestic shorthair MN H12 88 Domestic shorthair MN 
F13 21 Domestic shorthair FN H13 115 Domestic shorthair MN 
F14 40 Domestic shorthair MN H14 - Domestic shorthair - 
F15 87 British shorthair FN H15 131 Domestic shorthair FN 
F16 70 Domestic shorthair FN H16 131 Domestic shorthair M 
F17 114 Siamese MN     
F18 65 Domestic shorthair FN     
F19 90 Domestic shorthair FN     
F20 155 Siamese MN     
F21 72 Domestic shorthair MN     
F22 15 Domestic shorthair M     
F23 70 Domestic shorthair MN     
F24 204 Domestic shorthair F     
F25 126 Domestic shorthair FN     
F26 17 Domestic shorthair MN     
F27 43 Domestic shorthair MN     
F28 156 Domestic shorthair MN     
F29 120 Domestic shorthair FN     
F30 111 Domestic shorthair M     
F31 168 Domestic shorthair FN     
F32 168 Domestic shorthair MN     
Signalment of 32 cats with FCGS and 16 control cats, F: female; FN: female neutered; M: male; 
MN: male neutered, -: no data available. 
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Table 3.4: Column statistics of the age in years 
 FCGS Healthy 
Number of values 31 14 
     
Minimum 1.000 1.167 
25% Percentile 3.917 2.917 
Median 7.250 7.208 
75% Percentile 10.50 9.917 
Maximum 17.00 13.00 
     
Mean 7.565 6.738 
Std. Deviation 4.486 3.594 
Std. Error 0.8058 0.9605 
     
Lower 95% CI of mean 5.919 4.663 
Upper 95% CI of mean 9.210 8.813 
Statistics of ages of 31 cats with FCGS and 14 healthy cats. 
 
Figure 3.2: Sex distribution of 31 cats with FCGS and 14 healthy cats 
 
M: male; MN: male neutered; F: female; FN: female neutered. 
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Table 3.5: Vaccination status 
 Total vaccinated 
cats 
(%) 
FCV 
(%) 
FHV-1 
(%) 
FPV 
(%) 
FeLV 
(%) 
CF 
(%) 
Unknown 
(%) 
Regular  68.2 68.2 68.2 68.2 45.5 9.1  
Non-regular  27.3 4.5 4.5 4.5 4.5  22.7 
Unknown  4.5      4.5 
Percentage of 22 cats with FCGS vaccinated against FCV, FHV-1, feline panleukopenia virus 
(FPV), FeLV and Chlamydophila felis (CF) every 12-18 months (regular) or over 18 months ago at 
the time of sampling (non-regular). 
 
Table 3.6: Clinical signs shown by each individual cat 
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F2             
F3             
F4             
F5             
F6             
F7             
F8             
F9             
F10             
F11             
F12             
F13             
F14             
F15             
F16             
F17             
F18             
F19             
F22             
F27             
F29             
F32             
Clinical signs for individual cats (F#), for which data was available shown in black marked cells. 
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Table 3.7: Clinical signs 
Clinical signs: % of cats showing signs 
Halitosis 54.6 
Excessive salivation 40.9 
Dysphagia 40.9 
Weight loss 40.9 
Change in grooming behaviour 40.9 
Pawing at the mouth 31.8 
Ungroomed coat 22.7 
Vomiting/retching 22.7 
Anorexia 13.6 
Facial swelling 13.6 
Change in drinking behaviour 9.1 
Pyrexia 0 
No signs 31.8 
The percentage of the 22 cats with FCGS which show the described clinical signs. 
 
Table 3.8: Days since medication before sample taking 
Cat ID Days since last 
antibiotic 
Days since last 
NSAID 
Days since last 
corticosteroid 
Days since last 
Interferon-ω  
F2 265 27 308 82 
F3 52 5 N.A. N.A. 
F4 0 7 42 N.A. 
F5 13 17 13 16 
F6 70 21 99 N.A. 
F7 18 10 18 N.A. 
F8 4 48 21 N.A. 
F9 4 4 380 N.A. 
F10 2 12 63 N.A. 
F11 175 9 242 367 
F12 41 N.A. N.A. N.A. 
F13 116 N.A. N.A. N.A. 
F14 113 N.A. N.A. 105 
F15 3 3 N.A. N.A. 
F16 13 27 20 20 
F17 169 155 62 N.A. 
F18 8 11 238 3 
F19  151 151 31 N.A. 
F28 6 38 126 N.A. 
F33 41 553 41 N.A. 
Days since the last antibiotic tablet/injection, NSAID injection/dispense of oral suspension, 
corticosteroid injection/tablet and/or interferon injection/dispense of oral solution were given. 
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Table 3.9: Last supplied medication before sample taking 
 Antibiotics NSAIDs Corticosteroid 
F2 Clindamycin capsules Meloxicam suspension Methylprednisolone inj. 
F3 Clindamycin capsules Meloxicam suspension N.A. 
F4 Clindamycin capsules Meloxicam suspension Methylprednisolone inj. 
F5 Clindamycin capsules Meloxicam suspension Prednisolone tablets 
F6 Enrofloxacin tabl. Meloxicam suspension Methylprednisolone inj. 
F7 Cefovecin inj. Meloxicam inj. Methylprednisolone inj. 
F8 Amoxycillin/Clavulanate 
tabl. 
Meloxicam suspension Methylprednisolone inj. 
F9 Cefovecin inj. Meloxicam suspension Dexamethasone inj. 
F10 Clindamycin capsules Meloxicam suspension Methylprednisolone inj. 
F11 Cefovecin inj. Meloxicam suspension Dexamethasone inj. 
F12 Cefovecin inj. N.A. N.A. 
F13 Clindamycin capsules N.A. N.A. 
F14 Amoxycillin/Clavulanate 
tabl. 
N.A. N.A. 
F15 Cefovecin inj. Meloxicam suspension N.A. 
F16 Amoxycillin/Clavulanate 
inj. 
Meloxicam suspension Dexamethasone inj. 
F17 Cefovecin inj. Meloxicam suspension Methylprednisolone inj. 
F18 Cefovecin inj. Meloxicam inj. Methylprednisolone inj. 
F19  Amoxicillin inj. Meloxicam inj. Dexamethasone inj. 
F28 Amoxicillin inj. Meloxicam suspension Prednisolone tablets 
F33 Cefovecin inj. Meloxicam inj. Depomedrone 
Inj: injection, tabl.: tablet 
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3.3.5 Tooth health assessment 
Plaque accumulation was recorded in 12 cats with FCGS. Sixty-six percent of the cats 
showed a moderate accumulation of plaque. No plaque accumulation was noted in 8.3% 
of cats suffering from FCGS (Table 3.10A). 
Accumulation of dental calculus was recorded in 21 cats with FCGS. No calculus was 
seen in 23.8% of these cats. Mild accumulation was recorded in 28.6% of the cats, as was 
moderate accumulation, and 19.1% showed severe accumulation of calculus (Table 
3.10A).  
The presence and severity of tonsillitis was recorded in 12 cats with FCGS. Sixty-seven 
percent of the cats did not show signs of tonsillitis during physical examination of the 
oral cavity. Twenty-five percent had mild tonsillitis, 8.3% had moderate tonsillitis and 
none of the cats had severe tonsillitis at the time of examination (Table 3.10A).  
All 21 cats that had an assessment of periodontal disease, showed at least grade 1 
periodontal disease (gingivitis). Ten percent of the cats showed grade 2 and 33% showed 
grade 3 periodontal disease. Severe periodontal disease (grade 4) was not recorded in 
combination with FCGS (Table 3.10B). 
The presence of TR lesions in combination with FCGS was assessed in 21 cats. Of these 
cats, 33% showed TR lesions (Table 3.10C). 
3.3.6 Severity of oral inflammation 
Recordings were made of the location and the severity of oral inflammation in 21 cats 
with FCGS (Table 3.11). In 19 cats at least one of the assessed locations was severely 
inflamed. Two of the eight assessed sites were most often severely inflamed; the 
maxillary attached gingiva and the mucosa lateral to the palatoglossal folds (Figure 3.3 
and 3.4). At these two locations, grade 3 inflammation was recorded in 66.7% of the 
cats. Moreover, none of the cats was free of inflammation in these areas and these two 
locations showed at least mild inflammation in all 21 cats (Table 3.12). 
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Table 3.10: Clinical examination results 
A 
 None 
(% of cats) 
Mild 
(% of cats) 
Moderate 
(% of cats) 
Severe 
(% of cats) 
 
Plaque 
 
8.3 16.7 66.7 8.3  
Calculus 
 
23.8 28.6 28.6 19.1  
Tonsillitis 
 
66.7 25 8.3 0  
B 
 Grade 0 
(% of cats) 
Grade 1 
(% of cats) 
Grade 2 
(% of cats) 
Grade 3 
(% of cats) 
Grade 4 
(% of cats) 
Periodontal disease 
 
0 57.1 9.5 33.3 0 
C 
 Present 
(% of cats) 
Not present 
(% of cats) 
   
Tooth resorption 
lesions  
33.3 66.7    
A: The severity of plaque (12 cats) and calculus (21 cats) accumulation and the presence of 
tonsillitis (12 cats) shown as a percentage of cats assessed. B: The grade of periodontal disease 
present (21 cats), as a percentage of cats assessed. C: Percentage of 21 cats assessed that were 
recorded to have tooth resorption lesions in combination with FCGS. 
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 Figure 3.3: Intra-oral photograph of severe FCGS 
 
Intra-oral photograph after anaesthetic premedication of case F7 showing severe involvement of 
the attached gingiva and mucosa lateral to the palatoglossal folds. 
Figure 3.4: Side view of severe FCGS 
 
Intra-oral photograph after anaesthetic premedication of case F7 showing severe involvement of 
attached gingiva and buccal mucosa. 
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Table 3.11: Inflammation severity for each anatomical site for each affected cat 
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F2                                 
F3                                 
F4                                 
F5                                 
F6                                 
F7                                 
F8                                 
F9                                 
F10                                 
F11                                 
F12                                 
F13                                 
F14                                 
F15                                 
F16                                 
F17                                 
F18                                 
F19                                 
F22                                 
F27                                 
F32                                 
Severity of inflammation for each individual cat (F#) for which data was available shown in black 
marked cells; 0: no inflammation; 1: mild inflammation; 2: moderate inflammation; 3: severe 
inflammation. 
 
Table 3.12: Inflammation severity at each assessed site 
Inflamed site None 
(%) 
Mild 
(%) 
Moderate 
(%) 
Severe 
(%) 
Maxillary buccal mucosa 14.3 4.8 42.9 38.1 
Mandibular buccal mucosa 28.6 19.1 19.1 33.3 
Maxillary attached gingiva 0 23.8 9.5 66.7 
Mandibular attached gingiva 4.8 14.3 28.6 52.4 
Lateral to the palatoglossal folds 0 14.3 19.1 66.7 
Molar salivary gland 52.4 14.3 19.1 14.3 
Oropharynx 76.2 14.3 9.5 0 
Lingual/sublingual mucosa 81.0 4.8 4.8 9.5 
Percentages of inflammation severity per site in 21 cats with FCGS. 
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The two oral sites that were least affected were the oropharynx and lingual mucosa. 
These two locations were free of inflammation in 76.2% and 81.0% of the cats, 
respectively. In the oropharynx no severe inflammation was recorded and only two out 
of 21 cats showed severe inflammation at the lingual or sublingual mucosa (Tables 3.11 
and 3.12). 
The molar salivary gland area showed no signs of inflammation in 52.4% of cases. A 
variety of mild, moderate and severe inflammation was seen in the rest of the cases. 
The other assessed sites, the maxillary and mandibular buccal mucosa and the 
mandibular attached gingiva, showed signs of mild, moderate or severe inflammation in 
the majority of cases (Tables 3.11 and 3.12). 
3.3.7 Blood biochemistry 
The blood biochemistry results of 29 cats are shown in Figure 3.5 and Table 3.13. 
Sodium, potassium and sodium:potassium ratios were within the reference ranges in 
100%, 86.2% and 93.1% respectively of the 29 cats tested. An increase in potassium was 
seen in four cats and a decrease of the ratio in two of these four cats. Chloride levels 
were increased in two cats (6.9%). One cat (3.4%) showed a slight increase in calcium 
levels. Phosphate levels were decreased in three cats (10.3%) and increased in one cat 
(3.4%). Urea and creatinine levels were increased in 13 cats (44.8%) and 2 cats (6.9%) 
respectively. Cholesterol levels were increased in two cats (6.9%) and triglyceride 
values increased in nine (31.0%) of the tested cats. Alkaline phosphatase (ALP) levels 
were increased in two cats (6.9%). Aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) concentrations were both above the reference range in 18 cats 
(62.1%). The total protein concentration was above the reference range in five cats 
(17.2%). Albumin levels were decreased in 11 cats (37.9%) and globulin levels were 
increased in 14 cats (48.3%). The albumin-globulin ratio was decreased in 14 cats 
(48.3%). Total bilirubin and γ-glutamyl transpeptidase (GGT) levels were within the 
reference range in all cats. 
  
Chapter 3 Clinical signs and laboratory diagnostic evaluation 56 
 
Figure 3.5: Blood biochemistry results 
 
The number of cats with blood biochemical values within, above or below the reference range. 
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 Table 3.13: Biochemistry blood results of 29 cats with FCGS 
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Ref 
Range 
145-
160 
2.6-
5.2 
27- 
94-
120 
1.6-
2.65 
1.29-
2.84 
2.7-
9.2 
91-
180 
1.8-
5.2 
-0.6 -10 -100 -30 -35 -15 
60-
85 
26-
36 
27-
45 
0.6-
1.5 
F2 151.8 4.95 30.7 119.3 2.48 1.92 16.1 219 3.63 0.28 2.9 42 15 44 0 67 23 44 0.52 
F3 155.7 2.85 54.6 119.9 2.44 0.74 9.5 148 2.35 1.53 4.4 61 23 33 0 60 30 30 1 
F4 156.3 4.33 36.1 115.3 2.25 1.61 9.1 108 4.27 0.18 1.7 80 65 334 0 70 29 41 0.71 
F5 150.2 4.22 35.6 116.8 2.35 1.55 7.9 117 4.94 0.71 0.7 52 20 28 0 67 30 37 0.81 
F6 150.9 3.17 47.6 113 2.42 1.61 9 121 4.2 1.11 0 42 20 27 0 69 27 42 0.64 
F7 149.1 3.79 39.3 110.8 2.3 1.26 6.8 133 2.56 0.27 0.4 33 29 26 2 95 22 73 0.3 
F8 150.3 5.5 27.3 111.8 1.74 1.79 6.3 130 2.71 0.48 0 34 25 33 0 81 28 53 0.5 
F9 151.9 4.8 31.6 109.9 2.12 2.36 6.4 91 4.1 0.14 3 9 43 71 2 86 27 59 0.5 
F10 148.4 3.8 39.1 111.8 2.41 1.69 10.2 122 2.83 0.49 0 20 44 22 1 87 25 62 0.4 
F11 146.8 5 29.4 112.8 2.14 2.47 9.1 129 4.29 0.09 1 13 42 29 0 82 22 60 0.4 
F12 149.7 4.7 31.9 111.6 2.5 2.27 11.6 151 5.34 0.23 1 158 29 39 0 71 32 39 0.8 
F13 156.9 4.6 34.1 114.6 2.41 2.01 8.9 126 1.93 0.12 2 46 48 45 0 80 34 46 0.7 
F14 147.6 4 36.9 111.8 2.46 1.44 9.1 152 5.04 0.18 1 37 44 68 0 72 30 42 0.7 
F15 149.3 4.4 33.9 113 2.19 1.68 10 143 3.64 0.15 2 42 47 63 0 76 24 52 0.5 
F16 151.5 3.4 44.6 118.5 2.39 1.24 5.5 90 3.32 0.14 2 47 24 50 0 70 31 39 0.8 
F17 152.9 3.6 42.5 114.5 2.38 1.35 12.4 117 3.16 0.33 0 46 42 83 2 78 29 49 0.6 
F18 148.6 4 37.2 116.5 2.16 1.54 7 131 3.01 0.31 0 3 28 31 0 91 20 71 0.3 
F19 146.8 4.7 31.2 112 2.3 1.9 7.2 135 2.19 0.61 4 67 20 35 0 60 27 33 0.8 
F20 149.5 4.5 33.2 113.6 2.32 1.69 11.5 223 4.19 1.14 0 70 42 74  77 27 50 0.5 
 Table 3.13 continued 
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Ref 
Range 
145-
160 
2.6-
5.2 
27- 
94-
120 
1.6-
2.65 
1.29-
2.84 
2.7-
9.2 
91-
180 
1.8-
5.2 
-0.6 -10 -100 -30 -35 -15 
60-
85 
26-
36 
27-
45 
0.6-
1.5 
F21 147.2 6.9 21.3 113.4 2.18 3.14 10.2 128 3.36 0.44 1 38 81 51 2 77 24 53 0.5 
F22 155.5 5.2 29.9 116 2.67 2.33 8.8 116 5.38 0.22 1 104 76 68 1 74 35 39 0.9 
F23 149.8 4.9 30.6 114.9 2.29 1.46 9.1 103 3.86 1.47 3 47 56 72 3 70 27 43 0.6 
F24 149.7 4.5 33.3 123.7 1.81 2.11 8.5 122  0.26 10 6 50 63 6 62 18 44 0.4 
F25 145 5.2 27.9 119.1 2.11 2.13 11.7 173 3.69 0.52 2 47 43 79 0 69 19 50 0.4 
F26 149.6 6 24.9 116.8 2.25 2.64 9.3 172 2.25 0.36 3 76 47 44 0 67 24 43 0.6 
F27 149.4 4 37.4 114.6 2.21 1.71 9.9 91 2.34 1 0 35 30 29 0 82 27 55 0.5 
F28 147.9 4.4 33.6 115.1 2.25 2.84 12.4 162 2.81 0.34 1 49 40 41 0 66 25 41 0.6 
F29 154 5.4 28.5 120.1 2.23 1.86 7.3 101 3 1.01 0 54 47 30 0 60 28 32 0.9 
F32 150.7 4.4 34.3 115.5 2.35 1.65 10 162 3.97 0.78 0 68 34 41 1 91 29 62 0.5 
Values above reference range (purple), values below reference range (green). ALP: alkaline phosphatase, AST: aspartate aminotransferase, ALT: alanine 
aminotransferase, GGT: glutamyl transpeptidase. 
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3.3.8 Haematology results 
The haematology results of 28 cats are shown in Figure 3.6 and Table 3.14. The 
hematocrit (HCT) and haemoglobin (Hb) values were below the reference range in 15 
(53.6%) and 16 (57.1%) of cats respectively. In addition, the red blood cell count (RBCC) 
was below the reference range in four cats (14.3%). The mean cell volume (MCV), mean 
cell haemoglobin (MCH) and mean cell haemoglobin concentration (MCHC) were within 
the reference ranges in 89.3-96.4% of the tested cats.  
The WBCC was below the reference range in 3 cats (10.7%) and was above the reference 
range in six cats (21.4%). Lymphocyte numbers were below the reference range in 13 
cats (46.4%). Neutrophils, eosinophils and monocytes were increased in number in 4 
(14.3%), 2 (7.1%) and 1 (3.6%) of the cats with FCGS respectively. Band neutrophils were 
detected in six cats (21.4%) but were all within the reference range. Basophils were 
detected in six cats (21.4%), and were above the reference range in three cats (10.7%). 
Normoblasts were present in one cat (3.6%). 
Blood smear analysis showed a poorly regenerative anaemia in 14 cats (50%). Increased 
rouleaux formation was seen in 15 cats (53.6%). Six cats (21.4%) showed a mild toxic 
change in the neutrophils. Spiculing was seen in 13 cats (46.4%) but was noted as a 
possible artefact in 10 cats (35.7%) (Table 3.15). 
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Figure 3.6: Haematology results 
 
The number of cats with blood results within, above or below the reference ranges. 
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 Table 3.14: Haematology results of 28 cats with FCGS 
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range 
5.0-
10.0 
10.0-
15.0 
30-45 
39.0-
55.0 
12.5-
17.5 
30.0-
36.0 
5.5-
15.5 
0.00-
0.3 
2.5-
12.5 
1.5-7.0 
0.00-
0.85 
0.00-
1.50 
0.00-
0.1 
 
F2 5.29 6.5 21.5 40.6 12.3 30.3 8.34 - 7.423 0.5 0.197 0.25 0 - 
F3 7.17 9.7 29.7 41.4 13.6 32.8 7.56 0.076 6.88 0.302 0.151 0.076 0.076 - 
F4 6.4 10.5 33.4 52.2 16.4 31.5 6.51 - 5.989 0.26 0.13 0.13 0 - 
F5 4.32 6.1 18.6 43.1 14.2 33 4.72 - 2.738 1.322 0.378 0.142 0 - 
F6 5.86 8.3 25.2 43 14.2 33 10.25 - 7.38 1.948 0.41 0.512 0 - 
F7 7.07 10.2 31.3 44.2 14.4 32.6 8.94 0.089 5.811 1.788 0.805 0.447 0 - 
F8 8.12 12.2 37.1 45.7 15.1 33 10.9 - 8.611 0.545 0.645 0.981 0.109 - 
F9 8.45 10.4 34.1 40.3 12.3 30.6 20.25 - 18.427 1.418 0.203 0.203 0 - 
F10 5.31 7.7 24.8 46.7 14.5 31 13.52 - 10.005 2.298 0.27 0.946 0 - 
F11 5.97 8.4 26.2 43.8 14.1 32.2 16.62 - 12.465 2.659 0.499 0.665 0.332 - 
F12 10.09 13.1 37 36.7 12.9 35.2 7.64 0.153 2.598 4.584 0.229 0.076 0 0 
F13 7.57 11.6 34.9 46.1 15.4 33.4 6 - 4.2 1.5 0.24 0.06 0 - 
F14 8.03 12.1 36.9 46 15 32.7 5.54 - 3.601 1.662 0.111 0.166 0 - 
F15 7.4 9.6 28.7 38.7 13 33.4 6.3 - 3.843 2.142 0.126 0.189 0 - 
F16 5.89 9.8 28.9 49.1 16.6 33.8 6.06 - 4.484 1.091 0.182 0.303 0 - 
F17 6.36 10.9 33.7 53.1 17.1 32.3 11.26 - 9.909 0.788 0.338 0.225 0 - 
F18 4.86 8.1 25 51.4 16.7 32.5 13.57 - 10.042 1.9 0.95 0.543 0.136 - 
F19 8.12 12.2 38.2 47.2 15 31.8 4.49 - 3.637 0.359 0.225 0.225 0.045 - 
 Table 3.14 continued 
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15.5 
0.00-
0.3 
2.5-
12.5 
1.5-7.0 
0.00-
0.85 
0.00-
1.50 
0.00-
0.1 
 
F20 7.52 11.6 35.1 46.6 15.4 33.1 15.93 - 11.948 1.912 0.159 1.752 0 0.159 
F21 6.49 9.5 30.7 47.4 14.6 30.9 17.24 - 14.309 0.69 0.172 2.069 0 - 
F22 7.38 11.2 33.8 45.8 15.2 33.2 8.93 0.268 7.055 1.072 0.179 0.357 0 0 
F23 5.77 9 27.6 47.8 15.6 32.7 13.63 - 11.177 1.363 0.545 0.545 0 - 
F24 3.12 5.5 14.3 45.7 17.6 38.5 20.4 - 13.464 4.896 0.816 1.224 0 - 
F25 3.32 5.5 14 42.2 16.5 30.7 7.58 - 3.411 2.729 0.227 1.213 0 - 
F26 6.48 10.3 31.6 48.7 15.9 32.6 6.47 0.194 4.205 1.876 0 0.129 0.065 - 
F27 5.24 8 23.2 44.3 15.2 34.3 20.68 - 14.269 5.584 0.207 0.62 0 - 
F28 5.79 8.3 24.2 41.8 14.3 34.3 4.94 - 4.501 0.593 0.099 0.198 0 - 
F32 8.6 12.5 39.6 46.1 14.5 31.5 13.27 0.133 10.351 1.99 0.531 0.265 0 - 
Values above reference range (purple), values below reference range (green). RBC: red blood cell count, Hb: haemoglobin, HCT: hematocrite, MCV: mean cell 
volume, MCH: mean cell haemoglobin, MCHC: mean cell haemoglobin concentration, WBC: white blood cell count. -: no value provided by the laboratory. 
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Table 3.15: Blood smear analysis 
Findings % of cats 
Poorly regenerative anaemia 50 
Increased rouleaux formation 53.6 
Mild toxic change 21.4 
Poikilocytes 14.3 
Acanthocytes 10.7 
Platelets above reference range 3.6 
Heinz body formation 3.6 
Keratocytes 3.6 
Lymphoblasts 3.6 
Plasmacytoid-lymphoid 3.6 
Schistocytes 3.6 
Spiculing  10.7 
Spiculing, possible artefact 35.7 
Description of findings in blood smears of 28 cats with FCGS. 
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3.4 Discussion 
Investigations of the signalment of cats suffering from FCGS are sparse. It has been 
suggested that gingivitis/stomatitis/pharyngitis is mostly seen in young cats and is 
gradually progressive (Diehl and Rosychuk, 1993). In a UK study of 34 cats with FCGS, 
two age peaks were seen, 1 to 5 years and 10 to 13 years (Healey et al., 2007). A non-
significant increase in age was seen in the group of cats with FCGS when compared to a 
random group of cats visiting the veterinary surgery. In the current study, the FCGS 
affected cats had a non-significant increase in age when compared to the healthy cats. 
The age distribution was similar in cats with FCGS and healthy cats. The age distribution 
differed from the results found by Healey et al. (2007) with most of the cats with FCGS 
in the current study being in the category of 5 to 10 years (61-119 months). The mean 
age in the present study of 7.6 years is comparable to other studies that show the age 
of cats with FCGS. Mean ages of 8.3 (Johnessee and Hurvitz, 1983), 7.1 (White et al., 
1992) 8 (Hennet, 1997), 6.9 and 8.2 years (Hennet et al., 2011) have been described.  
As described in Section 1.7.2, a variety of breeds including Siamese, Himalayan and 
Burmese have been suggested as being predisposed to FCGS (Frost and Williams, 1986; 
Diehl and Rosychuk, 1993). The current study showed a higher percentage of pedigree 
cats in the FCGS population when compared to a random group of 4858 cats visiting a 
veterinary surgery (Healey et al., 2007). In the current study, pedigree cats accounted 
for six (19.4%) of the 31 cats where the breed was recorded, compared to 482 (9.9%) of 
the 4858 cats studied by Healey et al. (2007). Siamese was the most prevalent breed. Of 
31 cats with FCGS a total of four cats (12.9%) were Siamese or Siamese cross. Healey et 
al. (2007) reported that Siamese cats accounted for 93 (2%) of the total population of 
cats visiting a veterinary surgery. Although the present study shows a higher number of 
pedigree cats in the FCGS group, any breed predisposition remains questionable. The 
cases in this study were collected from a veterinary specialist and it is possible that a 
higher proportion of pedigree cats will be visiting a referral practice as compared to a 
first opinion practice as studied by Healey et al. (2007). 
The sex distribution of cats with FCGS normally shows a proportion of female and male 
cats comparable to the normal population (Johnessee and Hurvitz, 1983; White et al., 
1992; Healey et al., 2007). In this study a slightly higher proportion of male cats were 
seen, 19 (61.3%) of 31 cats for which the sex was recorded. This could be due to the 
small group of cats that was studied. An interesting finding was that a high proportion 
(83%) of the purebred cats with FCGS were male.  
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The source of the samples in a referral practice makes previous treatment from the first 
opinion practice inevitable. The cats shown in this study did not respond to initial 
treatment, which often includes antibiotics and steroid therapy. Any treatment given 
could have interfered with the results in the study. For the immunology and 
histopathology results corticosteroid treatment and interferon-ω are of importance. 
While all cats were showing the clinical signs of FCGS during time of sample taking, 
these immune modulators can interfere with the results. Five cats in the cohort 
received corticosteroids within one month of sample taking, and can therefore possibly 
have altered results, most likely, the reaction to an anti-inflammatory dose of 
corticosteroids is however a dampening of the immune reaction. For the bacteriology 
the antibacterial treatment is of importance. All cats received antibiotics and 9 cats 
within two weeks of sampling. Results could have been influenced by the use of 
antimicrobial therapy. The two most often used antibiotics were clindamycin and 
cefovecin. Clindamycin is known for its action against aerobic and anaerobic gram-
positive cocci and anaerobic gram-negative bacteria. Cefovecin is a broad-spectrum 
antibiotic with bacteriocidal action against gram-positive and gram-negative bacteria.  
Sixty-eight percent of 22 cats with FCGS in the study were vaccinated every 12-18 
months for FCV, FHV-1 and FPV. This is comparable with a recent web-based 
questionnaire study on cat vaccination in the UK, in which 69% of cat owners reported 
vaccination in the last 12 months (Habacher et al., 2010). Another study that used a 
telephone-based questionnaire reported that 58% of cats had been vaccinated in the 
previous year (Murray et al., 2009). The vaccination status of the cats in the current 
study might have been higher than in a general population, due to the fact that the cats 
were referred to a specialist and owners of such cats might be more likely to ensure 
regular vaccination of their pets. 
Halitosis was the most common reported clinical sign and was observed in 55% of cats. 
Halitosis is reported in other studies affecting 33% (White et al., 1992) and 75% (Bellei 
et al., 2008) of cats with gingivostomatitis. Other signs that were common in the 
current study were excessive salivation, dysphagia, weight loss and a change in 
grooming behaviour, which were all reported in 41% of cats. Dysphagia and anorexia 
together were reported in 44% of cases (White et al., 1992). Another study described 
72% of the cases suffering from dysorexia and 16% of cases having dysphagia (Bellei et 
al., 2008). These signs are variable and difficult to standardise. These investigations 
require the use of questionnaire-based studies, and the owners are important in 
reporting the signs in their cats. The results will differ between households and studies. 
The questionnaire gives very useful information on the severity of the cases and 
provides the owners with key signs for monitoring any improvement during treatment. 
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Accumulation of calculus was recorded in 76% of the cats in this study, which was much 
higher than the 20% reported by White et al. (1992). It could be suggested that cats 
referred to a specialist have already been treated and have not responded to the initial 
treatment. Therefore it is possible that the cases seen in this study are more severe. All 
the FCGS cases seen in the study also had periodontal disease, with mild gingivitis being 
the minimal sign seen. This result is comparable to the gingivitis and periodontitis 
incidence of 93% reported by Hennet et al. (1997). FCGS has been described by Healey 
at al. (2007) in combination with ‘visible dental diseases’ in 70% of cases. 
Periodontopathy has been described in 69% of cases in a study of 32 cats with FCGS 
(Bellei et al., 2008). TR lesions as assessed radiographically were seen in 33% of the cats 
with FCGS. In other studies the proportion of cats with FCGS showing at least one TR 
lesion was 41% (Bellei et al., 2008) and 66% (Hennet, 1997). 
In Section 1.2.1.2, the most important sites of inflammation in the oral cavity of cats 
with FCGS were described. The most severe form of FCGS is when there is inflammation 
at the palatoglossal folds and the attached gingiva. All the cases in the current study 
had at least mild inflammation at both these sites. Reports on the location of 
inflammation vary and for example caudal inflammation is present in 68%-100% of cats 
with FCGS (Johnessee and Hurvitz, 1983; Hennet, 1997; Healey et al., 2007; Bellei et 
al., 2008; Hennet et al., 2011). The lingual and sublingual mucosa (19.1%) and the 
oropharynx (23.8%) were the sites in the current study that demonstrated the lowest 
levels of inflammation. These findings are consistent with those from other studies that 
showed 9% to 18% of cases with involvement of the tongue (White et al., 1992; Hennet, 
1997; Bellei et al., 2008). One study described inflammation of the pharynx and tongue 
as ‘infrequent’ (Healey et al., 2007) and another study showed no inflammation of the 
tongue in any of the nine cases investigated (Johnessee and Hurvitz, 1983). 
In the introduction of this Chapter, FCGS is defined as a poorly described disease. With 
the current study, a contribution can be made that shows comparison to the more 
recent literature, describing the involvement of the caudal mucosa and attached gingiva 
and the rare involvement of lingual and sublingual inflammation. The cases shown in 
this study are referral cases and can therefore be considered to be the most severe and 
difficult to treat. FCGS should be described as an inflammation of the oral cavity with 
at least inflammation of the caudal oral cavity. 
In the current study, most blood biochemistry changes that were observed were only 
mild. A mild increase in the enzymes AST and ALT was seen in 62.1% of the cases. 
Together with ALP and GGT, these enzymes are often used for the screening of 
hepatobiliary disease. However these enzymes may be elevated without any clinically 
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significant hepatobiliary disease (Webster, 2005). Corticosteroids are known to increase 
ALP, GGT, ALT and AST levels in dogs (Webster, 2005). Few studies have been done in 
cats, but high doses of glucocorticoids can increase ALT (Lowe et al., 2008). This reason 
can be excluded in the current study in cases that did not receive corticosteroids prior 
to the sample collection (Table 3.8 and 3.9). Hepatotoxicity due to long term use of 
NSAIDs has not been studied in cats (Sparkes et al., 2010), but NSAIDs are known for 
their potential to cause hepatotoxicity in dogs (MacPhail et al., 1998). Increase in liver 
enzymes can be induced by several other factors that include neoplasia, muscle injuries 
and systemic infections (Webster, 2005). The mild changes in AST and ALT are not 
considered clinically relevant in the current study and no other signs of liver disease 
were apparent in these cats. 
A change in the albumin:globulin ratio was seen in 48.3% of the FCGS cases in the 
current study. The globulins were increased in 48.3% and albumin decreased in 37.9% of 
cases. Total protein was increased in 17.2% of cases. Serum globulin levels are known to 
increase in chronic infections and have been reported to be increased in cats with FCGS 
(Johnessee and Hurvitz, 1983; White et al., 1992; Mihaljevic, 2003). An increase in the 
total protein concentration was seen in 77% of cases by White et al (1992). No decrease 
of albumin has been reported in these studies. In the current study a compensatory 
hypoalbuminaemia was the most likely explanation of the lowered albumin levels 
(Couto, 2003b; duFort, 2005). 
Urea levels were slightly increased in 44.8% of cats. It is likely that this had a prerenal 
cause (diBartola, 2005). Only a minority of the cases also had a slight increase in 
creatinine. The clinical relevance of the increased urea concentration needs to be 
assessed together with urine analysis and the clinical features of the patient. 
Another biochemical change that was seen in a relatively high percentage of the cats 
was an increase in triglyceride levels (31.0% of the cats). Triglyceride increase can be a 
normal physiologic process after a meal, which normally resolves in 2-10 hours. Other 
causes for hyperlipidaemia include endocrine disorders and the use of glucocorticoids 
(Elliot, 2005). 
Total blood counts were performed in 28 cats. The most commonly seen abnormality 
was a mild anaemia (53.6% of cats). The two most likely explanations of this are the 
anaemia of chronic disease (ACD) and the anaemia of inflammatory disease (AID). ACD is 
characterised by a mild, normocytic, normochromic, non-regenerative anaemia and 
with shortened erythrocyte life span (Gaschen, 2005). Similar findings are seen in AID 
which also shows a mild normocytic, normochromic, non-regenerative anaemia. AID is 
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mediated by inflammatory cytokines and is seen as the most common cause of anaemia 
in veterinary medicine. It is caused by a relative deficiency of iron, a decline in red cell 
survival and a decrease in erythropoietic response. Iron reduction is a metabolic 
response to deprive infectious organisms of the iron needed for their metabolism, and 
the decline in red cell survival is likely to be the most important factor in the onset of 
anaemia in cats (Feldman, 2005).  
In the current study the WBCC was above the reference range in 21.4% of the cats and 
below the reference range in 10.7% of the cats. Johnessee and Hurvitz (1983) reported a 
mild elevation in WBCC in 33% of cats with FCGS and a leukocytosis in 20% of cats was 
observed by White et al. (1993). White blood cells increase in inflammation and 
infection through the acute phase response in which cytokines activate the leucocyte 
production (Paltrinieri, 2008). Other causes of elevated white blood cell levels include 
stress and glucocorticoid administration. A decrease in the WBCC can be caused by an 
increased white blood cell consumption (duFort, 2005; Paltrinieri, 2008). Lymphocytes 
were reduced in 46.4% of the cases in the current study, a similar finding to that 
observed previously in a study of nine cats with FCGS of which five showed an absolute 
lymphopenia and five showed a neutrophilia with a mild left shift (Johnessee and 
Hurvitz, 1983). Lymphopenia in cats can be caused by stress or by administration of 
corticosteroids and other often seen causes are acute viral infections e.g. FeLV, FIV and 
FPV. A ‘stress-induced’ change may be seen in cats, the typical ‘stress leukogram’ 
shows a decrease in lymphocyte numbers in combination with an increase in neutrophil 
numbers under the influence of an endogenous release (or exogenous administration) of 
corticosteroids (Couto, 2003a). In the current study 14.3% of the cases had an increase 
in neutrophil numbers and a mild toxic change was seen in 21.4% of cases. A toxic 
change is the morphological change of the cytoplasma in neutrophils and can be seen 
during bacterial infections or severe inflammation. Increases in the numbers of 
eosinophils and monocytes were also observed, and this can be caused by chronic 
infections and tissue damage. A toxic change in the neutrophils is regarded as an 
important indicator of the severity of disease in cats (Segev et al., 2006; Paltrinieri, 
2008). 
In the current study a group of cats in the age range 1 to 17 years was investigated. A 
higher proportion of purebred cats were seen during the study when compared to a 
population attending first opinion veterinary practice. The clinical signs were mostly 
related to the oral inflammation and the pain it causes. The inflammation was most 
severe in the caudal parts of the oral cavity and the maxillary attached gingiva and all 
cats were affected by periodontal disease. The mild changes in blood biochemistry and 
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haematology that were reported in this study are most likely related to the chronic 
inflammatory disease and the ‘stress’ it causes. 
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Chapter 4 Virological investigations 
4.1 Introduction 
A number of different viruses have been implicated in the aetiopathogenesis of FCGS 
particularly FeLV, FIV, FHV-1 and FCV. 
In cats infected with FeLV, oral inflammation is a common clinical sign (Cotter et al., 
1975; Frost and Williams, 1986). No definite correlation with FCGS has been shown and 
the percentage of cats positive for FeLV in FCGS populations is not greater than 17% 
(Johnessee and Hurvitz, 1983; Knowles et al., 1989; White et al., 1992; Hennet, 1997; 
Quimby et al., 2008). 
The most commonly described clinical signs of cats infected with FIV are oral lesions. 
Studies have investigated the possible relationship between FIV and FCGS. Up to 80% of 
cats with FCGS are positive for FIV (Knowles et al., 1989) and an increase in the severity 
of oral lesions in cats with FCGS was seen when FIV infection was present (Dawson et 
al., 1991; Tenorio et al., 1991; Waters et al., 1993). 
Few studies were able to show a correlation between FCGS and FHV-1 (Quimby et al., 
2008; Dowers et al., 2010). Clinical signs of FHV-1 infection can include oral ulceration 
but this is not common (Gaskell et al., 2007). One study showed 88% of cats with FCGS 
were infected with a combination of FCV and FHV-1, compared to 21% of the cats with 
only periodontal disease (Lommer and Verstraete, 2003). 
The role of FCV in FCGS has been investigated in many studies, with most showing that 
a high percentage of cats with FCGS are positive for the virus (Knowles et al., 1989; 
Lommer and Verstraete, 2003; Bellei et al., 2008). When cats with caudal stomatitis 
were selected from a group of cats with oral inflammation, 100% tested positive for the 
presence of FCV (Reubel et al., 1992). 
In this chapter, the presence of FeLV, FIV, FHV-1 and FCV in healthy cats and those with 
FCGS was assessed. 
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4.2 Materials and methods 
All virus diagnostics were performed by the Veterinary Diagnostics Service, School of 
Veterinary Medicine, University of Glasgow 
4.2.1 FeLV ELISA 
Plasma samples were tested for FeLV gag protein p27 by an ELISA to detect FeLV 
infection (Lutz et al., 1983). The test was performed using two anti-p27 monoclonal 
antibodies coated onto an ELISA plate. Serum samples were added in addition to a 
biotinlyated anti-p27 antibody; after the reaction time it was developed with a 
streptavidin-akaline-phosphatase system. Samples with a positive optical density (OD) 
reading were considered reactive for p27 antigen. Positive tests were confirmed using 
virus isolation (Jarrett et al., 1964). 
4.2.2 FIV IFA 
Plasma samples were analysed using an Immunofluorescence antibody (IFA) test. The 
test was carried out using infected and uninfected cells in wells of a 96-well teflon-
coated microscope slide. Serial dilutions of test sample were placed on the wells and 
allowed to react; an anti-feline IgG conjugated with fluorescein isothiocyanate (FITC) 
was added before final examination under an ultraviolet (UV) microscope. The endpoint 
was taken as the last dilution showing fluorescence. 
4.2.3 FCV and FHV-1 virus isolation 
Virus isolation was performed on the VTM samples. The samples were centrifuged to 
pellet any debris and 0.5 ml was inoculated onto a feline embryonic fibroblast (FEA) cell 
line. Cells were checked daily for the appearance of the typical cytopathic effect (CPE) 
before being declared negative if no CPE was seen after the fourth day. 
4.2.4 FHV-1 PCR 
The VTM samples were tested for FHV-1 using a real-time PCR assay based on the feline 
herpesvirus thymidine kinase gene (Accession No. M26660). For crude DNA preparation, 
pelleted samples were resuspended in 2% 0.1M dithiothreitol (DTT) and boiled. All 
reactions were carried out in 96-well optical reaction plates in 25 l volumes. DNA 
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amplification was performed using a 7500 real-time PCR System (Applied Biosystems, 
Paisley, UK) and the results were analysed using the 7500 System Sequence Detection 
Software (Applied Biosystems). 
4.2.5 Statistical analysis 
Graphical representations and Fisher’s exact tests of virological investigations were 
prepared in GraphPad Prism for Windows, version 5. 
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4.3 Results 
The data for the presence of FeLV, FIV, FHV-1 and FCV in cats with and without FCGS is 
shown in Table 4.1 and Table 4.2 respectively and in Figure 4.1. 
4.3.1 Feline leukaemia virus 
Of the 29 cats with FCGS tested for the FeLV antigen, none were positive. Of six healthy 
cats tested, two (33.3%) were positive for FeLV antigen. A Fisher’s exact test showed 
that a significantly higher proportion of the healthy cats were positive for FeLV antigen 
when compared to the cats with FCGS (p=0.03). 
4.3.2 Feline immunodeficiency virus 
Of the 29 cats with FCGS tested for the presence of FIV antibodies, one (3.4%) cat was 
positive. Of six healthy cats tested, two (33.3%) were positive for FIV antibodies. 
4.3.3 Feline herpes virus - 1 
Twenty-nine cats with FCGS were tested for FHV-1 by qPCR, two (6.9%) cats were 
positive. Thirty-one cats were tested for FHV-1 by virus isolation. No virus was isolated 
in any of these cats. In the 15 healthy cats tested, no virus was isolated and none of the 
cats tested positive by the qPCR test. 
4.3.4 FCV 
Thirty-one cats with FCGS were tested for FCV and the virus was isolated from 22 (71%) 
cats. Fifteen healthy cats were tested and FCV was isolated from two (13.3%) cats. A 
Fisher’s exact test showed that the presence of FCV was significantly higher in cats with 
FCGS when compared to the healthy cats (p=0.0004). 
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Table 4.1: Presence of FeLV, FIV, FCV and FHV-1 in cats with FCGS 
Cat ID FeLV antigen FIV antibodies Virus isolation 
FCV/FHV-1 
FHV-1 PCR 
F1 - - - - 
F2 Negative Negative FCV isolated Negative 
F3 Negative Negative No virus isolated Negative 
F4 Negative Negative FCV isolated Negative 
F5 Negative Negative No virus isolated Negative 
F6 Negative Negative FCV isolated Negative 
F7 Negative Negative FCV isolated Negative 
F8 Negative Negative FCV isolated Negative 
F9 Negative Negative FCV isolated Negative 
F10 Negative Negative FCV isolated Negative 
F11 Negative Negative FCV isolated Negative 
F12 Negative Negative FCV isolated Negative 
F13 Negative Negative No virus isolated Negative 
F14 Negative Negative No virus isolated Negative 
F15 Negative Negative No virus isolated Negative 
F16 Negative Negative FCV isolated Negative 
F17 Negative Negative FCV isolated Negative 
F18 Negative Negative FCV isolated Negative 
F19 Negative Negative No virus isolated Negative 
F20 Negative Negative FCV isolated Negative 
F21 Negative Positive FCV isolated Negative 
F22 Negative Negative FCV isolated Negative 
F23 Negative Negative FCV isolated Negative 
F24 Negative Negative FCV isolated Negative 
F25 Negative Negative No virus isolated Negative 
F26 Negative Negative FCV isolated Negative 
F27 Negative Negative FCV isolated Negative 
F28 Negative Negative FCV isolated Positive 
F29 Negative Negative No virus isolated Negative 
F30 - - FCV isolated Negative 
F31 - - No virus isolated Positive 
F32 Negative Negative FCV isolated - 
-: Not tested. 
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Table 4.2: Presence of FeLV, FIV, FCV and FHV-1 in healthy cats 
 Cat ID FeLV Antigen FIV Antibodies Virus isolation 
FCV/FHV-1 
FHV-1 PCR 
H1 - - - - 
H2 Negative Positive FCV isolated Negative 
H3 Negative Positive No virus isolated Negative 
H4 Positive Negative No virus isolated Negative 
H5 Negative Negative No virus isolated Negative 
H6 Negative Negative No virus isolated Negative 
H7 - - No virus isolated Negative 
H8 - - No virus isolated Negative 
H9 - - No virus isolated Negative 
H10 - - No virus isolated Negative 
H11 - - No virus isolated Negative 
H12 - - No virus isolated Negative 
H13 - - No virus isolated Negative 
H14 - - FCV isolated Negative 
H15 - - No virus isolated Negative 
H16 Positive Negative No virus isolated Negative 
-: Not tested 
 
Figure 4.1: Percentage of cats positive for each virus in the healthy and FCGS groups 
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4.4 Discussion 
Feline viruses have been implicated in the aetiopathogenesis of FCGS. The presence of 
the viruses FeLV, FIV, FHV-1 and FCV in cats with and without FCGS was assessed. 
In the current study, none of the 29 cats with FCGS that were tested were positive for 
the FeLV antigen. Studies on FeLV in cats with FCGS show varying results but the 
numbers of cats positive for FeLV are relatively low. In two studies, the prevalence of 
FeLV was between 4% and 17% (Knowles et al., 1989; White et al., 1992). Other studies 
have shown no tested cats with FCGS to be positive for the FeLV antigen (Johnessee and 
Hurvitz, 1983; Thompson et al., 1984; Hennet, 1997; Quimby et al., 2008). Of six 
healthy cats that were tested in the current study, two (33.3%) cats were positive for 
FeLV, a higher number than that previously reported where 1-5% of cats were 
asymptomatically infected with FeLV (Hosie et al., 1989; Levy, 2005; de Lange, 2008; 
Gleich et al., 2009). However only a small number of healthy cat samples were tested in 
the present study. Knowles et al. (1989) showed that 4% of cats with FCGS and 11% of 
cats in a time-matched control group were positive for FeLV. The evidence available 
suggests that FeLV is unlikely to play a role in the aetiopathogenesis of FCGS. 
Of the 29 cats with FCGS tested in the current study, one (3.4%) tested positive for FIV 
antibodies. Other studies have shown higher levels of positivity but results are highly 
variable, ranging from 13% (Hennet, 1997) to 81% (Knowles et al., 1989) of cats with 
FCGS being positive for FIV. In the healthy cohort in the current study, two (33.3%) cats 
tested positive. This relatively high prevalence may be due to the low number of 
healthy cats tested and the fact that two cats were from a cat shelter and both tested 
positive. High numbers of FIV-positive cats in the control groups have been observed in 
other studies, with FIV prevalences ranging from 8.3-50% (Knowles et al., 1989; Quimby 
et al., 2008). The role of FIV in FCGS is uncertain, but the severity of clinical signs may 
increase in FIV-positive cats (Dawson et al., 1991; Tenorio et al., 1991; Waters et al., 
1993). 
In the current study two methods were used to determine the presence of FHV-1, 
namely virus isolation and PCR. Since FCV grows more rapidly than FHV-1, this can mask 
the growth of FHV-1 in cats also infected with FCV when virus isolation is used (Radford 
et al., 2009). Reduced survival of FHV-1 during sampling and transport has also been 
described (Reubel et al., 1993). Therefore qPCR is considered to be a more reliable and 
sensitive test for FHV-1 (Sykes et al., 1997), and was performed in tandem with virus 
isolation. Of the cats tested, two (6.9%) cats were positive for FHV-1 by qPCR in the 
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FCGS group and none were positive by virus isolation. Of the two cats that were positive 
for FHV-1 by qPCR, one was also positive for FCV by virus isolation. Few studies have 
tested cats with FCGS for the presence of FHV-1. One study determined the presence of 
FHV-1 and FCV in 25 cats with FCGS and 24 cats with periodontal disease by virus 
isolation (Lommer and Verstraete, 2003). Of the cats with FCGS, 88% shed both viruses 
as did 22% of the cats with periodontal disease. One cat (4%) with FCGS was positive for 
only FHV-1. Another study showed that 100% of cats with FCGS were positive for FHV-1 
antibodies by ELISA, which compared with 97% of the cats in the control group (Quimby 
et al., 2008). When PCR was performed none of the cats with FCGS and 8.3% of the 
control group were positive. High prevalence rates of FHV-1 are often observed by 
serological testing. This is due to the widespread use of vaccines for FHV-1 and FCV, 
which increases the antibody titres in the population of healthy cats (Radford et al., 
1997; Quimby et al., 2008). The vaccines against FHV-1 protect against disease but not 
against infection or the development of a carrier-state (Gaskell et al., 2007) Viral 
shedding seems to be reduced in vaccinated cats compared to unvaccinated controls. Of 
the 15 healthy cats studied in the current study, none tested positive for FHV-1. The 
prevalence of FHV-1 is thought to be approximately 1% in clinically healthy cats (Binns 
et al., 2000). The current study could not confirm a correlation between FHV-1 and 
FCGS. 
Of 31 tested cats in the current study, 22 (71%) were positive for FCV by viral isolation. 
As with FHV-1, vaccination against FCV protects against classical oral/respiratory 
disease reasonably well but does not protect against infection or development of a 
carrier-state (Radford et al., 2007). This explains the high percentage of FCV positive 
cats regardless of vaccination. FCV has been described in cats with FCGS with a 
prevalence ranging from 40.5% (Dowers et al., 2010) to 92% (Knowles et al., 1989) of 
cases (Thompson et al., 1984; Lommer and Verstraete, 2003; Bellei et al., 2008). One 
study showed that none of nine cats with FCGS were positive for FCV by PCR (Quimby et 
al., 2008). FCV is most likely to play a role in the aetiopathogenesis of FCGS but studies 
have failed to induce FCGS by infecting cats with FCV isolates collected from cats with 
FCGS (Knowles et al., 1991). Over the ten months duration of the study, chronic oral 
inflammation did not develop and only acute signs were observed. However, most 
studies have shown that high numbers of cats with FCGS are infected with FCV. Reubel 
et al. (1992) showed that cats with caudal stomatitis were all positive for FCV. Most 
studies, however, showed that less than 100% of the cats with FCGS are positive for 
FCV. When virus isolation is used for detection, false negative results are possible due 
to inactivation of the virus during transport, the presence of small numbers of virions 
and the presence of antibodies in the sample (Radford et al., 2009). The current study 
showed that 13.3% of the healthy cats tested were positive for FCV. Prevalence rates of 
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between 10% and 40% have been reported in normal cats (Wardley et al., 1974; Gaskell, 
2005; Radford et al., 2007). 
In conclusion, the prevalence of both, FCV and FHV-1 was higher in the FCGS group 
compared to the healthy group. Conversely, the prevalence of FeLV and FIV was higher 
in the healthy cats. 
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Chapter 5 Identification of bacteria associated with 
FCGS 
5.1 Introduction 
The aetiopathogenesis of FCGS is unclear and multiple factors have been suggested 
including, viruses and an immune-mediated component (Tenorio et al., 1991; Dowers et 
al., 2010; Southerden, 2010). Bacteria have also been implicated to play a role in the 
aetiopathogenesis of FCGS (Love et al., 1989; Sims et al., 1990; Harvey, 1991). 
Several studies have isolated bacteria from the feline oral cavity (Mallonee et al., 1988; 
Love et al., 1989; Love et al., 1990; Mihaljevic and Klein, 1998). Bacteria that have 
been isolated from the healthy oral cavity include Bacteroides species, Actinomyces 
species and Pasteurella species (Love et al., 1990). An overview of known bacterial 
species in the feline oral cavity is given in Tables 1.2 and 1.3. 
Studies on the bacterial flora in oral-associated diseases of cats have primarily 
concentrated on periodontal disease (Mallonee et al., 1988; Norris and Love, 1999a). In 
FCGS the grade of periodontal disease ranges from none to severe but gingivitis is often 
part of the clinical signs. Periodontal disease is considered to be of a different 
pathogenic background and, as in human periodontal disease, specific bacteria can be 
described as an indicator for the severity of the disease (Norris and Love, 1999a; Booij-
Vrieling et al., 2010). 
To investigate the possible importance of bacteria in FCGS, a comparison of the 
bacterial flora in the healthy oral cavity with that in cats with FCGS has been made. 
This is the first study to use 16S rRNA gene cloning and sequencing to identify the 
bacterial flora in cats. The use of 16S rRNA gene sequencing makes it possible to 
identify a broader range of bacteria than would be expected using conventional 
methods only. Culture-independent techniques give the opportunity to identify non-
cultivable species or slow-growing bacteria that would not be identified using culture-
dependent methods. The technique has proven successful in detecting bacteria in the 
complex flora of the gut and human oral cavity (Hutter et al., 2003; Woo et al., 2008; 
Suchodolski et al., 2010). Using this culture-independent method together with 
conventional culture methods allows an even wider range of bacteria to be detected 
and makes it possible to demonstrate the complex microbiological diversity that is 
found in the oral cavity. 
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5.2 Materials and methods 
5.2.1 Bacteriological culture methods 
5.2.1.1 Culture of the samples 
From the material eluted from each swab, six 10-fold serial dilutions were prepared. 
From each dilution, 50 µl was plated by use of a spiral plater (SpiralSystems inc., 
Cincinatti, USA) on both Colombia agar (Sigma-Aldrich) containing 7.5% v/v defibrinated 
horse blood for aerobic culture and fastidious anaerobe agar (FAA) (BioConnections, 
Leeds, UK) containing 7.5% v/v defibrinated horse blood for anaerobic culture. Aerobic 
incubation of the Colombia blood agar (CBA) was performed at 37ºC. FAA plates were 
incubated at 37ºC in an anaerobic chamber with an atmosphere of 85% N2, 10% CO2 and 
5% H2. After incubation for a maximum of seven days, up to eight morphologically 
distinct colonies were sub-cultured and incubated for three days under the same 
conditions to obtain pure colonies. 
Culture of the samples by the Veterinary Diagnostic Service was performed on Colombia 
agar containing 5% v/v sheep blood (E&O laboratories Ltd., Bonnybridge, UK) and 
MacConkey agar (E&O Laboratories Ltd.) aerobically for 48h. FAA containing 5% horse 
blood (E&O Laboratories) was incubated anaerobically for 48h and chocolate agar (E&O 
Laboratories Ltd.) was incubated at an atmosphere of 5%CO2 for 48h. All incubation was 
performed at 37°C. Isolated bacteria were identified by API system (bioMérieux UK Ltd., 
Hampshire, UK). 
5.2.1.2 Cryopreservation of the isolates 
A scraping of each pure culture was taken with a sterile loop and immersed in a mixture 
of de-ionised water, beef extract, peptone, sodium chloride, 20% glycerol and 20-25 
ceramic beads in cryopreservation vials (Technical Service Consultants Ltd, Heywood, 
UK). The vials were inverted six times and set for 30 s to let the suspension be absorbed 
by the ceramic beads. The broth was removed and the beads stored at -80ºC. When 
required, the isolates were cultured on CBA and FAA by rubbing the bead over the agar. 
Plates were incubated as described before. From each isolate a scraping was taken and 
immersed in 95 μl nuclease-free water. DNA was extracted and the microorganisms 
were identified by 16S rRNA gene sequencing as described below. 
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5.2.2 16S rRNA gene sequencing 
5.2.2.1 DNA extraction 
DNA extraction of the FAB swab eluate was performed by proteinase-K digestion. 
Proteinase-K (Invitrogen, Paisley, UK), a non-specific serine protease, was added to a 
final concentration of 1000 µg/ml and incubated at 55°C for a minimum of 60 min. Each 
sample was then incubated for 10 min at 100°C to ensure denaturation of the 
proteinase-K. The samples were diluted 1:10, 1:50 and 1:100 and stored at -20°C until 
required. To extract DNA from the bacterial isolates the same method was used with a 
scraping of the isolated bacteria from the plate eluted in nuclease-free water 
containing 1000 µg/ml proteinase-K. 
5.2.2.2 Bacterial 16S rRNA gene PCR amplification 
Each dilution (1:10, 1:50 and 1:100), of the DNA extract and the neat sample were 
amplified by PCR. To amplify the 16S rRNA gene, universal primers 63F and 1387R were 
used (numbering is based on the Escherichia coli 16S rRNA gene sequence) (Marchesi et 
al., 1998). The primer sequences were 63F 5’CAG GCC TAA CAC ATG CAA GTC 3’ and 1387R 5’ 
GGG CGG WGT GTA CAA GGC 3’ (W=A+T). Primers were synthesised commercially (Sigma 
Genosys, Cambridge, UK). The PCR reactions were carried out in a total volume of 50 µl 
containing 5 µl of the extracted DNA dilution and 45 µl reaction mixture. The reaction 
mixture was prepared using 1 x GoTaq® PCR buffer (Promega, Southampton, UK), 1.25 
units of GoTaq® polymerase (Promega), 1.5 mM MgCl2 (Promega), 0.2 mM 
deoxynucleotide triphosphates (dNTPs) (New England Biolabs, Hitchin, UK) and each 
primer at a concentration of 0.2 µM. The PCR cycling protocol comprised an initial 
denaturation phase of 2 min at 95ºC followed by 35 cycles of 95ºC, denaturation for 
1 min, 60ºC annealing for 1 min, 72ºC extension for 1.5 min and a final extension cycle 
of 10 min at 72ºC. 
5.2.2.3 PCR quality control 
Negative and positive controls were included with each batch of samples being 
analysed. The positive control comprised a standard PCR reaction mixture containing 10 
ng bacterial DNA instead of sample; the negative control contained sterile water instead 
of sample. Each PCR product was subjected to gel electrophoresis as described in 
Section 5.2.2.4. 
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5.2.2.4 Gel electrophoresis 
A 2% agarose gel was prepared by dissolving 2 g of agarose (Roche, Burgess Hill, UK) in 
100 ml 0.5% TBE buffer by heating and swirling. The solution was left to cool to 50°C 
before adding ethidium bromide at a concentration of 0.5 µg/ml. The gel was poured 
into a gel box and after solidifying, 5 µl of each PCR product was mixed with 2 µl 6 x 
loading buffer (New England Biolabs) and loaded into the wells, and the last well was 
loaded with 1 µl 100 bp ladder (New England Biolabs, Hitchin, UK) and 2 µl 6x loading 
buffer. The gel was run at 70 V for 1 hr. Examination of the gel was performed using a 
Gel DocTM XR+ System with Image labTM software (Bio-Rad Laboratories Inc., Hemel 
Hempstead,UK). 
5.2.2.5 Bacterial 16S rRNA gene cloning 
The 16S rRNA genes were cloned into the cloning vector pSC-A-amp/kan using the 
StrataClone™ PCR Cloning Kit (Agilent Technologies, Cheshire, UK). For incubation, L-
agar plates containing 100 µg/ml of ampicillin (Sigma-Aldrich), plated with 40 µl of 5-
bromo-3-indolyl-β-D-galactopyranoside (Bluo-Gal) (40 µg/µl) were used. A 5-min ligation 
reaction allowed Adenine-Uracil (A-U) base-pairing between the U-overhangs of the 
vector and the A overhangs of the PCR products. Strand ligation was mediated by 
topoisomerase-I. The linear molecule was transformed into the competent cell line that 
expressed Cre-recombinase. Cre-recombinase mediated the formation of a circular DNA 
molecule able to replicate in cells growing on ampicillin-containing agar (Figure 5.1). 
5.2.2.6 Bacterial 16S rRNA gene insert PCR re-amplification 
Following cloning, the 16S rRNA gene inserts were re-amplified by PCR. Approximately 
fifty white clones were randomly selected from each generated library and amplified 
using the primer pair M13 SIF (5’ to 3’) CCC TCG AGG TCG ACG GTA TC and M13 SIR (5’ to 3’) 
CTC TAG AAC TAG TGG ATC CC. The M13SIF binding site is located 61 base pairs downstream 
of the M13 reverse primer binding-site, and the M13SIR binding site is located 56 base 
pairs upstream of the M13 forward primer binding-site in the pSC-A-amp/kan cloning 
vector (Figure 5.2). The PCR reactions were carried out in a total volume of 30 μl. The 
mastermix was prepared using 1.1 x ReddyMix PCR mastermix (containing 1.5 mM MgCl2) 
(Thermo Scientific, Epsom, UK), 0.2 μM of each primer and nuclease-free water to a 
total volume of 30 μl. One clone was added to the reaction mixture and the PCR cycling 
protocol used was as previously described (Section 5.2.2.2). Each single clone used was 
grown on a fresh ampicillin/agar plate and incubated overnight. 
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5.2.2.7 Clone cryopreservation 
After incubation, each clone was taken from the plate and transferred into bijoux flasks 
containing 2 ml LB-broth. The clones were incubated under agitation at 37°C overnight 
and 0.5 ml of the medium containing the clones was then transferred into 1.5 µl tubes 
and mixed with 0.5 ml of 0.5% glycerol. The clones were stored at -80ºC until required.  
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Figure 5.1: Overview of the Strataclone PCR cloning method 
 
 
Reproduced from StrataClone PCR Cloning Kit Instruction Manual (#240205). The cloning vector in 
the kit contained two DNA arms, charged with topoisomerase I on one end, containing modified 
U overhangs and a loxP recognition sequence on the other end. The vector also contained a lacZ’ 
α-complementation cassette, when an insert was present the lacZ’ gene was disrupted, the Bluo-
Gal present on the agar plates was cleaved in the presence of an intact lacZ’ gene which 
presented as a blue colour, therefore colonies containing no insert presented as blue, while 
colonies with an insert presented as white on the agar plates after incubation. 
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Figure 5.2: PSC-A-amp/kan PCR cloning vector PCR Product insertion Site region 
 
 
Adapted from StrataClone PCR Cloning Kit Instruction Manual (#240205). Sequence shown: 4261-
4270, 1-250. Blue boxes show primer location for SIF/SIR. 
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5.2.2.8 Restriction enzyme analysis 
Each re-amplified 16S rRNA gene insert was analysed using restriction enzyme analysis. 
Approximately 0.5 μg of each PCR product was digested in a total volume of 15 μl with 
2.0 U of each of the restriction enzymes RsaI and MnlI (Fermentas Life Sciences, York, 
UK) at 37ºC for 1 hr. The restriction fragments were visualised by agarose gel 
electrophoresis as described previously. For each library, clones were first sorted in 
groups according to the RsaI restriction digestion profiles. Further discrimination was 
achieved by digestion with MnlI. Clones with identical restriction profiles for both 
enzymes were grouped together in distinct restriction fragment length polymorphism 
(RFLP) groups. 
5.2.2.9 PCR product purification 
The PCR product of one representative clone from each RFLP group was purified using 
the ‘QiaQuick PCR Purification Kit’ (Qiagen, Crawley, UK). Five volumes of Buffer PB 
(Qiagen) were added to one volume of PCR reaction and mixed. The mix was transferred 
into the QiaQuick spin column and centrifuged for 60 s to allow the DNA to absorb onto 
the silica membrane. The DNA was washed with 750 µl of buffer PE (Qiagen) and 
centrifuged for 60 s. The flow-through was discarded and the spin column was 
centrifuged for another 60 s to ensure the ethanol containing buffer PE was removed 
completely. The column was placed into a clean 1.5 ml centrifuge tube and the DNA 
eluted in 30 µl of nuclease-free water by centrifuging for 60 s at 13000 rpm. The DNA 
yield was assessed using the ND-1000 NanoDrop® (Thermo Scientific) 
spectrophotometer. 
5.2.2.10 Sanger DNA Sequencing 
Each purified 16S rRNA gene insert was sequenced. To perform sequence reactions the 
SequiTherm EXCEL™ II DNA Sequencing Kit (Cambio Ltd., Cambridge, UK) with IRD800-
labelled 357f primer was used in a LI-COR Gene ReadIR 4200S automated DNA 
sequencing system (MWG Biotech, Milton Keynes, UK). The loading gel was prepared as 
follows: 21 g of urea (Sigma-Aldrich), 7.5 ml of rapid gel (Affymetrix/USB, High 
Wycombe, UK), 28.0 ml double distilled water, 5.0 ml 10 x TBE Buffer and 500 µl DMSO 
(Fisher Scientific, Loughborough, UK) were added to a one-armed flask, mixed and 
degassed using a vacuum pump. The gel solution was poured into a beaker and 50 μl 
TEMED (Sigma-Aldrich) and 350 μl (0.1 g/ml) ammonium persulphate (Sigma-Aldrich) 
were added. Prior to pouring, the gel plates were cleaned with different chemicals in 
the following order; 0.5M HCl, 0.5M NaOH, double distilled water and ethanol. The gel 
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plates were put together, separated by plastic spacers. The gel was poured from the 
top and the loading comb was inserted. The gel was left to polymerise for 1.5 h before 
placing into the LI-COR automated DNA sequencing system with 1 x TBE Buffer, 
following the manufacturer’s instructions. The SequiTherm reactions were set up in 4 
tubes per sample to which 2 µl of one of the four termination mixtures (A, C, T, G) was 
added. Sequence mixtures were prepared for each reaction containing 2.5 µl sequencing 
buffer, 1 µl Taq DNA polymerase, 1.5 µl 357F primer, template DNA (Cambio Ltd.) and 
deionised water to a total volume of 18 µl. 4 µl of the mixture was added to each of the 
termination mixes. A drop of mineral oil was placed on top of each reaction. The 
sequencing cycling protocol had the following parameters: (i) initial denaturation at 
95ºC for 30 s, (ii) 10 s at 95ºC, 30 s at 57ºC and 30 s at 70ºC for 20 cycles and (iii) 10 s at 
95ºC and 30 s at 70ºC for 15 cycles. After thermocycling, 3 µl of Stop/Loading Buffer 
was added and approximately 1.5 μl of each reaction mixture was loaded onto the gel 
and run on the LI-COR DNA sequencing system overnight.  
DNA sequencing was also performed by GATC Biotech, London and DNA Sequencing & 
Services, University of Dundee using Applied Biosystems Big-Dye Version 3.1 chemistry 
on an Applied Biosystems model 3730 automated capillary DNA sequencer. 
5.2.2.11 Analysis of sequencing data 
Sequence data generated from the LI-COR system were compiled using LI-COR Base 
ImagIR 4.0 software and converted to FASTA format. Sequence data obtained from 
external sources were provided in a variety of formats (FASTA format from GATC 
Biotech and raw sequences from DNA Sequencing & Services) that did not need 
conversion before searching the databases. All sequence data were compared against 
the EMBL/GenBank sequence databases using the nucleotide MEGABLAST algorithm. The 
program was run through the National Centre for Biotechnology Information website 
(http://www.ncbi.nlm.nih.gov /BLAST). Sequences that had at least 98% identity with a 
known sequence were considered to be of the same species as the matching sequence 
with the highest score. Sequences with less than 98% identity were classified as 
potentially novel phylotypes. On several occasions the matching sequences will be 
described as ‘uncultured bacteria’ in the result section. These are sequences in the 
database that have not been previously cultured but have been identified by sequencing 
techniques and are uploaded to the database under the common name of ‘uncultured 
bacteria’. 
Chapter 5 Identification of bacteria associated with FCGS 88 
 
5.2.3 Phylogenetic analysis 
5.2.3.1 Sequence analysis of clones representing potentially novel phylotypes 
Sequences with less than 97% identity with any known sequence from the databases 
were tentatively classified as potentially novel phylotypes at the start of the project 
(Section 5.3.2.5). From FCGS samples F1-F6 and healthy samples H1-H3 the potentially 
novel clones were revived from storage on ampicillin/agar plates and incubated 
overnight at 37°C. The clones were subjected to PCR with primers M13SIF and M13SIR as 
described previously. Each clone was sequenced with primers M13SIF and M13SIR to 
obtain the nearly complete 16S rRNA gene sequence (1202 to 1325 bp). 
5.2.3.2 Phylogenetic analysis 
Near full-length 16S rRNA gene sequences were aligned using the ClustalW2 multiple 
sequencing alignment tool through the phylogenetic analysis program MEGA version 5 
(Tamura et al., 2011). The maximum-likelihood method was used to perform 
phylogenetic analysis based on the Tamura-Nei model (Tamura and Nei, 1993). The tree 
with the highest log likelihood was used and initial trees were obtained automatically; 
when the number of common sites was < 100 or less than one quarter of the total 
number of sites, the maximum parsimony method was used. The BIONJ method with 
MCL distance matrix was used in all other cases. The phylogenetic tree was drawn to 
scale and the branch lengths were measured in the number of substitutions per site. 
Positions containing gaps and missing data were eliminated. 
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5.3 Results 
5.3.1 Culture-dependent methods 
5.3.1.1 Bacterial culture 
Using standard culture methods, 22 FCGS and 13 healthy samples showed bacterial 
growth following both aerobic and anaerobic incubation. Blood plates were incubated 
for three to six days with spiral plated ten-fold serial dilutions of FAB in which the swab 
samples were emerged (Table 5.1). The growth density varied greatly per individual 
sample and growth was sparse in samples F7, F11, F18, F19 and F21. Up to eight 
morphologically different isolates were collected from each plate and isolated (Table 
5.1). 
5.3.1.2 DNA extraction and PCR 
A standard proteinase-K DNA extraction method was used on all isolates and the 16S 
gene was successfully amplified from 131 healthy and 161 FCGS isolates. All amplified 
16S rRNA genes were sequenced. 
5.3.1.3 BLAST database comparison 
All 16S rRNA sequences were compared against the BLAST database and the isolates that 
were identified from 22 FCGS and 13 healthy samples are shown in Table 5.2. The most 
frequently isolated bacteria in the FCGS samples were P. multocida subsp. multocida, 
(9.9%), P. multocida subsp. septica (9.9%) and uncultured bacterium (21.7%). The most 
frequently isolated bacteria from healthy samples were P. multocida subsp. septica 
(9.9%) and uncultured bacterium (30.5%). A large number of isolated bacteria were 
matched in the BLAST database to uncultured bacteria for both the healthy and FCGS 
samples. A subdivision of these results is made in Table 5.3 according to the accession 
number. For F12-F22 and H6-13 bacterial counts were performed (Table 5.4). In the 
FCGS group, an increase in the average CFU/ml can be seen in all Pasteurella sp. 
(except P. stomatitis) when compared to the healthy group. 
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Table 5.1: Number of different isolates from all samples 
Sample Number of isolates Plated dilution Incubation time 
(days) CA FAA CA FAA 
F1 N.R. N.R. N.R. N.R. N.R. 
F2 5 6 N.R. N.R. 3 
F3 7 4 N.R. N.R. 4 
F4 6 8 N.R. N.R. 4 
F5 7 7 N.R. N.R. 3 
F6 8 7 N.R. N.R. 3 
F7 8 8 neat neat 5 
F8 7 8 N.R. N.R. 5 
F9 8 5 N.R. N.R. 5 
F10 7 6 N.R. N.R. 6 
F11 5 6 N.R. N.R. 5 
F12 6 3 10-3 10-2 6 
F13 5 5 10-6 10-5 5 
F14 8 6 10-2 10-3 5 
F15 5 4 10-3 10-2 6 
F16 6 6 10-2 10-3 5 
F17 3 3 10-5 10-2 4 
F18 1 2 neat 10-1 5 
F19 4 2 10-2 10-2 4 
F20 4 4 10-3 10-3 5 
F21 3 3 neat neat 5 
F22 4 4 10-2 10-2 6 
H1 N.R. N.R. N.R. N.R. N.R. 
H2 6 6 N.R. N.R. 4 
H3 6 7 N.R. N.R. 4 
H4 8 6 N.R. N.R. 5 
H5 6 4 10-2 10-2 5 
H6 6 5 10-2 10-2 4 
H7 8 8 10-2 10-2 5 
H8 8 8 10-2 10-2 6 
H9 8 6 10-3 10-3 6 
H10 8 8 10-1 10-1 6 
H11 8 8 10-3 10-1 5 
H12 8 8 10-2 10-2 6 
H13 8 8 10-2 10-2 5 
Number of morphologically different bacteria isolated from 22 FCGS samples and 13 healthy 
samples and the number of different bacteria identified by 16S rRNA gene sequencing. 
CA: Columbia agar, FAA: Fastidious anaerobe agar, N.R.: Not recorded. 
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Table 5.2: Identification of bacterial isolates 
 
Species 
 
Healthy FCGS 
No. of isolates  
(% of total) 
n=131 
No. of isolates  
(% of total) 
n=161 
Actinomyces canis 4 (3.1) 1 (0.6) 
Actinomyces hordeovulneris   8 (5.0) 
Anaerococcus sp./Peptostreptococcus sp.* 1 (0.8)   
Bacillus simplex   1 (0.6) 
Bacillus sp. 1 (0.8)   
Bacteroides heparinolyticus   1 (0.6) 
Bacteroides pyogenes   1 (0.6) 
Bacteroides tectus 2 (1.5) 4 (2.5) 
Bergeyella sp.  3 (2.3) 1 (0.6) 
Bergeyella zoohelcum 2 (1.5)   
Capnocytophaga cynodegmi 1 (0.8)   
Carnobacterium divergens 1 (0.8)   
Catonella sp. 1 (0.8)   
Chryseobacterium sp.   2 (1.2) 
Citrobacter braakii   1 (0.6) 
Clostridium perfringens 1 (0.8)   
Comamonadaceae bacterium   1 (0.6) 
Corynebacterium felinum 1 (0.8)   
Corynebacterium sp. 1 (0.8)   
Cupriavidus basilensis   1 (0.6) 
Curculio sikkimens/Serratia 
grimesii/Pectobacterium carotovorum* 
2 (1.5)   
Cythophaga sp. 1 (0.8)   
Enterococcus casseliflavus 1 (0.8)   
Enterococcus faecalis   1 (0.6) 
Enterococcus sp. 1 (0.8) 1 (0.6) 
Escherichia coli/Shigella flexneri*   5 (3.1) 
Eubacteriaceae bacterium 1 (0.8)   
Filifactor villosus 3 (2.3) 1 (0.6) 
Fusobacterium equinum 1 (0.8)   
Fusobacterium rusii   1 (0.6) 
Gordonia otidis   1 (0.6) 
Hafnia sp.   2 (1.2) 
Lactobacillales bacterium 2 (1.5) 2 (1.2) 
Microbacterium sp.   2 (1.2) 
Moraxella ovis 1 (0.8) 1 (0.6) 
Moraxella sp. 1 (0.8)   
Mycoplasma arginini 1 (0.8)   
Neisseria canis   2 (1.2) 
Neisseria shayeganii   2 (1.2) 
Neisseria zoodegmatis 3 (2.3)   
Neissseria sp. 7 (5.3)   
Pantoea agglomerans 1 (0.8)   
Pasteurella canis   4 (2.5) 
Pasteurella multocida strain 3 (2.3) 1 (0.6) 
Pasteurella multocida subsp. multocida 1 (0.8) 16 (9.9) 
Pasteurella multocida subsp. septica  13 (9.9) 16 (9.9) 
Pasteurella multocida subsp. 
septica/multocida* 
  7 (4.3) 
Pasteurella pneumotropica 3 (2.3) 5 (3.1) 
Pasteurella sp. 3 (2.3) 5 (3.1) 
Pasteurella stomatis  2 (1.5)   
Peptostreptococcus sp.  2 (1.5)   
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Table 5.2 continued 
 
Species 
 
Healthy FCGS 
No. of isolates 
(% of total) 
n=131 
No. of isolates 
(% of total) 
n=161 
Porphyromonas canoris   1 (0.6) 
Porphyromonas circumdentaria 5 (3.8) 1 (0.6) 
Porphyromonas gulae g 2 (1.5) 1 (0.6) 
Porphyromonas sp. 1 (0.8) 1 (0.6) 
Propionibacterium acnes 1 (0.8)   
Pseudomonas reactans   1 (0.6) 
Pseudomonas sp.   3 (1.9) 
Rhodococcus   1 (0.6) 
Shigella sp   2 (1.2) 
Staphylococcus aureus   1 (0.6) 
Staphylococcus epidermidis 2 (1.5)   
Staphylococcus pasteuri   1 (0.6) 
Staphylococcus sp.   1 (0.6) 
Streptococcus minor 1 (0.8) 2 (1.2) 
Streptococcus sobrinus   1 (0.6) 
Tannerella forsythia 1 (0.8)   
Uncultured bacterium 40 (30.5) 35 (21.7) 
Uncultured beta proteobacterium   1 (0.6) 
Uncultured Capnocytophaga   1 (0.6) 
Uncultured Citrobacter   3 (1.9) 
Uncultured Haemophilus sp. 1 (0.8)   
Uncultured Micrococcus   1 (0.6) 
Uncultured Porphyromonas   1 (0.6) 
Virgillobacillus halophilus   4 (2.5) 
Xanthomonadaceae bacterium  5 (3.8) 1 (0.6) 
Bacterial species identified by 16S rRNA gene sequencing of isolates obtained following 
microbiological culture from 13 healthy samples and 22 FCGS samples. 
* Unable to distinguish between two or more species, therefore grouped generically. 
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Table 5.3: Isolates identified as previously uncultured bacteria 
 
Accession number 
 
Healthy FCGS 
No of isolates  
(% of total) 
n=131 
No of isolates  
(% of total) 
n=161 
AB368999 1 (0.8) 1 (0.6) 
AY850486   1 (0.6) 
DQ447792 1 (0.8)   
DQ860033   1 (0.6) 
EF511977   1 (0.6) 
EF516089   1 (0.6) 
EU472784   1 (0.6) 
EU535692   1 (0.6) 
EU681991   4 (2.5) 
EU762526   1 (0.6) 
FM872599   1 (0.6) 
GQ010287 1 (0.8)   
GQ010438   1 (0.6) 
GQ110814 1 (0.8) 3 (1.9) 
GQ110821   1 (0.6) 
GQ111117 1 (0.8)   
GQ111197 1 (0.8)   
GQ111280 2 (1.5) 1 (0.6) 
GQ114820 1 (0.8)   
GQ158316 7 (5.3)   
HM278514 1 (0.8)   
HM326498 4 (3.1)   
JF032321 1 (0.8)   
JF041223 1 (0.8) 1 (0.6) 
JF092143   1 (0.6) 
JF104340 1 (0.8) 1 (0.6) 
JF108085   2 (1.2) 
JF108316 2 (1.5)   
JF108357 2 (1.5)   
JF147582 1 (0.8)   
JF154679 2 (1.5) 5 (3.1) 
JF174825 2 (1.5) 1 (0.6) 
JF175431 3 (2.3) 1 (0.6) 
JF176465   1 (0.6) 
JF180219   1 (0.6) 
JF223924 1 (0.8)   
JF224016   1 (0.6) 
JF240330   1 (0.6) 
JF240812 1 (0.8)   
JF241047 1 (0.8)   
JF241102 1 (0.8)   
Previously uncultured bacteria (ordered by accession number) isolated from 13 healthy and 22 
FCGS samples. 
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Table 5.4: Bacterial counts of the isolates 
 
Species 
 
Healthy FCGS 
Average CFU/ml per 
sample  
(no of samples) 
Average CFU/ml per 
sample  
(no of samples) 
Actinomyces canis 4.1 103 (2)   
Bacteroides heparinolyticus   8.0 104 (1) 
Bacteroides pyogenes   6.0 104 (1) 
Bacteroides tectus 2.3 104 (1)   
Bergeyella sp.  2.3 104 (2) 8.0 103 (1) 
Bergeyella zoohelcum 1.9 104 (2)   
Capnocytophaga cynodegmi 1.0 105 (1)   
Citrobacter braakii   8.0 103 (1) 
Corynebacterium sp. 4.0 103 (1)   
Cythophaga sp. 1.0 103 (1)   
Enterococcus sp.   1.1 103 (1) 
Filifactor villosus 1.8 104 (1) 8.0 104 (1) 
Fusobacterium equinum 2.0 103 (1)   
Hafnia sp.   1.6 108 (1) 
Lactobacillales bacterium 1.7 104 (1) 1.5 102 (1) 
Moraxella sp. 2.2 105 (2)   
Neisseria canis   1.5 104 (1) 
Neisseria shayeganii   9.0 106 (2) 
Neisseria zoodegmatis 1.4 105 (3)   
Neissseria sp. 1.9 104 (2) 8.0 103 (1) 
Pasteurella multocida strain 1.3 104 (2) 2.6 104 (1) 
Pasteurella multocida subsp. multocida   8.2 104 (2) 
Pasteurella multocida subsp. septica  1.4 104 (5) 9.1 107 (2) 
Pasteurella sp. 4.2 104 (2) 5.2 107 (1) 
Pasteurella stomatis  6.0 103 (2)   
Peptostreptococcus sp.  2.0 103 (1)   
Porphyromonas circumdentaria 6.2 104 (4) 6.0 105 (1) 
Porphyromonas gulae g 5.3 104 (1)   
Porphyromonas sp. 8.0 105 (1)   
Propionibacterium acnes 6.0 103 (1)   
Pseudomonas sp.   3.3 106 (1) 
Staphylococcus epidermidis 2.0 102 (1)   
Staphylococcus pasteuri   2.0 106 (1) 
Streptococcus minor   1.8 105 (1) 
Tannerella forsythia 1.2 103 (1)   
Uncultured bacterium 3.5 104 (8) 3.3 104 (5) 
Uncultured beta proteobacterium   4.0 104 (1) 
Uncultured Capnocytophaga   1.0 104 (1) 
Uncultured Citrobacter   1.8 107 (1) 
Uncultured Porphyromonas   8.0 104 (1) 
Xanthomonadaceae bacterium  3.6 104 (3)   
Average bacterial counts in colony forming units (CFU) per millilitre per sample, of the isolated 
bacteria from nine FCGS (F12-F21) and eight healthy samples (H6-H13). 
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5.3.1.4 Veterinary Diagnostics Service – microbiological culture 
Samples F2 to F19 were cultured as part of the Veterinary Diagnostic Service at the 
University of Glasgow companion animal diagnostics laboratory. The results are shown in 
Table 5.5 next to the different species per sample detected by 16S rRNA gene 
sequencing. From the diagnostic laboratory no results were given for samples F11 and 
F18.  
5.3.2 Culture-independent methods 
5.3.2.1 Bacterial DNA amplification 
All 22 FCGS samples analysed were positive for the presence of bacteria as determined 
by 16S rRNA PCR. A small amount of bacterial DNA was identified in samples F7, F11 and 
F21. All 13 healthy samples were positive for the presence of bacteria. 
5.3.2.2 Cloning 
All 35 samples were subjected to cloning. During cloning, the use of bluo-gal ensured 
blue coloured colonies were formed when no insert was present. Blue, light blue and 
white colonies formed on the plates. Light blue colonies became darker and easier to 
distinguish from the white colonies when kept at 4°C for at least 4 days. Of the 22 FCGS 
samples, F7 had a low cloning efficiency, showing a high percentage of blue and light 
blue colonies in comparison to the white colonies. Low colony numbers were also 
observed in samples F11 and F21 and re-amplification failed to isolate clones with 16S 
rRNA gene inserts. Purification of the PCR product before cloning did not change this 
outcome. All thirteen healthy samples were cloned successfully. From each individually 
cloned sample, a library of approximately 50 clones was re-amplified with the exception 
of sample F7 where, due to low cloning efficiency, only 27 clones were successfully re-
amplified by PCR (Table 5.6).  
5.3.2.3 Enzyme digestion 
All re-amplified clones were digested with the enzymes RsaI and MnlI and depending on 
the different product sizes the clones were grouped according to their restriction 
fragments length polymorphism (RFLP) profiles. One clone was sequenced from each 
RFLP group. Between four and 34 clones were sequenced per individual sample (Table 
5.6).  
Chapter 5 Identification of bacteria associated with FCGS 96 
 
Table 5.5: FCGS isolates 
Sample 16S sequencing Veterinary diagnostics (culture) 
F2 Pasteurella multocida multocida/septica 
Pasteurella pneumotropica 
Staphylococcus aureus 
Pseudomonas 
Chryseobacterium 
 
Pasteurella multocida (moderate 
pure) 
F3 Pasteurella multocida multocida/septica 
Pasteurella pneumotropica 
 
Pasteurella multocida (profuse) 
Staphylococcus (sparse) 
F4 Pasteurella multocida multocida 
Bacteroides tectus 
Moraxella ovis 
Staphylococcus sp. 
Streptococcus sobrinus 
 
Pasteurella multocida (profuse pure) 
F5 Pasteurella multocida multocida/septica 
Pasteurella pneumotropica 
Pasteurella sp. 
Chryseobacterium sp. 
Cupriavidus basilensis 
Enterococcus faecalis 
Pseudomonas reactans 
Pseudomonas sp. 
 
Pasteurella multocida (moderate) 
Streptococcus (sparse) 
Gram negative rods (sparse) 
F6 Pasteurella canis 
Pasteurella multocida septica 
Bacteroides tectus 
Fusobacterium rusii 
Porphyromonas canoris 
 
Pasteurella multocida (moderate 
pure) 
F7 Actinomyces hordeovulneris 
Rhodococcus 
Cellulomonas/microbacterium sp.  
Porphyromonas asaccharolytica 
Bacteroides ureolyticus 
(moderate mixed culture) 
 
F8 Pasteurella sp. 
Bacteroides tectus  
Actinomyces hordeovulneris 
Shigella sp. 
 
Coliform (sparse) 
Pasteurella multocida (moderate) 
Bacteroides (profuse) 
F9 Actinomyces canis 
Actinomyces hordeovulneris 
Microbacterium sp. 
Pasteurella multocida multocida 
Corynebacterium proinquum 
Streptococcus 
(sparse mixed culture) 
F10 Bacillus simplex 
Xanthomonadaceae bacterium 
Comamoadeceae bacterium 
Actinomyces hordeovulneris 
 
Pasteurella multocida (profuse pure) 
 
F11 Pasteurella sp. 
Porphyromonas gulae 
 
No results 
 
F12 Pasteurella multocida septica 
Porphyromonas sp. 
 
Pasteurella multocida (profuse pure) 
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Table 5.5 continued 
Sample 16S sequencing Veterinary diagnostics (culture) 
F13 Neisseria shayeganii 
Pasteurella sp. 
Hafnia sp. 
Staphylococcus pasteuri 
Pasteurella multocida septica 
Pasteurella sp. 
Streptococcus 
(profuse mixed culture) 
 
F14 Pasteurella multocida multocida 
Bacteroides pyogenes 
Filifactor villosus 
Neisseria shayeganii 
 
Pasteurella multocida 
Pasteurella sp. 
(moderate profuse mixed culture) 
F15 Pseudomonas sp. 
Uncultured beta proteobacterium 
Uncultured Capnocytophaga 
 
Gram negative large rods (sparse) 
F16 Bacteroides heparinolticus 
Bergeyella sp. 
Pasteurella multocida 
Porphyromonas circumdentaria 
 
Pasteurella multocida (moderate) 
Beta-haemolitic Escherichia coli 
(sparse) 
F17 Escherichia coli/Shigella flexneri 
Pasteurella multocida septica 
 
Beta haemolytic Escherichia coli 
(profuse pure) 
 
F18 Enterococcus sp. 
Neisseria canis 
No results 
 
F19 Pasteurella multocida multocida 
Neisseria sp. 
Pasteurella multocida (sparse) 
Gram negative coccobacillus (sparse) 
Morphologically different bacteria identified by 16S rRNA gene sequencing, and most represented 
bacteria isolated from Columbia agar and fastidious anaerobe agar by the laboratory at the 
Veterinary Diagnostics Service. 
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Table 5.6: Analysed clones per sample library 
FCGS Healthy 
Sample Total clones 
analysed 
Number of 
RFLP groups 
Sample Total clones 
analysed 
Number of 
RFLP groups 
F1 51 27 H1 50 34 
F2 50 19 H2 56 22 
F3 50 12 H3 51 29 
F4 52 9 H4 54 20 
F5 50 24 H5 53 22 
F6 51 28 H6 46 17 
F7 27 10 H7 51 15 
F8 48 15 H8 51 18 
F9 50 13 H9 51 23 
F10 48 15 H10 49 14 
F11 0 0 H11 51 10 
F12 51 15 H12 51 14 
F13 49 17 H13 49 15 
F14 47 22    
F15 51 5    
F16 51 19    
F17 51 4    
F18 46 10    
F19 52 10    
F20 51 8    
F21 0 0    
F22 50 7    
Total number of analysed clones and the number of RFLP groups per individual sample. 
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5.3.2.4 BLAST database comparison 
From the clone libraries generated from the 20 FCGS samples, 976 clones were analysed 
and 289 clones were sequenced. Bacteria identified with a similarity of 98% or more 
with known species in the used databases (Genbank, EMBL, DDBJ, PDB) are shown in 
Table 5.7. The most frequently identified bacteria in the cats with FCGS were P. 
multocida subsp. multocida (14.1% of clones analysed) P. multocida subsp. septica 
(11.5%), Pseudomonas sp. (7.3%), Tannerella forsythia (6.6%) and Porphyromonas 
circumdentaria (5.6%). A variety of uncultured bacteria represented 7.7% of all analysed 
FCGS clones. No individual uncultured species was over-represented in the FCGS group 
(Table 5.8) 
From the 13 healthy samples a total of 663 clones were analysed and 253 clones were 
sequenced. The bacteria identified are shown in Table 5.7. The predominant species in 
the healthy group were Xanthomonadaceae bacterium (6.2% of clones analysed), 
Capnocytophaga canimorsus (5.4%), Capnocytophaga cynodegmi (4.8%), Bergeyella 
species (4.5%) and P. multocida subsp. septica (4.4%). A large proportion of uncultured 
bacteria (29%) were found in the healthy group. Two of these uncultured bacteria were 
particularly well represented in these cats: GQ111280 (4.2%) which is the partial 
sequence of an uncultured bacterium clone nbw623c11c1 identified from a human skin 
swab of the antecubital fossa (Grice et al., 2009); and HM326498 (3.6%), a partial 
sequence of an uncultured bacterium clone ncd461e11c1 (direct submission) which was 
also identified from a human arm skin swab sample (Table 5.8). The five most prevalent 
bacterial species found in the healthy and FCGS samples are shown in Figure 5.1. 
The different phyla that were identified in the FCGS and healthy samples were 
compared (Figure 5.2). Healthy samples contained predominantly uncultured bacteria, 
Bacteroidetes and Proteobacteria. In the FCGS samples, Proteobacteria was 
predominant and a high proportion of Bacteroidetes was also seen. When the 
distribution of the genera within healthy and FCGS samples was compared, the 
predominant groups in the healthy samples were uncultured bacteria and 
Capnocytophaga species, whereas the predominant species in the FCGS group were 
Pasteurella species (Figure 5.3). 
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Table 5.7: Bacterial species identified by culture-independent (16S rRNA gene cloning) 
methods 
 
 
Species 
Healthy FCGS 
No. of clones 
analysed 
(% of total) 
n=663 
No. of clones 
sequenced 
(% of total) 
n=253 
No. of clones 
analysed 
(% of total) 
n=976 
No. of clones 
sequenced (% 
of total) 
n=289 
Abiotrophia defectiva  1 (0.2) 1 (0.4)     
Acinetobacter     2 (0.2) 2 (0.7) 
Actinobaccilus capsulatus       1 (0.3) 
Actinomyces     2 (0.2) 1 (0.3) 
Actinomyces canis     2 (0.2) 2 (0.7) 
Advenella sp./Pelistega 
europaea/tetrathibacter 
kashmirensis* 
1 (0.2) 1 (0.4)     
Afipia genosp.      4 (0.4) 2 (0.7) 
Bacterium cp04.13 4 (0.6) 4 (1.6) 2 (0.2) 1 (0.3) 
Bacterium enrichment culture 10 (1.5) 5 (2.0)     
Bacteroides pyogenes     1 (0.1) 1 (0.3) 
Bacteroides tectus 2 (0.3) 1 (0.4) 3 (0.3) 3 (1.0) 
Bergeyella sp.  30 (4.5) 11 (4.3) 3 (0.3) 2 (0.7) 
Capnocytophaga canimorsus 36 (5.4) 6 (2.4) 6 (0.6) 3 (1.0) 
Capnocytophaga cynodegmi 32 (4.8) 5 (2.0) 1 (0.1) 1 (0.3) 
Citrobacter amalonaticus/ 
Citrobacter sp.* 
1 (0.2) 1 (0.4)     
Clostridium botulinum/ 
Clostridium sporogenes* 
1 (0.2) 1 (0.4)     
Cythophaga sp. 1 (0.2) 1 (0.4) 9 (0.9) 3 (1.0) 
Desulfomicrobium orale  14 (2.1) 5 (2.0) 16 (1.6) 4 (1.4) 
Eubacterium sp.     2 (0.2) 2 (0.7) 
Flexistipes-like sp. Oral     2 (0.2) 1 (0.3) 
Fusobacterium canifelinum     4 (0.4) 4 (1.4) 
Haemophilus felis 2 (0.3) 2 (0.8) 1 (0.1) 1 (0.3) 
Kebsiella sp. 4 (0.6) 1 (0.4)     
Lysobacter sp.  1 (0.2) 1 (0.4)     
Moraxella canis 23 (3.5) 4 (1.6)     
Moraxella lacunata     1 (0.1) 1 (0.3) 
Moraxella ovis 3 (0.5) 2 (0.8)     
Moraxella sp. 12 (1.8) 5 (2.0) 1 (0.1) 1 (0.3) 
Neisseria canis     19 (1.9) 2 (0.7) 
Odoribacter denticanis     9 (0.9) 3 (1.0) 
Pasteurella canis     2 (0.2) 1 (0.3) 
Pasteurella multocida strain 13 (2.0) 7 (2.8) 2 (0.2) 1 (0.3) 
Pasteurella multocida 
multocida/septica* 
    41 (4.2) 4 (1.4) 
Pasteurella multocida 
multocida 
2 (0.3) 2 (0.8) 138 (14.1) 25 (8.7) 
Pasteurella multocida. septica  29 (4.4) 8 (3.2) 112 (11.5) 18 (6.2) 
Pasteurella pneumotropica 20 (3.0) 7 (2.8) 11 (1.1) 4 (1.4) 
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Table 5.7 continued 
 
 
Species 
Healthy FCGS 
No. of clones 
analysed 
(% of total) 
n=663 
No. of clones 
sequenced 
(% of total) 
n=253 
No. of clones 
analysed 
(% of total) 
n=976 
No. of clones 
sequenced (% 
of total) 
n=289 
Pasteurella sp. 6 (0.9) 3 (1.2) 26 (2.7) 6 (2.1) 
Pasteurella stomatis  1 (0.2) 1 (0.4)     
Peptococcus sp. (oral)     24 (2.5) 6 (2.1) 
Peptostreptococcus sp.  1 (0.2) 1 (0.4)     
Porphyromonas cangigivalis     2 (0.2) 1 (0.3) 
Porphyromonas canoris 3 (0.5) 2 (0.8) 14 (1.4) 4 (1.4) 
Porphyromonas circumdentaria 7 (1.1) 2 (0.8) 55 (5.6) 15 (5.2) 
Porphyromonas gulae     4 (0.4) 2 (0.7) 
Pseudomonas reactans     13 (1.3) 6 (2.1) 
Pseudomonas sp. 1 (0.2) 1 (0.4) 71 (7.3) 15 (5.2) 
Pseudomonas synxantha     1 (0.1) 1 (0.3) 
Shigella flexneri     26 (2.7) 2 (0.7) 
Simonsiella sp. 2 (0.3) 2 (0.8)     
Stenotrophomonas maltophilia     1 (0.1) 1 (0.3) 
Stenotrophomonas sp.     1 (0.1) 1 (0.3) 
Tannerella forsythia 6 (0.9) 4 (1.6) 64 (6.6) 13 (4.5) 
Treponema sp.     7 (0.8) 5 (1.7) 
Treponema vincentii     1 (0.1) 1 (0.3) 
Uncultured bacterium 192 (29.0) 70 (27.7) 75 (7.7) 46 (15.9) 
Uncultured Capnocytophaga 21 (3.2) 4 (1.6) 44 (4.5) 7 (2.4) 
Uncultured citrobacter     42 (4.3) 4 (1.4) 
Uncultured delta 
proteobacterium 
    4 (0.4) 1 (0.3) 
Uncultured endomicrobia     2 (0.2) 1 (0.3) 
Uncultured lachnospiraceae     1 (0.1) 1 (0.3) 
Uncultured propionivibrio sp. 3 (0.5) 1 (0.4)     
Uncultured Pseudomonas sp.     8 (0.8) 5 (1.7) 
Uncultured Termite group     1 (0.1) 1 (0.3) 
Uncultured Treponema     1 (0.1) 1 (0.3) 
Xanthomonadaceae bacterium  41 (6.2) 10 (4.0) 2 (0.2) 2 (0.7) 
Bacterial species (at least 98% identity) identified by 16S rRNA gene sequencing of clones from 13 
healthy and 20 FCGS samples. n= total amount of samples analysed or sequenced, in columns 
total amount of samples with at least 98% identity. 
* Unable to distinguish between two or more species, therefore grouped generically. 
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Table 5.8: Uncultured bacteria identified by culture-independent (16S rRNA gene cloning) 
methods 
 
 
Species 
Healthy FCGS 
No. of clones 
analysed 
(% of total) 
n=663 
No. of clones 
sequenced 
(% of total) 
n=253 
No. of clones 
analysed 
(% of total) 
n=976 
No. of clones 
sequenced (% 
of total) 
n=289 
DQ113703.1 10 (1.5) 2 (0.8)     
DQ113720.1 3 (0.5) 1 (0.4)     
DQ113762.1 5 (0.8) 2 (0.8)     
DQ925900.1     5 (0.5) 5 (1.7) 
EU540333.1     1 (0.1) 1 (0.3) 
EU681966.1 1 (0.2) 1 (0.4)     
EU681991.1     1 (0.1) 1 (0.3) 
EU681995.1 1 (0.2) 1 (0.4)     
EU828420.1     1 (0.1) 1 (0.3) 
FJ892840.1     1 (0.1) 1 (0.3) 
FJ893172.1     1 (0.1) 1 (0.3) 
FJ893207.1     2 (0.2) 1 (0.3) 
FJ894994.1     6 (0.6) 1 (0.3) 
GQ009341.1     1 (0.1) 1 (0.3) 
GQ010438.1 3 (0.5) 1 (0.4) 1 (0.1) 1 (0.3) 
GQ010546.1     4 (0.4) 2 (0.7) 
GQ016546.1 6 (0.9) 3 (1.2) 6 (0.6) 4 (1.4) 
GQ111117.1 8 (1.2) 5 (2.0) 3 (0.3) 2 (0.7) 
GQ111197.1 1 (0.2) 1 (0.4)     
GQ111229.1 1 (0.2) 1 (0.4) 2 (0.2) 1 (0.3) 
GQ111278.1 2 (0.3) 1 (0.4) 5 (0.5) 4 (1.4) 
GQ111280.1 28 (4.2) 3 (1.2) 1 (0.1) 1 (0.3) 
GQ111288.1 1 (0.2) 1 (0.4)     
GQ111657.1 4 (0.6) 2 (0.8)     
GQ113620.1 5 (0.8) 2 (0.8)     
GQ114820.1 3 (0.5) 3 (1.2)     
GQ158348.1 1 (0.2) 1 (0.4)     
GQ358873.1 1 (0.2) 1 (0.4)     
HM272460.1 1 (0.2) 1 (0.4)     
HM276442.1     2 (0.2) 1 (0.3) 
HM278396.1 1 (0.2) 1 (0.4)     
HM278403.1     1 (0.1) 1 (0.3) 
HM313082.1     2 (0.2) 1 (0.3) 
HM326498.1 24 (3.6) 8 (3.2) 4 (0.4) 1 (0.3) 
HM328219.1 2 (0.3) 1 (0.4)     
HM330153.1 5 (0.8) 2 (0.8) 4 (0.4) 3 (1.0) 
HM330648.1 4 (0.6) 1 (0.4)     
HM335226.1     2 (0.2) 2 (0.7) 
HM336336.1 2 (0.3) 1 (0.4)     
HM336349.1 10 (1.5) 1 (0.4)     
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Table 5.8 continued 
 
 
Species 
Healthy FCGS 
No. of clones 
analysed 
(% of total) 
n=663 
No. of clones 
sequenced 
(% of total) 
n=253 
No. of clones 
analysed 
(% of total) 
n=976 
No. of clones 
sequenced (% 
of total) 
n=289 
HM336383.1 1 (0.2) 1 (0.4)     
HM340972.1 8 (1.2) 4 (1.6) 3 (0.3) 2 (0.7) 
JF005737.1 1 (0.2) 1 (0.4)     
JF041223.1     2 (0.2) 1 (0.3) 
JF042996.1 2 (0.3) 2 (0.8)     
JF045026.1 1 (0.2) 1 (0.4)     
JF092109.1 4 (0.6) 3 (1.2) 5 (0.5) 3 (1.0) 
JF104340.1 1 (0.2) 1 (0.4)     
JF108085.1 2 (0.3) 2 (0.8)     
JF125670.1 15 (2.3) 2 (0.8)     
JF223781.1 3 (0.5) 1 (0.4) 6 (0.6) 1 (0.3) 
JF232582.1 3 (0.5) 1 (0.4)     
JF240378.1     1 (0.1) 1 (0.3) 
JF240413.1 1 (0.2) 1 (0.4)     
JF240735.1 16 (2.4) 2 (0.8)     
JF240930.1     1 (0.1) 1 (0.3) 
JF240949.1     1 (0.1) 1 (0.3) 
JF241102.1 1 (0.2) 1 (0.4)     
Uncultured bacteria cloned from thirteen healthy samples and twenty-two FCGS samples. 
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Figure 5.3: Most frequently identified bacterial species in the FCGS and healthy samples 
 
Five most prevalent bacterial species shown as a percentage of the total of all clones from 20 
FCGS and 13 healthy samples. 
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Figure 5.4: Distribution of phyla in FCGS and healthy samples 
 
Distribution of the different phyla identified by 16S rRNA gene sequencing of the clone libraries 
from healthy and FCGS samples. 
 
Figure 5.5: Distribution of genera in FCGS and healthy samples 
 
Distribution of the different genera identified by 16S rRNA gene sequencing of the clone libraries 
from healthy and FCGS samples. 
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5.3.2.5 Potentially novel phylotypes 
Species with less than 98% identity to a known sequence from the BLAST database were 
classified as potentially novel phylotypes. In the 20 FCGS samples 93 clones were 
potentially novel represented in 48 potentially novel RFLP groups. One hundred and 
thirty-seven clones in the 13 healthy samples were potentially novel, represented in 70 
potentially novel RFLP groups. In order to determine if some of the phylotypes were 
truly novel, near full-length 16S rRNA gene sequences were obtained for the clones 
representing potentially novel phylotypes from six FCGS (F1-F6) and three healthy (H1-
H3) samples. The potentially novel phylotypes whose 16S rRNA was not sequenced fully 
from the remaining 14 FCGS and 10 healthy samples are shown in Table 5.9. 
From samples F1 to F6, 25 clones from 17 RFLP groups were classified as potentially 
novel phylotypes. From three healthy samples (H1-H3) 69 clones from 37 different RFLP 
groups were classified as potentially novel phylotypes. The near full-length 16S rRNA 
gene was sequenced for 54 clones from the different RFLP groups. From 17 FCGS clones, 
four were found to be novel phylotypes and from the healthy samples a total of 18 
clones were confirmed as being novel phylotypes. The species most closely related to 
the identified novel phylotypes are shown in Table 5.10. Phylogenetic analysis for all 
species that were identified in these nine samples and for the 22 novel phylotypes is 
shown in Figure 5.4 
In the nine samples, six phyla were identified; Actinobacteria, Bacteroidetes, 
Firmicutes, Fusobacteria, Spirochaetes and Proteobacteria. Two novel clones branched 
into the Bacteroidetes phylum, three novel clones (including one FCGS clone) into the 
Firmicutes phylum and one clone branched into the Actinobacteria phylum. Fifteen 
novel clones (two from FCGS and 13 from healthy samples) branched away from the 
known species in a separate cluster, which also contained uncultured Capnocytophaga 
AF426105. 
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Table 5.9: Bacteria most closely related to potentially novel phylotypes 
 
 
Species 
Healthy FCGS 
No. of clones 
analysed 
(% of total) 
n=663 
No. of clones 
sequenced 
(% of total) 
n=253 
No. of clones 
analysed 
(% of total) 
n=976 
No. of clones 
sequenced  
(% of total) 
n=290 
Actinomyces sp. 2 (0.3) 2 (0.8)     
Bacterium 2 (0.3) 1 (0.4) 
    
Bacteroidales oral clone 1 (0.2) 1 (0.4) 1 (0.1) 1 (0.3) 
Bacteroides sp. 4 (0.6) 2 (0.8) 2 (0.2) 1 (0.3) 
Bacteroides tectus 
    
2 (0.2) 1 (0.3) 
Bergeyella sp.  1 (0.2) 1 (0.4) 
    
Capnocytophaga canimorsus 10 (1.5) 4 (1.6) 2 (0.2) 1 (0.3) 
Catonella sp. 
    
1 (0.1) 1 (0.3) 
Chryseobacterium sp. 1 (0.2) 1 (0.4) 
    
Comamonas sp.  2 (0.3) 1 (0.4)     
Desulfovibrio sp. 
    
1 (0.1) 1 (0.3) 
Eubacterium brachii 
    
2 (0.2) 1 (0.3) 
Mannheimia sp. 1 (0.2) 1 (0.4) 
    
Micromonas micros     2 (0.2) 1 (0.3) 
Moraxella ovis     2 (0.2) 2 (0.7) 
Neisseria sp. 1 (0.2) 1 (0.4) 
    
Parvimonas sp. 
    
1 (0.1) 1 (0.3) 
Pasteurella multocida multocida 
    
1 (0.1) 1 (0.3) 
Pasteurella pneumotropica 1 (0.2) 1 (0.4) 2 (0.2) 2 (0.7) 
Pasteurella pneumotropica/ 
stomatitis     
1 (0.1) 1 (0.3) 
Pasteurella sp. 1 (0.2) 1 (0.4) 
    
Pasteurella trehalosi 1 (0.2) 1 (0.4) 
    
Peptococcus sp. (oral)     3 (0.3) 3 (1.0) 
Porphyromonas sp. 10 (1.5) 5 (2.0) 1 (0.1) 1 (0.3) 
Prevotella sp. 4 (0.6) 1 (0.4) 
    
Sufflavibacter maritimus 1 (0.2) 1 (0.4) 
    
Treponema sp. 
    
1 (0.1) 1 (0.3) 
Uncultured actinobacterium 
    
7 (0.7) 2 (0.7) 
Uncultured anaerovorax 1 (0.2) 1 (0.4) 
    
Uncultured bacterium 46 (6.9) 23 (9.1) 34 (3.5) 17 (5.9) 
Uncultured Bacteroidetes 7 (1.1) 2 (0.8) 3 (0.3) 1 (0.3) 
Uncultured Capnocytophaga 19 (2.9) 10 (4.0) 
    
Uncultured Catonella 2 (0.3) 1 (0.4)     
Uncultured Endomicrobium 7 (1.1) 1 (0.4) 12 (1.2) 2 (0.7) 
Uncultured Firmicutes 2 (0.3) 2 (0.8) 6 (0.6) 2 (0.7) 
Uncultured Fusibacter 2 (0.3) 1 (0.4) 
    
Uncultured Lachnospiraceae     5 (0.5) 3 (1.0) 
Uncultured Peptococcus 1 (0.2) 1 (0.4) 
    
Uncultured Treponema     1 (0.1) 1 (0.3) 
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Table 5.9 continued 
 
 
Species 
Healthy FCGS 
No. of clones 
analysed 
(% of total) 
n=663 
No. of clones 
sequenced 
(% of total) 
n=253 
No. of clones 
analysed 
(% of total) 
n=976 
No. of clones 
sequenced 
(% of total) 
n=290 
Virgibacillus marismortui 1 (0.2) 1 (0.4)     
Virgibacillus marismortui/ 
Bacillus permians* 
5 (0.8) 1 (0.4)     
Virgibacillus sp./Salibacillus sp.*  1 (0.2) 1 (0.4)     
Potentially novel phylotypes identified by 16S rRNA sequencing of clones from 20 FCGS and 13 
healthy samples. 
* Unable to distinguish between two or more species, therefore grouped generically. 
 
Table 5.10: Phylotypes confirmed as novel 
Clone  Accession 
No. 
Most closely related bacterium Identity 
(%) 
H1cl11 EU535726.1 Uncultured bacterium clone nbt10b01 95.1 
H1cl29 AB243853.1 Virgibacillus halophilus 96.8 
H1cl32 GQ111117.1 Uncultured bacterium clone nbw621a08c1 96.4 
H1cl40 DQ232854.1 Uncultured Enterococcus sp. clone F28 93.9 
H1cl43 HM336282.1 Uncultured bacterium clone ncd1073b06c1 93.9 
H1cl63 EU681996.1 Uncultured bacterium clone DH5-10 94.2 
H2cl4 FJ672502.1 Uncultured bacterium clone Ll142-5G3 96.1 
H3cl8 AM420030.1 Uncultured Capnocytophaga sp. 94.6 
H3cl9 AM420030.1 Uncultured Capnocytophaga sp. partial 93.8 
H3cl23 FJ669153.1 Capnocytophaga canimorsus strain BD05-00029 92.6 
H3cl25 AM420030.1 Uncultured Capnocytophaga sp. 94.2 
H3cl27 AM420030.1 Uncultured Capnocytophaga sp. 94.2 
H3cl29 FJ669153.1 Capnocytophaga canimorsus strain BD05-00029 92.7 
H3cl37 FJ960029.1 Uncultured bacterium clone D940_095 95.2 
H3cl40 AM420030.1 Uncultured Capnocytophaga sp. 93.8 
H3cl41 FJ669153.1 Capnocytophaga canimorsus strain BD05-00029 92.5 
H3cl55 EU535726.1 Uncultured bacterium clone nbt10b01 96.9 
H3cl57 AM420030.1 Uncultured Capnocytophaga sp. 93.7 
F1cl64 EU409846.1 Uncultured gamma proteobacterium clone 95.8 
F2cl10 AB270004.1 Uncultured rumen bacterium 95.4 
F2cl20 AB195883.1 Uncultured bacterium gene 90.6 
F3cl37 AM420050.1 Uncultured Eubacterium sp. 96.3 
Novel bacterial phylotypes identified by 16S rRNA sequencing of clones from three healthy and 
six FCGS samples. 
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Figure 5.6: Phylogenetic analysis 
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Legend to Figure 5.6 
All bacterial species identified in six FCGS and three healthy samples (including confirmed novel 
phylotypes) 
Clones representing novel phylotypes: , FCGS; , healthy 
Clones representing known phylotypes (Dolieslager et al., 2011); , FCGS only, , healthy 
only; , FCGS and healthy 
Known phylotypes to which novel phylotypes are most closely related as determined by BLAST 
analysis: , FCGS; , healthy 
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5.4 Discussion 
Although it has been suggested that bacteria are an important part of the 
aetiopathogenesis of FCGS, their specific roles are unclear. Over the years, several 
studies have been conducted to identify bacterial species in the oral cavity of the cat. 
The most important bacteria that are implicated to play a role in FCGS are gram-
negative anaerobes and Bartonella species (Sims et al., 1990; Glaus et al., 1997). 
Research on Bartonella species shows contradictory results on the possible relationship 
between Bartonella henselae and feline oral diseases. In one study, a possible link 
between gingivitis and seropositivity for both FIV and Bartonella species was shown 
(Ueno et al., 1996). An increase in the frequency of diagnosing stomatitis in cats that 
are seropositive for B. henselae has also been reported (Glaus et al., 1997). In a study 
with 190 cats, no correlation was described between Bartonella species and oral lesions 
when PCR was performed on oral swab samples; however the same study showed cats 
were three to four times more likely to suffer from oral lesions when seropositive for B. 
henselae and B. clarridgelae (Namekata et al., 2010). A recent large-scale study used 
isolation of Bartonella species from blood samples in combination with serology tests. A 
correlation between FCGS and isolation of Bartonella species was found but no 
correlation between seropositivity and FCGS could be discovered (Sykes et al., 2010). 
Other studies failed to show any correlation between FCGS and the presence of 
Bartonella species (Quimby et al., 2008; Belgard et al., 2010; Dowers et al., 2010).  
In the current study no Bartonella species were detected in oral swabs from cats with 
FCGS or orally healthy cats. It is perhaps unsurprising that Bartonella species were not 
cultured. The organism needs a prolonged incubation period with an average of 21 days 
to form colonies on blood agar plates (Maggi et al., 2005). The standard culture media 
and incubation periods used to ensure growth of a broad range of bacteria would not be 
suitable for culture of Bartonella species. Also, there are no reports of Bartonella 
species having been cultured directly from oral swabs; detection of Bartonella species 
from the oral cavity has been achieved solely by the use of molecular detection 
methods. It is possible that Bartonella DNA may have originated from other sources 
(Quimby et al., 2008; Namekata et al., 2010). One way for bacterial DNA to enter the 
oral cavity is by grooming. In the case of Bartonella species, the ingestion of flea dirt in 
which Bartonella henselae can persist for at least three days might be significant 
(Finkelstein et al., 2002; Quimby et al., 2008). 
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No bacterial DNA from Bartonella species was detected by 16S PCR in any of the 
samples analysed in the current study. The universal primer combination of 63f and 
1387r that was utilised has been used previously to successfully detect strains of 
Bartonella species (Bai et al., 2008). A BLASTn test confirmed that the primers would be 
able to amplify Bartonella henselae DNA. In 16S rRNA gene sequencing the phenomenon 
of primer bias should always been taken into account. In the present study several 
organisms were isolated by culture that were not identified by culture-independent 
methods. Primer bias leads to unequal amplification of PCR products and consequent 
inaccuracies in the true number of species present within a sample (Suzuki and 
Giovannoni, 1996; Polz and Cavanaugh, 1998). 
Culture-dependent methods were initially used to analyse the bacterial flora at the 
gingival margin of cats with healthy gingiva and cats with inflamed gingiva (Love et al., 
1989). The bacteria that were isolated consisted of a combination of Bacteroides 
species, currently renamed and including Bacteroides, Prevotella and Porphyromonas 
species. All of these isolated species were found in higher numbers at the healthy 
gingival margin compared to the inflamed gingival margin. The current study focused on 
a combination of culture-dependent and culture-independent methods in an attempt to 
identify the microbial flora in cats with FCGS and in healthy cats. This is the first study 
to use molecular cloning and sequencing of bacterial 16S rRNA genes to identify bacteria 
in the oral cavity of the cat.  
One of the key findings in the current study is the proportion of P. multocida species in 
the cats with FCGS compared to the healthy oral cavity. P. multocida was identified in 
high numbers by all identification methods used (culture, direct 16S rRNA gene 
sequencing and in the culture results from the Veterinary Diagnostic Service). 
P. multocida, a gram negative proteobacterium, is a commonly found bacterium of the 
feline oral cavity (Baldrias et al., 1988; Love et al., 1990; Hariharan et al., 2011) and is 
also known for its important role in cat-bite infections (Love et al., 2000). P. multocida 
has also been found in feline periodontal disease, where its numbers were found to 
decrease with an increase of disease severity (Mallonee et al., 1988). Another study 
showed that the organism was significantly more prevalent in cats with inflamed gingiva 
compared to healthy gingiva, although cats with mild inflammation showed the biggest 
increase in P. multocida (Mihaljevic and Klein, 1998). Two single case studies on FCGS 
samples showed large numbers of P. multocida (Reindel et al., 1987; Addie et al., 
2003). P. multocida is a commensal in the oral cavity of the cat but strains of P. 
multocida are the named causative agent in several diseases, including atrophic rhinitis 
in swine, bovine haemorrhagic septicaemia and avian fowl cholera (Shivachandra et al.; 
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Subaaharan et al.; Davies et al., 2003). Swabs used in this study were taken directly 
from the oral lesions and showed a high concentration of bacteria at these sites, which 
implicates a possible role of P. multocida in this disease. It should be noted that P. 
multocida was not detected in all cats with FCGS, and colonisation of several other 
species was also seen. The species of P. multocida that were identified in cats with 
FCGS were P. multocida subsp. multocida and P. multocida subsp. septica. In the 
current study, P. multocida subsp. septica was found in high numbers in both healthy 
and FCGS samples but P. multocida subsp. multocida was found in very low numbers in 
the healthy cats and is the most represented species in the cats with FCGS. 
Another striking difference between the healthy and FCGS groups in the present study 
was the presence of Porphyromonas species, especially P. circumdentaria. 
Porphyromonas species were highly represented in the cats with FCGS but were 
identified in much lower numbers in the healthy samples. P. gingivalis has been 
accepted as one of the key aetiological agents in human periodontal disease and is 
often referred to in combination with T. forsythia and Aggregatibacter 
actinomycetemcomitans (Slots et al., 1986; Bragd et al., 1987; Socransky et al., 1998). 
P. gingivalis was not found in the current study but three other Porphyromonas species 
were identified. Finding Porphyromonas species in the feline oral cavity is not new, 
since in the first studies on feline oral microbiology black pigmented Bacteroides 
species, that may have been Porphyromonas species, were isolated (Mallonee et al., 
1988). Porphyromonas species have been isolated from cats with oral diseases and also 
from the healthy gingival margin (Love et al., 1989). In relation to periodontal disease 
in cats, Porphyromonas appears to be a good indicator of disease risk, as is the case in 
human periodontal disease. A positive correlation has been seen between the grade of 
periodontal disease and the quantity of Porphyromonas species at the canine and 
premolar sites where three species (P. gingivalis, P. circumdentaria, and P. salivosa) 
were studied (Norris and Love, 1999a). Periodontal pathogens found in cats and their 
owners were compared using culture-independent methods (Booij-Vrieling et al., 2010). 
The Porphyromonas species found in cats were P. gulae and in humans P. gingivalis. T. 
forsythia was found in both humans and cats. Human strains of P. gingivalis are being 
studied and a broad variety of virulence factors have been described. The variety of 
proteases described in P. gingivalis is not described in P. circumdentaria and therefore 
the mechanism behind the tissue destruction caused by hydrolysation of serum and 
tissue proteins cannot be transferred to P. circumdentaria (Grenier and Vu Dang, 2011). 
Further research into the host interaction of different Porphyromonas species, alone or 
in synergy with other possible pathogenic bacteria can give us insight into the role they 
might play in FCGS. 
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T. forsythia (formerly known as Bacteroides forsythus or Tannerella forsynthensis) is 
another well represented bacterium in the FCGS samples in the present study. As 
described previously, T. forsythia is a well-known periodontal pathogen in humans and 
virulence mechanisms have been studied. Activity of proteases and several surface 
factors are shown to play a role in the pathogenity of T. forsythia as are the synergetic 
abilities with other human pathogens like P. gingivalis and F. nucleatum (Sharma, 
2010). It has been described in the feline oral cavity in relation to periodontal disease 
but not in relation to FCGS. Unspecified Bacteroides species have previously been 
described in oral diseases in cats (Mallonee et al., 1988; Love et al., 1989). T. forsythia 
has been identified in plaque samples from cats with and without periodontal disease, 
where the proportion of T. forsythia was higher in cats with periodontitis (Booij-Vrieling 
et al., 2010). Tannerella species have been identified regularly by culture-independent 
methods but were only isolated on only one occasion in the current study. The organism 
requires a specific growth medium and the standard culture methods that were 
performed would not allow this species to be successfully cultured in high numbers 
(Wyss, 1989). 
In two of the FCGS samples, a high proportion of the bacteria identified were 
Pseudomonas species. Pseudomonas species are known to be present in the oral cavity 
of the cat during health and disease (Mihaljevic and Klein, 1998) but also cause a 
variety of problems in pets, such as otitis externa and otitis media, urinary tract 
infections and pyoderma (Kowalski, 1988; Gatoria et al., 2006; Hillier et al., 2006). 
Pseudomonas species are not known to be of importance in oral diseases. 
Potentially novel phylotypes were found in healthy and FCGS samples in the current 
study. A near full-length 16S rRNA gene sequence was obtained for the clones 
representing potentially novel phylotypes from six FCGS and three healthy samples. 
Eighteen clones from the three healthy samples analysed were confirmed as being novel 
phylotypes, compared to only four clones from the six FCGS samples. In the FCGS 
samples, 2.3% of all 304 analysed clones were novel and in the healthy cats 19.6% of the 
158 analysed clones were novel. In these samples a high proportion of P. multocida 
species was found in the FCGS samples and there was less microbial diversity compared 
to the healthy samples (Dolieslager et al., 2011). Therefore the lower proportion of 
novel phylotypes found in the FCGS samples is unsurprising. Phylogenetic analysis of 
these novel phylotypes showed a cluster of 15 clones branching away from known 
phylotypes. This cluster included one uncultured Capnocytophaga AF426105. Six clones 
were found branched into three known phyla. The cluster of 15 clones implicates a 
group of previously unidentified bacteria that might be found frequently in the oral 
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cavity of the cat. These identified novel bacterial phylotypes need further 
characterisation to elucidate their role in oral health and disease. 
Of the samples analysed, two (F11 and F18) demonstrated very sparse growth. No 
bacterial identification was performed on these samples in the Veterinary Diagnostic 
Services laboratory. A further two samples (F11 and F21) had a very low cloning 
efficiency and not enough inserts could be re-amplified from the clones to generate a 
library for analysis. The 16S rRNA PCR showed small amounts of DNA on the gel from 
these samples and the quantity was not enough to obtain a sufficiently efficient cloning 
reaction, as demonstrated by the low colony numbers observed after cloning. 16S rRNA 
gene sequencing was performed on the isolates for identification purposes. DNA could 
not be extracted from all isolates using the standard DNA extraction methods. During 
this study a standard proteinase-K extraction protocol was used to enable a time 
efficient and reliable DNA extraction from most bacteria. DNA from some bacteria, 
which are more challenging to lyse would not be able to be extracted by these standard 
methods. It should be taken into account that although a wide range of bacteria were 
identified in this study, it is likely that some species will not have been successfully 
identified. By using three different methods (standard diagnostic culture, culture with 
16S rRNA gene sequencing and direct 16S rRNA gene sequencing) in two different 
laboratories, we tried to maximise identification of the different bacterial species 
present. 
The antibacterial treatment given to cats suffering from FCGS could have influenced the 
bacterial species found. Antibiotic treatment had been given at different times and had 
been terminated up to one year prior to the study (Table 3.8 and 3.9). At the time of 
swab collection all cats had clinical signs of FCGS (as described in Section 1.2.1.2) 
despite any treatment given. Clindamycin is the antibacterial therapy most frequently 
described for treatment in FCGS. Clindamycin inhibits bacterial protein synthesis by 
binding to the 50S subunit of the ribosome (Scott, 2005). Clindamycin is often used in 
oral inflammation as it has a good action against anaerobes including Fusobacterium, 
Peptostreptococcus and Actinomyces species (Noli and Boothe, 1999). A study on orbital 
abcesses in dogs and cats showed however that none of the isolates in cats was 
susceptible to clindamycin (Wang et al., 2009). Orbital abcesses can be caused by tooth 
root inflammation or foreign body penetration through the oral cavity. Bacteria isolated 
in these abcesses are often of oral origin. As seen in this study Pasteurella sp. and 
Bacteroides sp. were most often isolated. Susceptibility in vitro can of course differ 
from the in vivo susceptibility and factors as tissue penetration and the presence of pus 
in abcesses can play a role, however if these two species, which were regularly isolated 
from the cats in the present study are not susceptible to clindamycin detecting these 
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bacteria could have been a result of the antibacterial treatment. Other antibacterial 
therapies that had been used prior to sampling included cefovecin. Cefovecin, an 
extended-spectrum cephalosporin antibiotic, is registered for the use in periodontal 
disease and has a known action against oral bacteria including P. multocida (Stegemann 
et al., 2006). In the current study, cefovecin has been prescribed in several cases. 
Numbers of individual bacterial species in the current study could have been disturbed 
by the use of antibacterial treatment. Which is why further studies into pathogen host 
interaction will be beneficial. A broad variety of bacteria have been discovered and, all 
cats were suffering from lesions during the time of sampling. In an ideal world, sampling 
lesions from cats during the same stage of disease without any treatment will give us 
the best results. In the current study, a variety of antimicrobials were used and a 
relative high number of samples were taken which showed a wide range of bacterial 
species. The study gives a good view on which species may be involved in the 
aetiopathogenesis of FCGS but given the fact that antibacterial treatment was used, 
species that are present in smaller numbers should not be overseen as they could be 
playing an important role.  
As outlined in the Section 1.4.2, not many studies have specifically focussed on the 
bacteriology of FCGS. Clinical signs of different feline oral diseases are often 
categorised under the title of FCGS (as described in Section 1.2.1.1). In this study, a 
group of cats with similar clinical signs and all having at least mild inflammation of the 
area lateral to the palatoglossal folds were included. All swabs were taken from the 
palatoglossal fold area and the results are therefore not comparable with previously 
published plaque-focused studies. In the current study we focussed on bacteria found 
locally on the lesions to find possible causative agents of FCGS. Studies on periodontal 
disease which focus on the site of the disease use plaque samples for analysis. In the 
current study, bacteria at the site of inflammation tended to show little diversity with a 
high abundance of only one or two species per sample being seen. Repeatedly high 
bacterial counts of P. multocida subspecies, T. forsythia, Pseudomonas and 
Porphyromonas species were found in different combinations. When the identified phyla 
in healthy and FCGS samples were compared, phyla that were not found in the healthy 
oral cavity but which were seen in the cats with FCGS included Fusobacterium and 
spirochaetes. A shift was seen from a mix of Bacteroidetes, uncultured bacteria and 
Proteobacteria in the healthy samples to predominantly Proteobacteria in the cats with 
FCGS. These results support the likelihood of an opportunistic infection by bacteria 
present in the oral cavity. This seems to correlate with the clinical experience of a 
temporary response to antimicrobial therapy in these cats. Confirmation that these 
maby be the most important bacteria in this disease could be obtained by the use of 
Chapter 5 Identification of bacteria associated with FCGS 117 
 
high throughput, next generation sequencing followed by further research into the 
interaction of these specific bacteria with different aspects of the immune system. 
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Chapter 6 Histopathological changes in tissue 
biopsies of cats with FCGS 
6.1 Introduction 
As described in section 1.2.1.1 and Table 1.1, many different terms are used in the 
literature to identify FCGS. Many refer to both the histopathological features of the 
lesions and the location of these lesions. Feline plasma cell gingivitis/pharyngitis, 
plasma cell stomatitis/pharyngitis and lymphoplasmacytic gingivitis are examples of 
the different names that are used (Johnessee and Hurvitz, 1983; White et al., 1992; 
Lyon, 1994). 
The oral mucosa consists of two components; the epithelium and the supporting 
connective tissue called the lamina propria (Nanci, 2008). The boundary between 
mucosa and submucosa is difficult to identify. The submucosa contains fat, small 
vessels and minor salivary glands in variable amounts throughout. The epithelium is a 
stratified squamous epithelium. Cells seen in the normal epithelium are melanocytes, 
Langerhans cells, Merkel cells and low numbers of inflammatory cells. The lamina 
propria is the connective tissue supporting the oral epithelium and consists of cells, 
blood vessels, neural elements and connective tissue fibres. Fibroblasts, 
macrophages, mast cells and other inflammatory cells are normally seen in the 
lamina propria. Fibroblast numbers increase during wound healing. Small numbers of 
plasma cells and lymphocytes can be observed in normal tissue, larger numbers 
represent a pathological change. In acute reactions, neutrophils are the dominant 
cell type and in chronic conditions lymphocytes, plasma cells and macrophages are 
often seen. In the current study the majority of the changes described affected the 
epithelium and lamina propria. 
Cats with clinical evidence of FCGS (Section 1.2.1.2) have been divided into two 
distinct pathological syndromes (Barker et al., 1992). Feline ulcerative stomatitis and 
glossitis or lymphocytic plasmacytic stomatitis is described as a chronic inflammation 
of the ‘fauces’, and can involve inflammatory changes at the palate, gingiva and 
tongue. A chronic active inflammation of the oral mucosa and submucosal connective 
tissues is seen and the dominant cells are lymphocytes and plasma cells. These 
changes are more prevalent in older cats and can include periodontitis. The second 
group is feline plasma cell gingivitis/pharyngitis or feline chronic gingivostomatitis, 
which is characterised by lesions in the palatoglossal folds often extending to the 
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palatopharyngeal arches and the gingiva. The mucosa is hyperplastic, ulcerated and 
the cells found are mainly plasma cells. Mott cells, plasma cells containing Russell 
bodies, as well as binucleated plasma cells can often be identified. Other cells 
described are neutrophils, lymphocytes and histiocytes (Barker et al., 1992). It is not 
clear if these two groups, which are distinguishable on the basis of cell type but can 
be associated with a similar clinical appearance, are the same disease. To date no 
studies have been conducted that compare the pathological findings in detail with 
other features of FCGS. In the current study the pathological findings of the 
palatoglossal fold tissue of these cats has been scored on severity of inflammation 
according to the scoring system previously described (Harley et al., 2011). The two 
pathological groups as described by Barker et al. (1992) are also used as a guideline 
to separate the samples. 
6.2 Material and methods 
6.2.1 Sample collection and processing 
Tissue biopsies were obtained from the palatoglossal fold area of cats under general 
anaesthesia. The tissue was fixed in 4% neutral buffered paraformaldehyde and sent 
to the veterinary diagnostic laboratory at the University of Glasgow. The tissue 
biopsies were embedded in paraffin wax. Sections were cut and stained with 
haematoxylin and eosin (H&E staining). Routine histological evaluation was 
performed. 
6.2.2  Scoring of inflammatory changes 
The severity of the inflammation in each biopsy was scored according to changes in 
the epithelium and the lamina propria. The epithelial changes included inflammatory 
cell infiltration and hyperplasia, degeneration and ulceration. The lamina propria 
changes included inflammatory cell infiltration, presence of granulation tissue and 
the presence of fibronecrotic material. The inflammatory cell infiltration within the 
lamina propria was scored. The scoring system used was that described by Harley et 
al. (2011) (Table 6.1). 
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Table 6.1: Grading system for histopathological changes 
 
Grade 0: Normal 
Stratified squamous epithelium with sparse intraepithelial 
lymphocytes. The lamina propria/submucosa contains 
sparse scattered mast cells and lymphocytes. The 
lymphocytes may form small subepithelial aggregates. 
 
 
 
 
 
 
 
Grade 1: Minimal to mild inflammation 
Variable, mild epithelial hyperplasia and parakeratosis. May 
have slightly increased numbers of intraepithelial 
lymphocytes and sparse exocytosing neutrophils. 
The lamina propria/submucosa contains a sparse to light, 
perivascular to interstitial population of plasma cells, 
lymphocytes, mast cells and rare macrophages. 
 
 
 
 
 
Grade 2: Moderate inflammation 
Epithelial hyperplasia variably with regions of degeneration 
or ulceration. Mild to moderate numbers of intraepithelial 
lymphocytes variably mixed with macrophages and 
neutrophils. The lamina propria/submucosa contains a 
moderate inflammatory cell infiltration of lymphocytes and 
plasma cells mixed with variable numbers of macrophages 
and neutrophils. The inflammatory cells may form a distinct 
‘lichenoid’ band within the superficial lamina propria. In 
the submucosa the infiltrating cells often extend around 
skeletal muscle fibres. 
 
 
Grade 3: Severe inflammation 
Often extensive regions of epithelial degeneration, 
spongiosis and ulceration and superficial exudation with 
many macrophages, neutrophils and lymphocytes. 
The lamina propria/submucosa contains a dense 
inflammatory infiltrate with variable proportions of 
lymphocytes, plasma cells, macrophages and neutrophils. In 
some sections the lamina propria is expanded or replaced 
by immature granulation tissue and fibrinonecrotic debris. 
 
  
Reproduced from Harley et al. (2011) 
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6.2.3 Grouping according to cell type 
All biopsies were grouped according to the different types of cell infiltration 
previously described in FCGS. Two groups according to cell type were standardised 
(Barker et al., 1992): 
- Group 1: Combined infiltration of plasma cells and lymphocytes 
- Group 2: Majority of plasma cells, including Mott cells, binucleate plasma 
cells and fewer neutrophils, lymphocytes and macrophages  
6.2.4 Statistical analysis of the histopathological changes 
The independent samples t-test was chosen to compare the mean age of the cats and 
the Mann-Whitney test to compare the duration of the disease since onset for each of 
the two groups defined in Section 6.2.3. The null hypothesis (H0) was that no 
significant difference occurred between the two groups. A Spearman’s correlation 
was performed to test the correlation between the severity of the inflammation 
(Section 6.2.2) and the cell type group (Section 6.2.3). Differences were considered 
statistically significant at p<0.05. 
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6.3 Results 
6.3.1 Cell types and histopathological features 
Of the 31 biopsies that were analysed, two were non-diagnostic: F19 due to crush 
artefacts and F29 due to insufficient sample size. In the other 29 biopsies, the 
epithelium and lamina propria were assessed. Glandular tissue was present in six 
biopsies; F21 showed no changes in the glandular tissue but inflammation adjacent to 
the ducts was observed in the remaining five samples (Table 6.2). The epithelium 
showed hyperplasia in 26 cats and exocytosis of inflammatory cells into the 
epithelium was seen in 25 cats. Of these cats, neutrophils were present in the 
epithelium in 14, plasma cells in three, lymphocytes in two and unidentified 
leucocytes in 12. Inflammatory cell types identified in the lamina propria were 
predominantly plasma cells in 14 cats, a combination of plasma cells and 
lymphocytes in 11, a combination of neutrophils and plasma cells as the predominant 
cells in two and mainly lymphocytes in two. Neutrophils marginating within vessels 
were seen in 25 of 31 cats. 
Eight healthy tissue samples were analysed (Table 6.3). One sample was non-
diagnostic due to only salivary gland tissue being present. Hyperplasia of the 
epithelium was minimal in two cats, mild in two cats and moderate in one cat. Five 
cats showed few inflammatory cells and two cats showed a mild inflammatory 
infiltrate in the lamina propria. A minimal to mild infiltration of neutrophils was seen 
marginating in vessels in four cats and minimal sialoadenitis was seen in two cats. 
One cat was diagnosed as having a mild gingivitis; six cats were thought to be 
normal. 
6.3.2 Severity of inflammation scores 
For the 29 tissue biopsies that were assessed, the inflammation score was graded 
(Harley et al., 2011). Pathological changes that were classified between two 
categories were scored as mild to moderate (1-2) or moderate to severe (2-3). 
Severity was graded mild in two cats, mild to moderate in five cats, moderate in ten 
cats, moderate to severe in five cats and severe in seven cats (Table 6.4, Figure 6.1). 
 
 Table 6.2: Cell types and histopathological features in epithelium and lamina propria in 29 FCGS samples 
 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 F17 
E
p
ith
e
liu
m
 
Dysplasia*          +  +     
Erosion*   +     + +     +  + 
Hyperpigmentation*    +             
Hyperplasia + + + ++ +  ++ + ++ + ++ +++ +  + ++ 
Rete pegging*       +  +  + +     
Spongiosis* + + + +   +  + +  + + + + + 
Thinning* +         +     +  
Ulceration* +  +  + +   +  +  +   + 
Bacteria     ++  +    +      
Leucocytes +  + +     +++  + +    ++ 
Lymphocytes       +          
Neutrophils   +  + +    ++     +  
Plasma cells       +   +++       
L
a
m
in
a
 p
ro
p
ria
 
Lymphocytes ++ + + ++ +++ + +++ + ++ ++ ++  + ++ + + 
Macrophages +            +   + 
Mitotic figures                 
Neutrophils + + ++  ++ + + + + ++ + + + ++ +  
Plasma cells ++ + +++ + +++ ++++ +++ + ++ ++++ ++ + +++ ++++ +++ +++ 
Binucleate plasma cells  +               
Mott cells  + ++   +    ++   + +  + 
Bacteria     ++      +      
Fibrosis* + + +  +      +      
Granulation tissue*      + + +   +  + +   
Necrosis*     + + +  +  +  +    
Oedema*  +  +   +    + +  +  + 
Marginating neutrophils ++ ++ + + + ++   + ++ + + +  ++ + 
Sialoadenitis   +              
  
 Table 6.2 continued 
 F18 F19 F20 F21 F22 F23 F24 F25 F26 F27 F28 F29 F30 F31 F32 
E
p
ith
e
liu
m
 
Dysplasia*     +  +         
Erosion* +   +  +    +    + + 
Hyperpigmentation*              +  
Hyperplasia  + + + + +  + + + ++  + + + 
Rete pegging*  +   + +  +     +   
Spongiosis* +  + + +  + + +  +   +  
Thinning*                
Ulceration     +  + +  + +     
Bacteria         +  +     
Leucocytes  +   +    +   +++  +   
Lymphocytes   ++             
Neutrophils   ++ + + ++ +  ++ ++    + + 
Plasma cells   ++             
L
a
m
in
a
 p
ro
p
ria
 
Lymphocytes   +++ + + + + + ++ ++  + ++ ++++ ++ 
Macrophages      + +    +     
Mitotic figures      +        +  
Neutrophils ++  ++ + +++ +++ ++ ++ + ++ +++   ++ ++ 
Plasma cells ++++  +++ +++ +++ ++++ ++++ ++++ ++ ++ ++++ + ++ +++ +++ 
Binucleate plasma cells   +    +    +     
Mott cells +  + ++  + ++ ++ +  ++    ++ 
Bacteria           +     
Fibrosis*   +  +  +  + +      
Granulation tissue*     +      +     
Necrosis*     +    +  +     
Oedema*   + +   + + + +     + 
Marginating neutrophils ++  + +++ ++ +++ + + + ++  +  ++ + 
Sialoadenitis      +  ++ ++      + 
Grading: +: Mild, ++: Moderate, +++: Moderate/severe, ++++: Severe. In subjects with a *, + means present. 
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Table 6.3 Cell types and histopathological features in epithelium and lamina propria of eight 
healthy samples 
 H2 H3 H4 H5 H6 H14 H15 H16 
E
p
ith
e
liu
m
 
Dysplasia*         
Erosion*         
Hyperpigmentation*         
Hyperplasia +/-  ++ + +/-   + 
Rete pegging*    +     
Spongiosis*         
Thinning*         
Ulceration*         
Bacteria         
Leucocytes         
Lymphocytes        +/- 
Neutrophils         
Plasma cells         
L
a
m
in
a
 p
ro
p
ria
 
Lymphocytes +  +/- + +/- +/- +/- +/- 
Macrophages +        
Mitotic figures         
Neutrophils         
Plasma cells +  +/- + +/- +/- +/- +/- 
Binucleate plasma cells         
Mott cells         
Bacteria         
Fibrosis*         
Granulation tissue*         
Necrosis*         
Oedema*         
Marginating neutrophils +     +/- +/- + 
Sialoadenitis      +/- +/-  
Grading: +/-: Minimal, +: Mild, ++: Moderate, +++: Moderate/severe, ++++: Severe. In subjects 
with a *, + means present. 
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Table 6.4: Cell groups, severity grades, age and time since onset of disease in 31 cats with 
FCGS 
Cat ID Cell group Severity grade Severity 
clinical 
inspection 
Age 
(months) 
Time since 
onset 
(months) 
F2 1 1-2 3 164 14 
F3 1 1 3 104 14 
F4 2 2 1 164 2 
F5 1 1-2 1 90 3 
F6 1 2-3 3 47 6 
F7 2 3 3 113 21 
F8 1 2 3 14 2 
F9 1 1 3 66 20 
F10 1 2 3 48 4 
F11 2 3 3 80 81 
F12 1 2 2 12 7 
F13 2 1-2 1 21 6 
F14 2 2 2 40 11 
F15 2 2-3 3 87 10 
F16 2 2 3 70 7 
F17 2 2 3 114 7 
F18 2 2-3 3 65 25 
F19 - - 2 90 21 
F20 1 2 - 155 - 
F21 2 2 3 72 - 
F22 2 2-3 2 15 - 
F23 2 3 3 70 - 
F24 2 3 3 204 - 
F25 2 3 - 126 - 
F26 1 1-2 - 17 - 
F27 1 2 3 43 22 
F28 2 3 - 156 - 
F29 - - - 120 9 
F30 1 1-2 - 111 - 
F31 1 3 - 168 - 
F32 2 2-3 3 168 28 
All samples were grouped according to cell type, cell group 1: lymphoplasmacytic infiltrate, cell 
group 2: plasmacytic infiltrate. All samples were graded according to severity. Shown in 
combination with the clinical appearance of the caudal oral cavity, the age in months and the 
time since disease onset in months. 
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Figure 6.1: Number of FCGS samples showing different severity of inflammation grades 
 
1: mild, 1-2: mild-moderate, 2: moderate, 2-3: moderate-severe, 3: severe 
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Variable results were seen when histopathological severity grading was compared to the 
clinical inspection of the caudal area of the oral cavity. Of the cats with clinical scores 
recorded, seven showed higher clinical severity scores, two showed higher 
histopathological scores and 13 cats showed a similar score in clinical and 
histopathology severity (Table 6.4). 
6.3.3 Cell groups 
From the 29 biopsy samples analysed, thirteen were categorised as cell group 1, a 
chronic inflammation in which plasma cells and lymphocytes are the dominant cells. 
The remaining sixteen were categorised as cell group 2, involving high numbers of 
plasma cells (Table 6.4, Figure 6.2). 
When cats from each severity group were classified according to the cell group, a 
significant correlation (p=0.004) was seen by a Spearman’s correlation test, showing 
that the majority of samples in the higher inflammation grades showed plasma cell 
infiltration (group 2) and the majority of samples in the lower inflammation grades were 
infiltrated with lymphocytes and plasma cells (group 1) (Figure 6.3). 
6.3.4 Comparison of age and the cell groups 
When the mean age of the cats classified as cell type group 1 was compared to the 
mean age of the cats in group 2 by a t-test, no significant difference was seen (p=0.88). 
The mean age in months ± SD for group 1 (n=13) was 79.92 ± 56.78 and for group 2 was 
(n=16) 97.81 ± 54.82 (Table 6.4, Figure 6.4). 
6.3.5 Comparison of time since onset of disease and cell groups 
Comparison of the time since onset of the disease in the cats placed in cell group 1 with 
the time since onset in the cell group 2 cats by a Mann-Whitney test showed no 
significant difference (p=0.12). The mean time since onset in months ± SD for group 1 
(n=10) was 9.800 ± 7.193 and for group 2 (n=11) was 20.18 ± 21.85 (Table 6.4, Figure 
6.5) 
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Figure 6.2: Photomicrographs of biopsies of the palatoglossal folds 
 
 
A: Severe lymphoplasmacytic infiltrate of the lamina propria B: Severe plasmacytic infiltrate of 
the lamina propria with Mott cells and neutrophils marginating the vessels. 
  
A 
B 
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Figure 6.3: Percentage of cats in the different severity of inflammation groups according to 
predominant cell group 
 
Group 1: lymphoplasmacytic infiltrate, group 2: plasmacytic infiltrate. Inflammation severity: 1: 
mild, 1-2: mild-moderate, 2: moderate, 2-3: moderate-severe, 3: severe. 
 
Figure 6.4: Age distribution of the two cell groups 
 
Each ● represents one biopsy, the line represents the mean. 
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Figure 6.5: Duration since onset of disease in the two cell groups 
 
Each ● represents one biopsy, line represents the mean. 
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6.4 Discussion 
Several studies have investigated the histopathology of FCGS. Standard findings within 
the epithelium of FCGS lesions include hyperplasia, ulceration, dysplasia and 
suppuration (Johnessee and Hurvitz, 1983; Hennet, 1997; Baird, 2005). In the current 
study, many of the FCGS biopsies showed hyperplasia of the palatoglossal folds. This 
was also evident in the healthy biopsies where it was considered ‘normal’. Ulceration, 
dysplasia and suppuration are pathological. A large proportion of the FCGS biopsies 
showed ulceration and erosion with 69% showing at least one of the two lesions. 
Dysplasia was much less common (13.7%). 
Pathological findings in the mucosa and submucosa are described as being 
lymphoplasmacytic (Hennet, 1997), lymphoplasmacytic and eosinophilic (Baird, 2005), 
sheets of plasma cells (Frost and Williams, 1986), predominantly plasma cells with 
binucleated cells and cells containing Russell bodies (Mott cells) and variable numbers 
of neutrophils, lymphocytes and histiocytes (Johnessee and Hurvitz, 1983). Other 
studies have described two different patterns, one being diffuse primarily plasmacytic 
and lymphocytic and the other having primarily plasma cells (White et al., 1992; Lyon, 
2005; Wiggs, 2007). An acute reaction in the oral mucosa is normally associated with 
neutrophil infiltration while chronic reactions show lymphocytes, plasma cells, 
monocytes and macrophages. Suppurative inflammation is characterised by neutrophils 
as the predominant cell type (Pedersen, 1992; Nanci, 2008). 
A number of samples in the current study had an infiltrate with a majority of plasma 
cells and low numbers of lymphocytes. This infiltrate, often seen in combination with 
Mott cells and binucleate plasma cells, can normally be seen in diseases with a 
suggested immune-mediated background such as rheumatoid arthritis and feline plasma 
cell pododermatitis (Perry et al., 1997; Dias Pereira and Faustino, 2003). Binucleate 
plasma cells were commonly found in multiple samples in the current study. Plasma 
cells are considered to be a fully differentiated state of the B-lymphocyte and therefore 
do not normally divide further. Binucleate and multinucleate plasma cells have been 
located in human rheumatoid arthritis (Perry et al., 1997) and several human oral 
diseases (Jinnfei and Ellabban, 1986), and have also been described in feline plasma cell 
pododermatitis (Dias Pereira and Faustino, 2003). The origin of binucleate plasma cells 
is controversial. One study suggested that they form through cell fusion (Jinnfei and 
Ellabban, 1986) but a later study reported that the morphology was more consistent 
with plasma cells that had undergone division (Perry et al., 1997). A rare disease in 
humans with a similar histopathological appearance is plasma cell mucositis 
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(Puvanendran et al., 2012). Histopathology shows an acanthotic epidermis and rete 
ridges as seen in histopathology of FCGS. A dense infiltrate of plasma cells is seen as 
well as Russell-bodies. The aetiopathogenesis of plasma-cell mucositis is not known but 
often a history of immunological dysfunction is described in the patients. Treatment is 
unreliable but most often corticosteroids are used in patients suffering from the 
disease. 
The cats in this study were all considered to have a similar clinical appearance, and to 
be suffering FCGS. The biopsies could, however, be divided into two groups according to 
the histopathological appearance as described by Barker et al. (1992). Group 1: 
lymphocytic plasmacytic stomatitis with a chronic inflammation, characterised 
predominantly by plasma cells and lymphocytes (present in 45% of cases) and group 2: 
feline plasma cell gingivitis, with predominantly plasma cells in the lamina propria and 
showing fewer lymphocytes, neutrophils and macrophages (present in 55% of cases). The 
two types of cell infiltrate were compared to the severity of the infiltrate. A significant 
correlation could be seen, with the most severely inflamed samples being part of the 
plasmacytic group (group 2) and the less severely inflamed samples being categorised 
into the lymphoplasmacytic group (group 1). White et al. (1992) showed that 70% of cats 
with FCGS had a predominantly plasma-lymphocytic infiltrate and 30% had a 
predominantly plasmacytic infiltrate. Russell bodies, neutrophils and eosinophils could 
be found in some sections. Another study reported that lymphocytes or plasma cells 
were predominant in 25% of cases and neutrophils were predominant in 50% of cases 
(Harvey, 1991). The study also showed that there was no significant correlation 
between gingival index and the type of cells seen; however, the severity of 
inflammation and gingival index were significantly correlated. A much higher proportion 
of cats in our study represented the plasmacytic group when compared to previous 
studies. Taking into account that the more severe cases were predominantly 
plasmacytic in nature, it is possible that a higher number of severe cases were seen in 
this study due to the origin of the samples. Samples were collected at a referral 
veterinary dentist where one could expect a higher number of severe cases being 
presented. 
Barker et al. (1992) reported that the lymphoplasmacytic type of infiltrate is more 
common in older cats. This was not verified by the current study. No difference in age 
was seen between the two cell-type groups. For 21 cats, an estimated start date of the 
disease was recorded but no difference could be seen in the time since disease onset 
between the two cell-type groups. The lymphoplasmacytic infiltrate has previously been 
described to be more common in cats having lesions of the tongue, palate and gingiva 
(Barker et al., 1992). In the current study, four cats possessed lesions of the tongue and 
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five had lesions of the oropharynx. Neither of the two cell-type groups was 
overrepresented in these cats. The clinical appearance was not always a good predictor 
of the histopathological features. 
The current study showed that there are two different cell-type groups seen within the 
FCGS biopsies: group 1, showing a predominant lymphoplasmacytic infiltrate and group 
2 showing a predominant plasmacytic infiltrate. There is a possible correlation between 
severity of inflammation and the cell-type groups seen. 
 
Chapter 7 Aspects of the innate immune response in cats with FCGS 135 
Chapter 7 Aspects of the innate immune response 
in cats with FCGS 
7.1 Introduction 
In addition to other factors, alterations in the innate immune response have been 
suggested to play a role in the aetiopathogenesis of FCGS (Harley et al., 1999). Changes 
that indicate this are observed in cytokine expression, histopathology and 
immunoglobulin concentration in serum and saliva (White et al., 1992; Harley et al., 
2003b; Arzi et al., 2010b; Harley et al., 2011). 
Histopathological investigation of FCGS shows a chronic inflammation typically 
characterised by plasma cells in combination with variable numbers of lymphocytes, 
neutrophils and macrophages (White et al., 1992; Lyon, 2005). Quantification of the cell 
types has shown an increase in the number of mast cells in cats affected by FCGS when 
compared to a group of healthy cats (Arzi et al., 2010b; Harley et al., 2011). Mast cells 
are an important cell group in the innate immune system and can influence the immune 
response by releasing mediators such as: cytokines, vasoactive amines and enzymes 
following stimulation (Walsh, 2003). Mast cells are commonly detected in the oral 
mucosal lamina propria and submucosa of healthy cats (Harley et al., 2003a). 
Immunohistochemistry on glossopalatine mucosal biopsies from cats with FCGS showed a 
significant increase in the number of mast cells and in the numbers of cells expressing 
cluster of differentiation (CD) antigens (CD3, CD4, CD8, CD79a) immunoglobulins (Ig) 
(IgG, IgM, IgA) and, the Langerhans cell antigen (L1) in the lamina propria and 
submucosa when compared to healthy cats (Harley et al., 2011). The most prevalent 
cells were those expressing CD79a, IgG and L1. 
Serum and salivary immunoglobulin levels have been shown to be elevated in cats with 
FCGS (White et al., 1992; Harley et al., 2003b). Analysis of cytokine gene expression in 
cats with FCGS has shown that they possess a mixed Th1-Th2 response as indicated by 
higher levels of expression of IL-2, IL-4, IL-6, IL-10, IL-12 and IFN-γ when compared to a 
predominantly Th1 type response in the healthy oral cavity (Harley et al., 1999). Cats 
with FCGS were subsequently treated but no significant change in the cytokine 
expression levels was detected before and after treatment. 
So far, studies on the immune response in cats with FCGS have not investigated the roll 
of Toll-like receptors (TLRs). TLRs are important in the early host defence against 
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pathogens (Akira and Takeda, 2004). Stimulation of TLRs leads to variable gene 
expression, which then leads to activation of innate and acquired immunity. A change in 
the expression of TLRs can give information about the possible pathogenic agents 
involved in the aetiopathogenesis of a disease. 
In this chapter, the expression of several cytokine and TLR genes was investigated in 
orally healthy cats and those with FCGS. Statistical analysis was performed to 
investigate the relationship between the five most commonly identified bacterial 
species, virological data and histopathological features, with changes in immune 
mediators (cytokines) and receptors (TLRs). 
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7.2 Materials and methods 
7.2.1 Tissue samples 
Tissue biopsies were collected from the mucosa lateral to the palatoglossal folds from a 
total of 39 cats. Tissue was collected from 31 cats with FCGS and 8 healthy cats. One 
biopsy was directly submerged in RNAlater (Sigma-Aldrich) and another was placed in 
neutral buffered 4% paraformaldehyde. The samples were then posted to the 
laboratory. The tissue samples in RNAlater were stored at 4°C until required. 
7.2.2 Tissue homogenisation 
Three different methods were tested to homogenise the tissue prior to RNA extraction: 
I. Bead beater (Biospec Products, Bartlesville, USA) 
The sample was sliced into approximately 1.0 mm pieces and added with lysis buffer to 
a 2.0 ml screw cap microtube with 1.0 mm beads. The sample was then placed into the 
bead beater for 3 min. 
II. Tissue Ruptor (Qiagen) 
The biopsy was placed into lysis buffer and disrupted for 1 min at full speed with the 
tissue ruptor using disposable autoclavable tips. 
 
III. Motorised pellet pestle (Sigma-Aldrich) 
The sample was sliced into approximately 1.0 mm pieces and placed into lysis buffer. 
The sample was homogenised for 1 min with a disposable autoclavable pestle. 
7.2.3 RNA extraction 
RNA extraction was performed on samples homogenised by method III, which proved to 
be the easiest method with best tissue disruption and homogenisation achieved. The 
samples were homogenised for 1 min by a motorised pellet pestle when submerged in 
buffer RLT (Qiagen). RNA was extracted using the RNA extraction kit RNeasy® mini kit 
for fibrous tissue (Qiagen). The sample was diluted after homogenisation and a 
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proteinase-K solution was added. The mixture was incubated at 55ºC for 10 min. Ethanol 
was added to the supernatant and it was run through the RNeasy Mini spin column 
containing RNA-binding silica membrane. DNAse digestion was performed on the spin 
column to remove DNA. After DNase digestion, contaminants were washed away and 
nuclease-free water was used to elute the RNA. The extracted RNA yield was assessed 
using the ND-1000 NanoDrop® spectrophotometer. 
7.2.4 cDNA synthesis 
For cDNA synthesis, the SuperScript™ First-Strand Synthesis System for RT-PCR 
(Invitrogen) was used. A mixture of 1.0 µg of extracted RNA, Oligo (dT)12-18 primers and 
dNTPs was made and incubated at 65ºC for 5 min. The mixture was directly transferred 
to 50ºC and a master mix containing DEPC-treated water, 10x RT buffer, 25mM MgCl2, 
0.1M DTT and a recombinant RNase inhibitor was added. To allow cDNA synthesis the 
reaction was incubated for 50 min at 50ºC. The reaction was terminated at 70ºC for 15 
min and chilled on ice. To remove the RNA, RNase H was added to each tube and 
incubated for 20 min at 37ºC. Incubation was performed on a Primus96 plus 
thermocycler (MWG biotech). 
7.2.5 Primer design and optimisation 
7.2.5.1 Primer design 
Primers were designed using the online primer design tool at the National Centre for 
Biotechnology Information website (http://www.ncbi.nlm.nih.gov/tools /primer-blast) 
and were commercially synthesised (Invitrogen). Feline mRNA sequences of TLR2, TLR3, 
TLR4, TLR7, TLR9, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IFN-γ and TNF-α were used and 
primers were selected on the basis of similarity in length and melting temperature. At 
the time of primer design, the feline mRNA sequence for TLR5 was not accessible and 
therefore a published primer was used (Ignacio et al., 2005). Primer details are shown 
in Table 7.1. 
  
Chapter 7 Aspects of the innate immune response in cats with FCGS 139 
Table 7.1: Primers used for amplification of Toll-like receptor and cytokine genes 
Primer name Primer sequence 5’-3’ Product length 
GAPDH F  GAGCTGAATGGGAAGCTCAC 100 
GAPDH R  CGTATTTGGCAGCTTTCTCC 
IFN-γ F  TGCAGGTCCAGCGCAAAGCAA 120 
IFN-γ R  TCGATGCTCTACGGCCTCGAAACA 
IL-1β F  GACGGTTTTGTGTGTGATGC 92 
IL-1β R  TCGTATGAGCCAGACAGCAC 
IL-2 F ACGGTTGCTTTTGAATGGAG 146 
IL-2 R GCACTTCCTCCAGAGGTTTG  
IL-4 F  GCAGCCCCTAAGAACACAAG 102 
IL-4 R  TTTGAGGAATTTGGTGGAGC 
IL-6 F  CAGGGCTGTTCGGATAATGT 100 
IL-6 R  TCAGTTACATGCCCAGTGGA 
IL-10 F  TGTCTGAGGACAACTGCACC 108 
IL-10 R  GCTCGTCCTTGGTTTGAAAG 
IL-12 F  TCAACAGTGTGACTGTGCCA 116 
IL-12 R  ATTGATGGTCACTGCACGAA 
TLR2 F  CCTGAAAATGATGTGGGCTT 99 
TLR2 R  CGCTCGCTGTAAGACACAAA 
TLR3 F  GACAACAACTTCCCAGGCAT 199 
TLR3 R  GACAAGAAAAAGCGCCACTC 
TLR4 F  CTGGAACAGGTGTCCCAAGT 176 
TLR4 R  TGCCGTAGTTCTTGCTCCTT 
TLR5 F TTCCTTCCGCCAGGAGTATTTAGC 217 
TLR5 R GGAGTTCGCACTCACAGATGAACT  
TLR7 F  TTGAGAAGCCCCTTCAGAAA 149 
TLR7 R  GGTCACGTGATTGTCTGTGG 
TLR9 F  GAGAGCTCAACCTCAGTGCC 144 
TLR9 R  CCAGCAAGAAGTCCACGAAG 
TNF-α F  CTTCCAACTGGAGAAGGGTG 93 
TNF-α R  ATCCCAAAGTAGACCTGCCC 
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7.2.5.2 Primer efficiency 
The efficiency of the primers was tested to validate the use of the Comparative CT 
method. Each primer was tested with a minimum of three serial dilutions. The CT values 
were plotted against log10 of the sample volume and the efficiency calculated from the 
formula: 
Efficiency = -1+10 (-1/slope) 
Efficiencies were accepted when between 0.9 and 1.1. 
7.2.5.3 Primer optimisation 
For each primer a melt curve analysis was performed. To ensure a single product the 
product needed to yield a single peak. Annealing temperatures were standardised for 
each primer when a single peak was observed. 
7.2.6 Quantitative PCR 
Quantitative PCR was performed using SYBR-Green Mastermix (Invitrogen). Each 
reaction was performed in triplicate in a total volume of 25 µl per well containing 12 µl 
SYBR green mix, 11 µl H2O, 1 µl cDNA and 1 µl primer mix. A primer mixture was created 
of reverse and forward primers at 10 µmol per primer. Reactions were performed in a 
MX300P™ real time PCR system (Stratagene, Cambridge, UK) with the following cycles: 
Initial denaturation at 95°C for 10 minutes, 50 cycles of denaturation at 95°C for 30 s, 
annealing at 55° for 1 min (for TLR2, TLR4, TLR7, TLR9, TNF-α and IL-1β) or 60°C (for 
TLR3, IFN-γ, IL-4, IL-6, IL-10 and IL-12A), extension at 72°C for 1 min. Finally a melting 
curve was created at the end of the assay with a gradient of increasing temperatures 
until the amplicons were fully dissociated, Thus a unique melt temperature was 
determined for each primer set. The data was rejected when a peak at the wrong melt 
temperature, or a wide or stepped peak was found. 
7.2.7 Data analysis 
Data analysis was performed using Microsoft Excel and SPSS version 18 for windows (IBM, 
Toronto, USA). All samples were adjusted to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) by the 2-dCt method. As all results were in triplicate, the average dCT was used 
to calculate the relative expression ratio (R=2dCT). R was used for statistical analysis. 
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The data used was continues without a normal distribution, therefore a Mann-Whitney U 
test was used. The nominal data that had to be compared consisted of more than two 
groups therefore the Kruskall-Wallis test was performed with the Dunn’s comparison 
test as post-hoc analysis. Differences were considered statistically significant at p<0.05. 
To visualise the combined results, data were normalised to the TLR2 expression in 
control samples, the barchart shows mean with standard deviation error bars. All box 
and whisker plots show whiskers for minimum and maximum values. Data graphics were 
constructed in GraphPad Prism software version 5.  
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7.3 Results 
7.3.1 Sample collection 
Biopsies were collected from the oral mucosa lateral to the palatoglossal folds from 31 
cats with FCGS and eight orally healthy cats. 
7.3.2 RNA extraction 
A comparison of different methods was made to determine the best method for 
extracting total cellular RNA from tissue samples. Three different methods of 
homogenising the tissue (Section 7.2.2) were investigated: 
I. Bead beater 
II. Tissue Ruptor 
III. Motorised pellet pestle 
Methods I and II were not suitable for the tissue used in this study. The tissue structure 
was too strong to be disrupted by the bead beater and the Tissue Ruptor was not 
suitable for the small pieces of tissue collected. Method III proved to be the quickest 
and easiest method. 
RNA extraction was performed on all samples. Samples F14, F16 and F26 did not yield 
sufficiently good quality RNA to be used for cDNA synthesis; the extracted RNA yield was 
below 50ng/µl and of a substandard quality. RNA was successfully extracted from a total 
of 28 FCGS and 8 healthy samples and these were used for cDNA synthesis and further 
analysis. 
7.3.3 Primer efficiency 
The quality of the product and the efficiency of PCR reactions were validated. For each 
sample, dissociation curves were analysed to ensure a single product was present at the 
end of the reaction. Single dissociation peaks with a unique product-dependent melting 
temperature were obtained for each of the gene products TLR2, TLR3, TLR4, TLR7, 
TLR9, TNF-α, IL-4, IL-6, IL-10 and IL-12. In contrast, results showed that the primer sets 
designed to detect the products of the IL-2, TLR5 and IFN-γ genes did not show a single 
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dissociation peak and therefore were excluded from the study. Two new primers (IFN-γ 
2 and IFN-γ 3) were designed and tested for IFN-γ. Melt curves for IFN-γ 2 showed a 
double peak and therefore the primer was not used further. IFN-γ 3 showed a good 
dissociation curve and the efficiency was tested. To test the primer efficiency in the 
PCR reaction, for all primers ten-fold serial dilutions of a cDNA template were made. 
Some of the primer sets, where the abundance of the template in the sample was low, 
failed to produce a Ct value distinguishable from the assay threshold at higher dilutions 
of the cDNA. Where necessary, two- or five- fold dilutions of cDNA were re-tested in 
PCR reactions. The working concentration was always included. Primer efficiencies are 
shown in Table 7.2. 
The primer efficiency for IL-4 amplification could not be ascertained in the samples 
used for validation, presumably because the total amount of IL-4 cDNA was too low. No 
Ct value was produced with the second dilution of the cDNA for IL-4 mRNA expression in 
the validation sample. 
GAPDH proved to be a suitable housekeeping gene by showing a stable expression across 
both cohorts when samples with a similar cDNA concentration were compared (Figure 
7.1). The efficiency was determined to be between 0.9 and 1.1 at both annealing 
temperatures (Table 7.2). 
7.3.4 Toll-like receptor mRNA expression 
Expression of TLR2, TLR4, TLR7 and TLR9 genes was increased in the FCGS samples 
compared to the control. A significant increase was seen in TLR2 (p=0.01) and TLR7 
(p=0.047) mRNA expression (Figure 7.2 and 7.3). A slight decrease was seen in the TLR3 
mRNA expression in the FCGS group compared to the control group (Figure 7.2). When 
the fold-change was calculated a down-regulation was seen in TLR3 mRNA abundance in 
the FCGS group. All other mRNAs encoding the TLRs were up-regulated in the FCGS 
group (Figure 7.4). 
7.3.5 Cytokine mRNA expression 
The expression of TNF-α, IFN-γ IL-1β, IL-4, IL-6 and IL-10 was greater in the FCGS group 
than in the healthy group. After statistical analysis, the TNF-α (p=0.032), IFN-γ 
(p=0.017), IL1-β (p=0.017) and IL-6 (p<0.0001) genes showed a significantly higher 
expression in the FCGS group (Figure 7.3 and 7.5).  
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Table 7.2: Primer efficiencies 
Primer name Primer sequence 5′-3′ Product length Primer 
efficiency 
GAPDH F  GAGCTGAATGGGAAGCTCAC 100 93%-99%  
GAPDH R  CGTATTTGGCAGCTTTCTCC 
IFN-γ F  TCTAACCTGAGGAAGCGGAA 84 N.A. 
IFN-γ R  ATATTGCAGGCAGGACAACC 
IFN- γ 2 F CTGCAGGTCCAGCGCAAAGC 120 N.A. 
IFN- γ 2 R CGATGCTCTACGGCCTCGAAACA   
IFN-γ 3 F TGCAGGTCCAGCGCAAAGCAA 120 91% 
IFN-γ 3 R TCGATGCTCTACGGCCTCGAAACA   
IL-1β F  GACGGTTTTGTGTGTGATGC 92 106% 
IL-1β R  TCGTATGAGCCAGACAGCAC 
IL-2 F ACGGTTGCTTTTGAATGGAG 146 N.A. 
IL-2 R GCACTTCCTCCAGAGGTTTG   
IL-4 F  GCAGCCCCTAAGAACACAAG 102 Not 
determined IL-4 R  TTTGAGGAATTTGGTGGAGC 
IL-6 F  CAGGGCTGTTCGGATAATGT 100 90% 
IL-6 R  TCAGTTACATGCCCAGTGGA 
IL-10 F  TGTCTGAGGACAACTGCACC 108 105% 
IL-10 R  GCTCGTCCTTGGTTTGAAAG 
IL-12 F  TCAACAGTGTGACTGTGCCA 116 105%  
IL-12 R  ATTGATGGTCACTGCACGAA 
TLR2 F  CCTGAAAATGATGTGGGCTT 99 90% 
TLR2 R  CGCTCGCTGTAAGACACAAA 
TLR3 F  GACAACAACTTCCCAGGCAT 199 107% 
TLR3 R  GACAAGAAAAAGCGCCACTC 
TLR4 F  CTGGAACAGGTGTCCCAAGT 176 109% 
TLR4 R  TGCCGTAGTTCTTGCTCCTT 
TLR5 F TTCCTTCCGCCAGGAGTATTTAGC 217 N.A. 
TLR5 R GGAGTTCGCACTCACAGATGAACT   
TLR7 F  TTGAGAAGCCCCTTCAGAAA 149 90% 
TLR7 R  GGTCACGTGATTGTCTGTGG 
TLR9 F  GAGAGCTCAACCTCAGTGCC 144 112% 
TLR9 R  CCAGCAAGAAGTCCACGAAG 
TNF-α F  CTTCCAACTGGAGAAGGGTG 93 108% 
TNF-α R  ATCCCAAAGTAGACCTGCCC 
Efficiencies, length and sequence of the primers used and tested. 
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Figure 7.1: GAPDH Ct value in both cohorts 
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Distribution of GAPDH Ct values between the two groups with a similar cDNA concentration based 
on the RNA concentration used for synthesis. 
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Figure 7.2: TLR mRNA expression in FCGS and healthy samples 
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All samples were adjusted to GAPDH by the 2-dCt method and statistical analysis was performed 
using the Mann-Whitney U test. A: Expression of the TLR2 gene. B: Expression of the TLR3 gene. 
C: Expression of the TLR4 gene. D: Expression of the TLR7 gene. E: Expression of the TLR9 gene. 
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Figure 7.3: TLR and cytokine mRNA expression in healthy and FCGS samples 
All values were adjusted to GAPDH and normalised to healthy TLR2 gene expression. 
 
Figure 7.4: Fold change in TLR mRNA levels in healthy and FCGS samples 
 
The change in expression levels between cats with FCGS (28) and healthy (8) cats is shown. 
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Figure 7.5: Cytokine mRNA expression in healthy and FCGS samples 
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All samples were adjusted to GAPDH by the 2-dCt method and statistical analysis was performed 
using the Mann-Whitney U test. A: TNF-α mRNA. B: IFN-γ mRNA. C: IL-1β mRNA. D: IL-4 mRNA. E: 
IL-6 mRNA. F: IL-10 mRNA. G: IL-12 mRNA.  
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IL-12A mRNA levels showed a slight decrease in the FCGS group, and the increase in IL-4 
mRNA was not significant statistically. When the fold change was calculated IL-12A 
mRNA showed a down-regulation in expression in the cats with FCGS, where all other 
genes showed an up-regulation of mRNA expression (Figure 7.6). 
7.3.6 TLR mRNA expression in cats with and without FCV 
Cats from the healthy and FCGS group were taken together and gene expression in 
tissue biopsies from cats with and without FCV was compared. mRNA expression levels 
for TLR2, TLR3, TLR4, TLR7 and TLR9 are shown in Figure 7.7. Using the Mann-Whitney 
U-test, a higher expression of TLR2 mRNA (p=0.012) was seen in FCV-positive cats 
compared to FCV-negative cats. TLR7 mRNA levels were not significantly different 
(p=0.057) but the median expression level was higher in cats positive for FCV. The 
expression of other TLR genes did not show a significant difference between FCV-
positive and FCV-negative cats. 
7.3.7 Cytokine mRNA expression in cats with and without FCV 
Cytokine gene expression in FCV-positive and FCV-negative cats from the healthy and 
FCGS populations was also analysed. Expressions of TNF-α, IFN-γ, IL-1β, IL-4, IL-6, IL-10 
and IL-12 genes are shown in Figure 7.8. A significantly higher expression of IFN-γ 
(p<0.001), IL-1β (p=0.048) and IL-6 mRNA (p=0.008) was seen in the FCV group. 
7.3.8 TLR mRNA expression in cats with and without T. forsythia 
A Mann-Whitney U-test was performed on healthy cats and cats from the FCGS group 
with and without T. forsythia, as detected by 16S rRNA gene sequencing (Section 
5.3.2.4) The expression of TLR2 (p=0.004), TLR4 (p=0.005), TLR7 (p=0.007) and TLR9 
(p=0.017) mRNA was significantly higher in the group where T. forsythia was present 
(Figure 7.9).  
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Figure 7.6: Fold change of cytokine gene expression in healthy and FCGS samples 
 
The change in each of the cytokine mRNA levels between cats with FCGS (28) and healthy (8) 
cats is shown. 
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Figure 7.7: TLR mRNA expression in cats with and without FCV 
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All samples were adjusted to GAPDH by the 2-dCt method and statistical analysis was performed 
using the Mann-Whitney U test. Expression is shown in FCV-positive and FCV-negative cats in the 
healthy and FCGS group combined. A: TLR2 mRNA. B: TLR3 mRNA. C: TLR4 mRNA. D: TLR7 
mRNA. E: TLR9 mRNA.  
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Figure 7.8: Cytokine mRNA expression in cats with and without FCV 
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All samples were adjusted to GAPDH by the 2-dCt method and statistical analysis was performed 
using the Mann-Whitney U-test. Expression is shown in FCV-positive and FCV-negative cats in the 
healthy and FCGS group combined. A: TNF-α mRNA. B: IFN-γ mRNA. C: IL-1β mRNA. D: IL-4 
mRNA. E: IL-6 mRNA. F: IL-10 mRNA. G: IL-12 mRNA.  
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Figure 7.9: TLR mRNA expression in cats with and without T. forsythia 
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T. forsythia was detected by 16S rRNA gene sequencing of bacteria from oral swabs of cats with 
and without FCGS. All samples were adjusted to GAPDH by the 2-dCt method and statistical 
analysis was performed using the Mann-Whitney U test. A: TLR2 mRNA. B: TLR3 mRNA. C: TLR4 
mRNA. D: TLR7 mRNA. E: TLR9 mRNA.  
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7.3.9 Cytokine mRNA expression in cats with and without 
T. forsythia 
Expression of cytokine genes was analysed in cats where T. forsythia was detected and 
in cats without T. forsythia for healthy and cats with FCGS. A significant increase in 
expression of TNF-α (p=0.004) and IL-1β (p=0.017) genes was seen in the group where T. 
forsythia was present (Figure 7.10). 
7.3.10 TLR mRNA expression in cats with and without P. multocida 
subsp. septica 
TLR gene expression was analysed in all cats where P. multocida subsp. septica was 
detected by 16S rRNA gene sequencing and compared to the cats where no P. multocida 
subsp. septica was detected. TLR7 mRNA expression was significantly higher in the 
group where no P. multocida supsp. septica was detected (p=0.024). The other TLR 
gene products, except TLR3, appeared to show lower expression levels in the 
P. multocida subsp. septica group but these differences were not statistically significant 
when compared to the cats that did not show the presence of P. multocida subsp. 
septica (Figure 7.11). 
7.3.11 Cytokine mRNA expression in cats with and without 
P. multocida subsp. septica 
Cytokine gene expression in all cats with and without P. multocida subsp. septica was 
analysed. Significantly higher expression was seen in the group that was free of P. 
multocida subsp. septica for TNF-α (p=0.017) and IFN-γ mRNA (p=0.040). All other 
cytokine genes did not show a significant difference in levels of expression (Figure 
7.12). 
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Figure 7.10: Cytokine mRNA expression in cats with and without T. forsythia 
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T. forsythia was detected by 16S rRNA gene sequencing of bacteria from oral swabs of cats with 
and without FCGS. All samples were adjusted to GAPDH by the 2-dCt method and statistical 
analysis was performed using the Mann-Whitney U-test. A: TNF-α mRNA. B: IFN-γ mRNA. C: IL-1β 
mRNA. D: IL-4 mRNA. E: IL-6 mRNA. F: IL-10 mRNA. G: IL-12 mRNA.  
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Figure 7.11: TLR mRNA expression in cats with and without P. multocida subsp. septica 
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P. multocida subsp. septica was detected by 16S rRNA gene sequencing of bacteria from oral 
swabs of cats with and without FCGS. All samples were adjusted to GAPDH by the 2-dCt method 
and statistical analysis was performed using the Mann-Whitney U-test. A: TLR2 mRNA. B: TLR3 
mRNA. C: TLR4 mRNA. D: TLR7 mRNA. E: TLR9 mRNA.  
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Figure 7.12: Cytokine mRNA expression in cats with and without P. multocida subsp. septica 
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P. multocida subsp. septica was detected by 16S rRNA gene sequencing of bacteria from oral 
swabs of cats with and without FCGS. All samples were adjusted to GAPDH by the 2-dCt method 
and statistical analysis was performed using the Mann-Whitney U test. A: TNF-α mRNA. B: IFN-γ 
mRNA. C: IL-1β mRNA. D: IL-4 mRNA. E: IL-6 mRNA. F: IL-10 mRNA. G: IL-12 mRNA. 
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7.3.12 TLR mRNA expression in cats with and without 
P. multocida subsp. multocida 
When expression of TLR genes was analysed in cats with and without P. multocida 
subsp. multocida it appeared that expression of all TLR genes was higher in the group 
that did not contain this organism (Figure 7.13). However these differences were not 
statistically significant. 
7.3.13 Cytokine mRNA expression in cats with and without 
P. multocida subsp. multocida 
When cytokine gene expression was analysed in cats with and without P. multocida 
subsp. multocida, no significant changes were seen (Figure 7.14). 
7.3.14 TLR mRNA expression in cats with and without 
Pseudomonas sp.  
No significant difference in TLR gene expression was seen between samples containing 
Pseudomonas sp. and samples where no Pseudomonas sp. were detected by 16S rRNA 
gene sequencing (Figure 7.15).  
7.3.15 Cytokine mRNA expression in cats with and without 
Pseudomonas sp. 
As was seen for TLR mRNA expression, no significant difference was seen in cytokine 
mRNA expression when cats were divided according to the presence of Pseudomonas sp. 
(Figure 7.16). 
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Figure 7.13: TLR mRNA expression in cats with and without P. multocida subsp. multocida 
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P. multocida subsp. multocida was detected by 16S rRNA gene sequencing of bacteria from oral 
swabs of cats with and without FCGS. All samples were adjusted to GAPDH by the 2-dCt method 
and statistical analysis was performed using the Mann-Whitney U test. A: TLR2 mRNA. B: TLR3 
mRNA. C: TLR4 mRNA. D: TLR7 mRNA. E: TLR9 mRNA. Pos: positive, Neg: negative.  
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Figure 7.14: Cytokine mRNA in cats with and without P. multocida subsp. multocida 
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P. multocida subsp. multocida was detected by 16S rRNA gene sequencing of bacteria from oral 
swabs of cats with and without FCGS. All samples were adjusted to GAPDH by the 2-dCt method 
and statistical analysis was performed using the Mann-Whitney U test. A: TNF-α mRNA. B: IFN-γ 
mRNA. C: IL-1β mRNA. D: IL-4 mRNA. E: IL-6 mRNA. F: IL-10 mRNA. G: IL-12 mRNA. Pos: positive, 
Neg: negative.   
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Figure 7.15: TLR mRNA expression in cats with and without Pseudomonas sp. 
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Pseudomonas sp. were detected by 16S rRNA gene sequencing of bacteria from oral swabs of cats 
with and without FCGS. All samples were adjusted to GAPDH by the 2-dCt method and statistical 
analysis was performed using the Mann-Whitney U-test. A: TLR2 gene. B: TLR3 gene. C: TLR4 
gene. D: TLR7 gene. E: TLR9 gene.  
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Figure 7.16: Cytokine mRNA expression in cats with and without Pseudomonas sp. 
Ps
eu
do
m
on
as
 n
eg
at
iv
e 
(n
=1
8)
Ps
eu
do
m
on
as
 p
os
iti
ve
 (n
=4
)
0
5.0×10 -6
1.0×10 -5
1.5×10 -5
0.004
0.008
0.012
T
N
F

 m
R
N
A
 e
xp
re
ss
io
n
Ps
eu
do
m
on
as
 n
eg
at
iv
e 
(n
=1
8)
Ps
eu
do
m
on
as
 p
os
iti
ve
 (n
=4
)
0
5.0×10 -4
1.0×10 -3
1.5×10 -3
2.0×10 -3
0.005
0.010
0.015
IF
N
 
m
R
N
A
 e
xp
re
ss
io
n
Ps
eu
do
m
on
as
 n
eg
at
iv
e 
(n
=1
8)
Ps
eu
do
m
on
as
 p
os
iti
ve
 (n
=4
)
0.000
0.005
0.010
0.02
0.04
0.06
IL
-1

 m
R
N
A
 e
xp
re
ss
io
n
Ps
eu
do
m
on
as
 n
eg
at
iv
e 
(n
=1
8)
Ps
eu
do
m
on
as
 p
os
iti
ve
 (n
=4
)
0
5.0×10 -6
1.0×10 -5
1.5×10 -5
2.0×10 -5
1.0×10 -4
2.0×10 -4
IL
-4
 m
R
N
A
 e
x
p
re
s
si
o
n
Ps
eu
do
m
on
as
 n
eg
at
iv
e 
(n
=1
8)
Ps
eu
do
m
on
as
 p
os
iti
ve
 (n
=4
)
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.16
0.20
IL
-6
 m
R
N
A
 e
x
p
re
s
si
o
n
Ps
eu
do
m
on
as
 n
eg
at
iv
e 
(n
=1
8)
Ps
eu
do
m
on
as
 p
os
iti
ve
 (n
=4
)
0.000
0.002
0.004
0.006
IL
-1
0
 m
R
N
A
 e
x
p
re
s
si
o
n
Ps
eu
do
m
on
as
 n
eg
at
iv
e 
(n
=1
8)
Ps
eu
do
m
on
as
 p
os
iti
ve
 (n
=4
)
0
1.0×10 -4
2.0×10 -4
3.0×10 -4
5.0×10 -4
1.0×10 -3
1.5×10 -3
IL
-1
2
 m
R
N
A
 e
xp
re
ss
io
n
A B
C D
E F
G
 
Pseudomonas sp. were detected by 16S rRNA gene sequencing of bacteria from oral swabs of cats 
with and without FCGS. All samples were adjusted to GAPDH by the 2-dCt method and statistical 
analysis was performed using the Mann-Whitney U test. A: TNF-α gene expression. B: IFN-γ gene 
expression. C: IL-1β gene expression. D: IL-4 gene expression. E: IL-6 gene expression. F: IL-10 
gene expression. G: IL-12 gene expression. 
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7.3.16 TLR mRNA expression in cats with and without 
P. circumdentaria 
When cats were divided into two groups according to the presence or absence of P. 
circumdentaria in the oral swabs, a significant difference between the two groups was 
seen in TLR2 (p=0.039) and TLR3 mRNA expression (p=0.01). The other TLR genes did 
not show a difference in levels of expression. All TLR genes except TLR3 showed a 
higher level of expression in the group where P. circumdentaria was present (Figure 
7.17). 
7.3.17 Cytokine mRNA expression in cats with and without 
P. circumdentaria 
Comparison of cats with and without P. circumdentaria showed a higher level of 
cytokine mRNA expression in the group where P. circumdentaria was present for all 
cytokines except IL-12. Cytokine mRNA expression in the P. circumdentaria group was 
not significantly different for any of the cytokine genes (Figure 7.18). 
7.3.18 TLR mRNA expression in different histopathological 
groupings 
Gene expression was analysed in cats divided into two different groups according to the 
type of inflammatory cells present as assessed by histopathological examination 
(Section 6.3.3). The median levels of the TLR mRNA levels appeared to be greater in 
cell group 2 (mainly plasma cells). This difference was only statistically significant for 
TLR3 gene expression (p=0.037) (Figure 7.19). 
7.3.19 Cytokine mRNA expression in different histopathological 
groupings 
Cytokine gene expression in the two histopathological cell groupings was analysed. The 
Mann-Whitney U-test showed a statistically significant increase in IFN-γ (0.045), IL-1β 
(p=0.021), IL-6 (p=0.045) and IL-10 (p=0.026) mRNA in group 2 (Figure 7.20). 
  
Chapter 7 Aspects of the innate immune response in cats with FCGS 164 
Figure 7.17: TLR mRNA expression in cats with and without P. circumdentaria 
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P. circumdentaria was detected by 16S rRNA gene sequencing of bacteria from oral swabs of cats 
with and without FCGS. All samples were adjusted to GAPDH by the 2-dCt method and statistical 
analysis was performed using the Mann-Whitney U test. A: Expression of the TLR2 gene. B: 
Expression of the TLR3 gene. C: Expression of the TLR4 gene. D: Expression of the TLR7 gene. E: 
Expression of the TLR9 gene. Pos: Positive, Neg: negative.  
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Figure 7.18: Cytokine mRNA expression in cats with and without P. circumdentaria 
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P. circumdentaria was detected by 16S rRNA gene sequencing of bacteria from oral swabs of cats 
with and without FCGS. All samples were adjusted to GAPDH by the 2-dCt method and statistical 
analysis was performed using the Mann-Whitney U test. A: TNF-α mRNA. B: IFN-γ mRNA, C: IL-1β 
mRNA. D: IL-4 mRNA. E: IL-6 mRNA. F: IL-10 mRNA. G: IL-12 mRNA. Pos: positive, Neg: negative.  
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Figure 7.19: TLR mRNA expression in two histopathological cell groupings 
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All samples were adjusted to GAPDH by the 2-dCt method and statistical analysis was performed 
using the Mann-Whitney U test. A: TLR2 mRNA. B: TLR3 mRNA. C: TLR4 mRNA. D: TLR7 mRNA. E: 
TLR9 mRNA. 
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Figure 7.20: Cytokine mRNA expression in two histopathological cell groupings 
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All samples were adjusted to GAPDH by the 2-dCt method and statistical analysis was performed 
using the Mann-Whitney U test. A: TNF-α mRNA expression. B: IFN-γ mRNA expression. C: IL-1β 
mRNA expression. D: IL-4 mRNA expression. E: IL-6 mRNA expression. F: IL-10 mRNA expression. 
G: IL-12 mRNA expression.  
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7.3.20 TLR mRNA expression according to histopathological 
severity 
Histopathological analysis showed five severity groups (Section 6.3.2). To make group 
numbers more equal, mild (group 1) and mild to moderate (group 1-2) were taken 
together. The other categories were moderate (2), moderate to severe (2-3) and severe 
(3). Differences between the groups were compared with a Kruskal-Wallis test. A 
significant difference was seen between at least one of the groups analysed for TLR4 
gene expression (p=0.042). Dunn’s multiple comparison test showed a difference 
between the mild/moderate and moderate/severe group (p<0.1) (Figure 7.21). No 
significant differences were seen in the expression of the other TLR genes. 
7.3.21 Cytokine mRNA expression according to histopathological 
severity 
Changes in cytokine mRNA expression between the different severity groups was 
determined using a Kruskal-Wallis test. A significant difference was shown for IL-1β 
mRNA in at least one of the groups (p=0.003). A Dunn’s multiple comparison test showed 
differences between the mild/moderate and moderate/severe groups (p<0.05) and 
between the mild/moderate and severe groups (p<0.05) No other differences were 
found to be significant (Figure 7.22). 
7.3.22 TLR mRNA expression according to clinical severity 
TLR mRNA abundance in the different groups of severity assessed during clinical 
investigation (Section 3.3.5) was analysed by a Kruskal-Wallis test. Group 1, mild 
inflammation and group 2, moderate inflammation, were taken together to equalise the 
group sizes. Group 0; no inflammation, represents the healthy cats. A significant 
difference in at least one of the groups was seen in TLR2 mRNA expression (p=0.012). A 
Dunn’s multiple comparison test showed a difference between group 0 and group 3 in 
expression of TLR2 mRNA (p<0.05) (Figure 7.23). 
7.3.23 Cytokine mRNA expression according to clinical severity 
The cytokine mRNA levels in the different clinical severity groups was analysed by a 
Kruskal-Wallis test. A significant difference in at least one of the groups was seen for 
IFN-γ (p=0.01), IL-1β (p=0.032) and IL-6 mRNA (p=0.0005). A Dunn’s multiple comparison 
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test showed a difference between group 0 and group 3 in the expression of IFN-γ 
(p<0.05), IL-1β (p<0.05) and IL-6 mRNA (p<0.05) (Figure 7.24). 
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Figure 7.21: TLR mRNA expression according to histopathological severity 
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All samples were adjusted to GAPDH by the 2-dCt method and statistical analysis was performed 
using the Kruskal-Wallis test followed by the Dunn’s multiple comparison test. A: Expression of 
the TLR2 mRNA. B: Expression of the TLR3 mRNA. C: Expression of the TLR4 mRNA * p<0.1. D: 
Expression of the TLR7 mRNA. E: Expression of the TLR9 mRNA. 
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Figure 7.22: Cytokine mRNA expression according to histopathological severity 
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All samples were adjusted to GAPDH by the 2-dCt method and statistical analysis was performed 
using the Kruskal-Wallis test, followed by the Dunn’s multiple comparison test. A: TNF-α mRNA 
expression. B: IFN-γ mRNA expression. C: IL-1β mRNA expression * p<0.05, ** p<0.05. D: IL-4 
mRNA expression. E: IL-6 mRNA expression. F: IL-10 mRNA expression. G: IL-12 mRNA expression.  
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Figure 7.23: TLR mRNA expression according to clinical severity 
0 
(n
=8
)
1-
2 
(n
=6
)
3 
(n
=1
3)
0.000
0.005
0.010
0.015
0.02
0.04
*
*
T
L
R
2
 m
R
N
A
 e
xp
re
ss
io
n
0 
(n
=8
)
1-
2 
(n
=6
)
3 
(n
=1
3)
0.000
0.001
0.002
0.003
T
L
R
3
 m
R
N
A
 e
xp
re
ss
io
n
0 
(n
=8
)
1-
2 
(n
=6
)
3 
(n
=1
3)
0.000
0.002
0.004
0.01
0.02
T
L
R
4
 m
R
N
A
 e
xp
re
ss
io
n
0 
(n
=8
)
1-
2 
(n
=6
)
3 
(n
=1
3)
0
5.0×10 -4
1.0×10 -3
1.5×10 -3
2.0×10 -3
0.01
T
L
R
7
 m
R
N
A
 e
xp
re
ss
io
n
0 
(n
=8
)
1-
2 
(n
=6
)
3 
(n
=1
3)
0
5.0×10 -4
1.0×10 -3
1.5×10 -3
2.0×10 -3
0.005
0.010
T
L
R
9
 m
R
N
A
 e
x
p
re
ss
io
n
A B
C D
E
 
All samples were adjusted to GAPDH by the 2-dCt method and statistical analysis was performed 
using the Kruskal-Wallis test, followed by a Dunn’s multiple comparison test. A: TLR2 mRNA, * 
p<0.05. B: TLR3 mRNA. C: TLR4 mRNA. D: TLR7 mRNA. E: TLR9 mRNA. 
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Figure 7.24: Cytokine mRNA expression according to clinical severity 
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All samples were adjusted to GAPDH by the 2-dCt method and statistical analysis was performed 
using the Kruskal-Wallis test, followed by a Dunn’s multiple comparison test. A: TNF-α mRNA 
expression. B: IFN-γ mRNA expression, * p<0.05. C: IL-1β mRNA expression, *p<0.05. D: IL-4 
mRNA expression. E: IL-6 mRNA expression * p<0.05. F: IL-10 mRNA expression. G: IL-12 mRNA 
expression.  
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7.4 Discussion 
Quantitative PCR is a reliable technique to assess cytokine and TLR gene expression 
when using validated primers (Fraga et al., 2008). For the current study, new primers 
were designed on the basis of feline mRNA sequences for the different genes. Primers 
used in previous studies were not designed for the real time PCR SYBR-green method as 
used in this study, since either the product length was not suitable for the purpose of 
the study or they had been validated in a Taqman assay (Harley et al., 1999; 
Leutenegger et al., 1999; Ignacio et al., 2005). A well performed SYBR green method is 
reliable, although there is always the possibility in these fine-tuned techniques for 
errors. Errors can occur due to pipetting, suboptimal primer efficiency or differences in 
RNA quality between samples. To ensure accurate results, all primers were tested for 
efficiency and melt-curve analysis was performed on each run. To reduce the influence 
of pipetting errors, all samples were run in triplicate and averages were calculated. 
Primer efficiency was accepted when they were between 90% and 110% (Fraga et al., 
2008). The primer efficiency for TLR9 mRNA detection was marginally greater at 112%, 
but consistent single peak melt curves were obtained. A second product was not 
observed in the amplification reactions and no amplicons were detected when the 
template was absent in the reaction. This discrepancy could be explained by 
experimental error. Primer efficiency for IL-4 could not be obtained because of the 
small amount of RNA in the samples. Only results with good dissociation curves were 
accepted, but due to the high number of null results no significant changes were found 
for this primer between different groups. At the time of primer design, the previously 
published TLR5 feline mRNA sequence was not accessible online and therefore a 
published primer set was used (Ignacio et al., 2005). For IL-2, TLR5 and IFN-γ gene 
analysis, no reliable melt curves could be obtained with the cDNA prepared from the 
samples, therefore these primers were not used for the final analysis. Due to the lack of 
RNA that could be extracted from the small tissue samples, there was only enough cDNA 
to run all the samples again for one new primer set and IFN-γ was chosen. For IFN-γ, 
two new primer pairs were designed and tested, yielding reliable results with good 
efficiency. 
GAPDH was chosen as a housekeeping gene. GAPDH is commonly used for this purpose 
and is expressed at high levels in different tissue types (Harley et al., 1999; Kipar et al., 
2001; Nguyen Van et al., 2006). Primers for GAPDH were designed and the efficiency of 
GAPDH was tested for both annealing temperatures used in the study. No substantial 
difference was found in GAPDH expression between both cohorts (healthy and FCGS) 
and therefore GAPDH was considered a suitable reference gene for this study. A study 
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on reference genes for qPCR in feline tissue where a number of different tissues were 
tested showed that other reference genes might be preferred over GAPDH in some 
circumstances (Penning et al., 2007). However no feline gingival tissue had been tested 
in that study and considering the validation tests that have been performed in the 
current study, GAPDH can be considered valid. A melt curve was made on each run for 
each primer to ensure a single product with no primer-dimers or DNA contamination. 
TLR gene expression was analysed in this study. TLRs activate adapter molecules after 
binding to their ligand. The activated cascade then leads to induction or suppression of 
genes that influence the inflammatory response (Akira and Takeda, 2004). The 
expression of mRNA encoding TLR2, TLR3, TLR4, TLR7 and TLR9 was measured. Two out 
of the five TLRs tested (TLR2 and TLR7) showed a significant increase in abundance of 
their respective mRNA in the FCGS group when compared to the healthy group. TLR2 is 
found on the cell surface. The ligands for TLR2 are derived from a variety of gram-
positive and gram-negative bacteria and include lipoprotein, peptidoglycan and 
glycolipids (Akira and Takeda, 2004). Zymosan is also one of the ligands for TLR2, 
indicating that TLR2 also recognises fungi. It is likely that host cells could be 
recognised, since heat-shock protein 70 (HSP70) is seen as a possible ligand. TLR2 mRNA 
abundance was significantly higher in the biopsies from cats with FCGS, compared to 
the biopsies from healthy cats. Since activation of TLR2 is known to cause an increase in 
expression of the TLR2 gene (Weiss et al., 2004) this might indicate a reaction to one of 
the known ligands. In this study an innate reaction to bacteria mediated by TLR2 is 
likely since a broad variety of gram-positive and gram-negative bacteria were identified 
in the oral cavity. TLR2 gene expression was significantly increased in cats harbouring T. 
forsythia. The involvement of TLR2 in T. forsythia recognition has been shown 
previously. Studies on the role of T. forsythia in periodontal bone loss have shown a 
TLR2-dependent pathway for cytokine expression (Myneni et al., 2011). The presence of 
another bacterial genus known to be important in human periodontal health, 
(Porphyromonas sp.) was also associated with a significant increase in the expression of 
TLR2. P. circumdentaria is from another subspecies, but the inflammatory response in 
the genus member P. gingivalis has been studied and is dependent on TLR2 (Burns et 
al., 2006). Interestingly, no significant difference was seen in the current study when 
groups with and without P. multocida subsp. septica, P. multocida subsp. multocida and 
Pseudomonas sp. were compared, and these species were detected regularly in cats 
with FCGS. A possible explanation for the lack of discrimination between gene 
expression profiles for P. multocida subsp. septica-positive and P. multocida subsp. 
septica-negative cats is the high abundance of the organism in the healthy group. 
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In the current study, TLR2 mRNA levels demonstrated significantly higher expression in 
the group positive for FCV when compared to the FCV-negative group, without an 
obvious explanation. FCV is seen in the majority of cases with FCGS. Severe 
inflammation has been seen in cats with FCV (Hennet et al., 2011) and the role of 
bacteria is unclear. However, a stronger reaction to bacteria by innate immunity, as 
shown by an increase in TLR2 mRNA expression in the current study, suggests that there 
may be a relationship between the two. Also a higher expression of TLR2 mRNA in the 
current study was seen in cats with more severe clinical disease in the caudal area of 
the oral cavity, suggesting that more severe cases show a more intense reaction to the 
bacteria that are present in the oral cavity. 
TLR3 recognises double stranded RNA (dsRNA) (Alexopoulou et al., 2001). Viruses with 
dsRNA, (reoviruses) were not investigated in this study. However, it has been speculated 
that TLR3 also recognises single-stranded RNA viruses during the replication process 
(Jacobs and Langland, 1996; Tabeta et al., 2004). The actual amount of dsRNA in cells 
infected with single-stranded RNA (ssRNA) viruses is unclear and the exact role of TLR3 
in the viral immune response is yet to be elucidated (Edelmann et al., 2004). It has 
been shown, however, that ssRNA viruses can cause an up-regulation of TLR3 gene 
expression (Guillot et al., 2005) but this has not been investigated for FCV specifically. 
The reaction of various TLRs following viral infection also seems to vary between cell 
types (Ignacio et al., 2005). When comparing healthy cats and cats with FCGS in the 
current study, no significant difference was observed between the groups for TLR3 
expression. A reduction of TLR3 mRNA was seen in the FCGS group when compared to 
the healthy group. A significantly higher expression of the TLR3 gene was seen in the 
group where no P. circumdentaria was present when compared to the group where the 
organism was present. One other significant finding was the higher expression in the 
histopathological cell group 2. Further investigation into the role of TLR3 is needed to 
explain the changes that have been seen in the current study.  
TLR4 recognises lipopolysaccharide (LPS) from several types of Gram-negative bacteria, 
but also has fusion and envelope proteins as a ligand and is therefore also known to 
recognise several viruses (Akira and Takeda, 2004). It has been described that host cells 
can be recognised by several ligands, including HSPs. In the current study, TLR4 mRNA 
expression appeared to be slightly up-regulated in the FCGS group when compared to 
the healthy group but no statistically significant difference was seen. A significantly 
higher expression of the TLR4 gene was found in cats that showed the presence of the 
Gram-negative bacterium T. forsythia, when compared to a group of cats where 
T. forsythia was not present. However, none of the other bacteria were associated with 
a significant difference in mRNA expression for TLR4. A significant difference in TLR4 
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mRNA was recorded between groups when divided according to the histopathological 
severity. The severity was judged on the number of cells present in the tissue samples. 
The increased numbers of immune cells probably accounted for the increased 
expression of TLR4 mRNA in the severely inflamed group, but up-regulation of TLR4 
gene expression on resident cells could also account for such a change. 
TLR7 has ssRNA as a ligand and therefore recognises ssRNA viruses. In the current study, 
the expression of TLR7 was significantly increased in the cats with FCGS. In some 
respects this might be expected, since a high percentage of the cats in the FCGS group 
were found to be positive for the ssRNA virus FCV. Other ssRNA viruses were 
investigated in this study, namely FIV and FeLV. These viruses, as well as FCV, were 
found in some healthy cats and FIV was also detected in one cat with FCGS. When 
healthy and FCGS cats were divided according to their FCV status the difference 
between the groups in TLR7 mRNA abundance just missed statistical significance using 
the two tailed Mann-Whitney test. The possibility of false negative results in the FCV 
test within the FCGS group could be an explanation for this difference. Other factors 
will play a role but the high expression of TLR7 in the FCGS group suggests that 
stimulation by viruses is contributing to activation of the immune system in some of the 
cats with FCGS. Other changes in the TLR7 expression were seen, but without a clear 
explanation. A significant difference in TLR7 mRNA abundance was seen when groups 
were divided according to the presence of T. forsythia. Cats with T. forsythia showed a 
higher expression of several TLRs and cytokines. Complex interactions between the viral 
and bacterial pathogens might be present in FCGS and other complex infectious 
diseases. TLR and cytokine mRNA expression were lower in cats where subspecies of 
P. multocida were identified. A significant difference in TLR7 mRNA levels was found 
between the cats with and without P. multocida subsp. septica, with cats without P. 
multocida subsp. septica showing a higher mRNA expression. Further investigation into 
the role of these bacteria in the oral cavity is required in order to explain these 
changes. 
CpG-containing DNA is a specific ligand for the endosomal TLR9, which can therefore 
recognise, fungi, bacteria and viruses (Hemmi et al., 2001; Ramaprakash et al., 2009). 
TLR9 mRNA levels appeared to be higher in the FCGS group in the current study but no 
significant difference was seen. However, a significant increase in expression of TLR9 
mRNA was seen in the group with T. forsythia present compared to cats where no T. 
forsythia was detected. 
The result of TLR ligation in general is the activation of second messenger systems, 
which share certain components of the pathways that activate nuclear factor κB. This 
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nuclear factor translocates to the cell nucleus to induce the transcription of many 
genes, including those encoding cytokines (Akira and Takeda, 2004). Certain aspects of 
cytokine gene expression were also investigated in this study. 
Cytokine gene expression in cats with FCGS has been studied previously (Harley et al., 
1999). Reverse transcription PCR was used with GAPDH as a housekeeping gene. An 
increase was seen in the expression of IL-2, IL-4, IL-6, IL-10, IL-12 and IFN-γ genes in 
the affected population. A shift from a predominant Th1 response in the healthy 
population to a combined Th1-Th2 response in the FCGS group was described. 
In the current study, a significant increase in cytokine mRNA expression was seen in the 
FCGS group for TNF-α, IFN-γ, IL-1β and IL-6. An increase was seen in IL-4 and IL-10 
mRNA levels but this was not statistically significant. IL-12 mRNA did show a slight 
reduction in the FCGS group. An abundance of mRNA encoding for the acute phase 
cytokines IL-1β, IL-6 and TNF-α was increased significantly in the FCGS group. The acute 
phase response induces the production of cortisol and can result in a leukocytosis by the 
release of high numbers of neutrophils into the bloodstream. Cytokines also increase the 
speed of neutrophil delivery to the tissues (Paltrienieri, 2008). The response is however 
not confined to the acute phase reaction since both Th1 and Th2 cytokine gene 
expression was increased in the current study as described previously (Harley et al., 
1999). However, in the current study no significant increase was shown in the 
abundance of IL-4 and IL-10 mRNA. Furthermore, IL-12 mRNA expression was not 
increased.  
How Th1, Th2 and Th17 cells and cytokines are involved in the pathogenesis of several 
diseases is still unclear, but in human periodontal disease studies it has been shown that 
cytokines from these different T cell subsets are expressed together (Preshaw and 
Taylor, 2011). The present study shows a significant increase in acute phase cytokines. 
Stimulation of TLRs induces the induction of inflammatory cytokines and LPS is known to 
be one of the important initiating factors in the host response to infection in human 
periodontal disease (Preshaw and Taylor, 2011). The disease can also progress by 
activation of macrophages through breakdown products produced during tissue damage, 
causing further cytokine secretion. 
Unfortunately, we were unable to extend our investigation to the IL-17 family of 
cytokines, produced by Th17 cells, due to a lack of information on the feline genome. 
The IL-17 family of cytokines have proven to be important mediators of inflammation 
involved in man and other species and are involved in a number of inflammatory 
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diseases in which T cells and B cells are involved (Johnson et al., 2004; Colic et al., 
2007; Bougarn et al., 2011). 
The high number of plasma cells that have been found in the histopathological analysis 
in the present study and the high titres of immunoglobulins found in saliva of cats with 
FCGS (Harley et al., 2003b) supports the involvement of the humoral immune response 
in the disease. A recent study on the cell populations in the caudal mucosa of cats with 
FCGS also showed that the predominant cell types identified, CD79a- and IgG- 
expressing cells, were part of the humoral immune response (Harley et al., 2011). 
As with TLR gene expression, cytokine gene expression was compared for groups with 
and without pathogens that were investigated in the current study. When a comparison 
was made between cats with and without FCV, a significant increase was seen in the 
inflammatory cytokines IL-1β and IL-6 mRNA expression in the group with FCV and also 
in the abundance of IFN-γ mRNA. IFN-γ is known to be synthesised in response to the 
activation of T lymphocytes and natural killer cells by virus infected cells (Goodbourn et 
al., 2000) and is therefore likely to be highly expressed in virus-infected cats. 
When divided into cats with and without T. forsythia a significant increase in the group 
with T. forsythia was seen in TNF-α and IL-1β mRNA expression. An increased expression 
of the acute phase cytokines IL-1β, TNF-α and IL-6 has been seen in human monocytes 
stimulated with DNA from T. forsythia (Sahingur et al., 2010). Therefore it is not 
surprising that the acute phase cytokines are increased in cats when this micro-organism 
is present. However, other bacteria, (P. multocida subspecies, Pseudomonas sp. and P. 
circumdentaria) were not associated with a higher expression of cytokine genes. One 
possible reason for this is that a large proportion of healthy cats also harboured some of 
these bacteria. In a group of cats where no P. multocida subsp. septica was isolated, a 
higher level of mRNA expression was detected for TNF-α and IFN-γ. For the groups with 
P. multocida subspecies and Pseudomonas species a lower (but not statistically 
significant) abundance of mRNA was seen for most of the cytokines. In the groups where 
T. forsythia and P. circumdentaria were isolated, expression of most cytokine genes 
were higher but in many cases this did not reach statistical significance. 
For the two different histopathological cell groups, plasma-lymphocytic (cell group 1) 
and plasmacytic (cell group 2), significant differences were observed in the abundance 
of mRNA in IFN-γ, IL-1β, IL-6 and IL-10, with a higher expression of these cytokines in 
cell group 2. High numbers of plasma cells were seen in most samples, but in cell group 
2 the cells were predominantly plasma cells. Consequently, the numbers of lymphocytes 
and neutrophils were lower. 
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When the cats were divided according to the histopathological severity, a significant 
difference in IL-1β gene expression was seen between the groups. The acute phase 
cytokine also showed a significant difference between groups when subdivided 
according to clinical severity. Very low expression of the cytokine was seen in the mildly 
inflamed groups and a higher expression was seen in the more severely inflamed groups. 
IFN-γ and IL-6 also showed a significant difference between the clinical severity groups. 
An increase in expression of the different cytokines in the more severe cases concurs 
with the findings of Harley et al. (1999). 
The results in this chapter show that a multifactorial aetiopathogenesis of FCGS is most 
likely. Bacteriological studies show that opportunistic bacterial infection is likely to play 
a role (Sims et al., 1990; Dolieslager et al., 2011). In the present study, the bacteria 
that seem to show the most powerful impact on the measured immune system 
parameters are T. forsythia and P. circumdentaria. These bacteria induce significantly 
higher expression of certain cytokine and TLR genes and therefore seem to play a role in 
the inflammatory process. A greater level of expression of gene transcripts encoding a 
number of cytokines and TLR genes was also seen in the cats infected with FCV. 
Environmental factors, bacterial infection and the host response to infection may act in 
combination with viral infection to influence the disease process (Tenorio et al., 1991; 
Addie et al., 2003).  
Analysing cytokine and TLR gene expression in vivo has the advantage that the possible 
link between TLR stimulation and cytokine production is maintained and can be 
investigated. Many factors involved in the process, including some features of the 
immune system, are not yet understood and require further investigation. Therefore, it 
is important to also investigate the possible reaction of each putative pathogen 
individually and in combination. This should involve studies on feline cells or a feline 
cell line in an in vitro model system. Although this will provide useful information on 
mechanisms involved in the induction of the feline innate immune response it would not 
address the translational problems involved in relating an in vitro model to an in vivo 
situation. 
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Chapter 8 Putative risk factors for FCGS 
8.1 Introduction 
Possible risk factors for FCGS that have been described are the signalment (breed, age), 
diet and environmental factors that cause stress (Frost and Williams, 1986; Diehl and 
Rosychuk, 1993; Addie et al., 2003). Stress factors in the cat’s environment that have 
been described include the presence of other cats in the household, changes that have 
been taking place within the environment and no opportunity to roam outdoors (Amat 
et al., 2009; Herron, 2010). Relevant changes in the environment could include a 
change in household members, redecoration and/or new (neighbourhood) pets. In 
Section 3.3.1 the signalment of cats with FCGS and healthy cats included in the current 
study were compared. More data was collected by the use of a questionnaire-based 
study. 
Feline viruses, in particular FCV, have been implicated in the aetiopathogenesis of FCGS 
(Gaskell and Gruffydd-Jones, 1976; Knowles et al., 1989; Reubel et al., 1992) and thus 
vaccination or lack of vaccination for FCV may be a possible risk factor. 
8.2 Materials and methods 
The questionnaire was prepared on the basis of possible risk factors for FCGS. A paper 
version of the questionnaire was sent out to veterinary surgeons that were a member of 
the British Veterinary Dental Association. An online version of the questionnaire was 
created and uploaded on the website on feline diseases (http://www.dr-
addie.com/stomatitis.html) created by Dr. D.D. Addie, BVMS, PhD (Institute 
Comparative Medicine, University of Glasgow) The complete questionnaire is presented 
in the Appendix. Contingency tables were made and Fisher’s exact tests were 
performed to analyse the possible risk factors. Mean age was compared by an 
independent samples t-test. All statistical analysis was performed in GraphPad Prism 
version 5.0. 
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8.3 Results 
A total of 72 questionnaires were received for cats with FCGS and 25 for healthy cats. 
8.3.1 Signalment 
8.3.1.1 Breed 
When the breeds of 72 cats with FCGS were compared to the breeds of 25 healthy cats, 
a total of 16 (22.2%) cats in the FCGS group were purebred cats, compared to a total of 
3 (12.0%) in the healthy group. Four (5.6%) and one (4.0%) of cats, respectively, were 
purebred crosses and the remaining cats were domestic short hair (DSH), domestic long 
hair (DLH) or domestic medium hair (DMH). Although a higher percentage of purebred 
cats was found in the FCGS group, there was no statistically significant difference 
between the FCGS and healthy cats with regard to number of domestic and purebred 
cats (Figure 8.1). 
8.3.1.2 Age 
The mean age of the 72 cats with FCGS was 7.0 years. Most cats (37.5%) fell into the age 
category of 5-10 years old (61-119 months). The mean age for the 25 healthy cats was 
5.7 years. Most cats (45.5%) from the healthy group were part of the 1-5 years old (0-60 
months) group (Figure 8.2). No significant difference in mean age was seen between the 
healthy cats and cats with FCGS. 
8.3.1.3 Sex 
Sex was recorded for 72 cats with FCGS and 25 healthy cats; 34 (47.2%) of the cats with 
FCGS were male (32 neutered) and 38 (52.8%) female (29 neutered). In the healthy 
group, 14 (56.0%) were male (11 neutered) and 11 (44.0%) female (6 neutered) Figure 
8.3). No significant difference was seen between the healthy cats and cats with FCGS. 
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Figure 8.1: Breed distribution of 72 cats with FCGS and 25 healthy cats 
 
 
Figure 8.2: Age distribution of 72 cats with FCGS and 25 healthy cats 
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Figure 8.3: Sex distribution in 72 cats with FCGS and 25 healthy cats. 
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8.3.2 Possible risk factors 
8.3.2.1 Single versus multi-cat households 
The cats from both groups were compared according to the presence of other cats in 
the household. The question on the presence of other cats was answered for a total of 
66 cats with FCGS and for 23 healthy cats. Of 66 cats with FCGS, 9 (13.6%) had no other 
cats present in the household and in 57 (86.4%) of the cases there were other cats 
present in the household (Figure 8.4). For the healthy group of 23 cats, no other cats 
were present in the household for 13 (56.5%) of the cases and in 10 (43.5%) of the cases 
other cats were present in the household. A Fisher’s exact test showed a significant 
difference between the healthy cats and cats with FCGS when the presence or absence 
of other cats in the household was compared (p=0.0001). 
8.3.2.2 Indoor versus outdoor environment 
The ability of cats to go outside was also compared in the FCGS group and the healthy 
group (Figure 8.5). Answers for this particular question were given for 63 cats with FCGS 
and 24 healthy cats. Of 63 cats with FCGS, 32 (50.8%) were indoor cats and 31 (49.2%) 
were outdoor cats. In the 24 healthy cats, four (16.7%) were indoor cats and 20 (83.3%) 
were outdoor cats. A Fisher’s exact test showed a significant difference between the 
healthy cats and the cats with FCGS when the ability to roam outdoors was compared 
(p=0.004). 
8.3.2.3 A combination of ‘stress factors’ within the household 
When cats with and without the ability to roam outdoors and the presence of other cats 
in the household were compared between the FCGS and healthy groups (Figure 8.6), 28 
(48.3%) cats in the FCGS group were unable to roam outdoors with other cats in the 
household, 4 (6.9%) cats were unable to roam outdoors without other cats, 26 (44.8%) 
were able to roam outdoors with other cats in the household and none were able to 
roam outdoors without other cats. In the healthy group, 1 (4.3%) of the cats came from 
an indoor-multi cat household. 3 (13%) were unable to roam outdoors cats without other 
cats present, 9 (39.1%) of the cats were able to roam outdoors with the presence of 
other cats and 10 (43.5%) were able to roam outdoors cats without other cats present in 
the household. The numbers were too small for statistical analysis. 
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Figure 8.4: Percentage of cats with and without FCGS living in a single cat or a multi-cat 
household. 
 
 
Figure 8.5: Percentage of cats with and without FCGS able and unable to roam outdoors. 
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Figure 8.6: Percentage of cats able and unable to roam outdoors, with or without other cats 
in the household. 
 
Indoor: cats unable to roam outdoors, outdoor: cats able to roam outdoors 
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8.3.2.4 Vaccination status 
When the vaccination status was compared in 63 cats with FCGS and 21 healthy cats, no 
difference was seen. Forty-one (65.1%) of the cats with FCGS and 14 (66.7%) of the 
healthy cats received regular vaccinations (Figure 8.7). 
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Figure 8.7: Percentage of cats with and without FCGS receiving regular vaccinations. 
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8.4 Discussion 
In the cats used for sample collection and those included in the questionnaire results, 
no difference was seen in breed between the healthy and FCGS groups. A higher 
percentage of purebred cats was seen in the FCGS group but no significant difference 
was found. Suggestions that certain breeds are predisposed for FCGS have been made 
(Frost and Williams, 1986; Diehl and Rosychuk, 1993) but this was not supported in a 
study by Healey et al. (2007). Also, no link between FCGS and age or sex could be shown 
in the current study. 
It is possible that stress might play a role in the aetiopathogenesis of FCGS. An 
unpredictable captive environment has been shown to elevate urine cortisol 
concentration in cats (Carlstead et al., 1993). Animals that are not able to perform 
natural behaviour have higher stress levels. Idiopathic cystitis is an example of a disease 
in cats that has been studied intensively for its association with environmental stress 
factors (Cameron et al., 2004; Westropp et al., 2006; Defauw et al., 2011). 
From the questionnaire results it was found that a significantly higher proportion of the 
cats with FCGS were living in the company of other cats when compared to the healthy 
group. Also, a difference was seen between cats confined to staying indoors and having 
the possibility to go outdoors, with a higher proportion of the cats in the FCGS group 
being indoor cats. When these two factors which can be seen as stress factors in the 
cats’ environment (Amat et al., 2009) were taken together, a clear division was seen. 
The proportion of cats kept outdoors while living with other cats in the household was 
similar in both groups. A difference was seen in the large proportion of cats with FCGS 
that were held indoors, together with other cats, compared to the healthy cats where 
the largest group were outdoor cats from a single-cat household. 
We can also speculate that if these stress factors are part of the aetiopathogenesis of 
FCGS, the higher proportion of purebred cats that is seen in the FCGS group is 
connected to the possibility that these cats are often held indoors and possibly live 
more often with other cats in the household. This should however be investigated 
further and a more in-depth epidemiological study is therefore required.  
Assessment of the diet covers a large part of the questionnaire. As described in Section 
1.3.1.1 diet may be of importance in the development of FCGS. All cats in the current 
study have at least a mild form of periodontal disease and as described before, diet can 
play a role in preventing the accumulation of plaque. Dried foods reduce plaque 
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accumulation when compared to wet foods. Another possibility is the presence of 
hypersensitivity towards certain food additives. Therefore a thourough investigation 
into the feeding history of cats with FCGS is of importance. 
Not all the answers from the questionnaire have been analysed in this chapter. A 
greater number of completed questionnaires are needed to be able to carry out more 
extensive statistical analyses. Answers to questions with too many variables could not 
be analysed because of low numbers. Some of the questions in the current 
questionnaire could be modified. As far as diet is concerned, it is important to 
specifically ask what the cat was being fed at the time FCGS was diagnosed. The same 
should be the case for dental prophylaxis, since these factors are likely to change as 
oral disease progresses. In addition to checking for other cats in the household, it would 
also have been interesting to check for the presence of dogs in the household and if 
there were any other cats or dogs in the close neighbourhood. A modified version of the 
questionnaire is produced and results are currently being collected. 
The data presented represents preliminary results of a study that has the potential to 
help us better understand the possible aetiopathogenesis of FCGS. More questionnaires 
should be analysed in order to make a wider statistical analysis possible. More 
questionnaires are being collected to expand the data for this study. 
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Chapter 9 General discussion 
FCGS is a severe and frustrating disease, which unfortunately has been very poorly 
described in literature. It is not only a painful and stress-inducing disease for the cat 
but because of the poor response to different treatment methods, it can be very 
worrying and challenging for owners. Studies have investigated possible causes of FCGS 
but the exact aetiopathogenesis remains unclear. Implicated pathogens are bacteria and 
viruses but immune-related causes have also been suggested. In the current study 
different aspects of FCGS and possible links with the immune system were investigated 
in an attempt to improve our knowledge of the aetiopathogenesis of FCGS. A summary 
of the factors that may contribute to the development of FCGS is shown in Figure 9.1. 
The clinical definition of FCGS has been poorly described as pointed out in Section 1.2.1 
of this thesis. The distribution of lesions in the cats studies for this thesis has been 
recorded by a board certified specialist in veterinary dentistry. Similar to the 
description in more recent studies (Hennet et al., 2011), inflammation of the tissue 
lateral from the palatoglossal folds, and the attached gingiva is described in all cats in 
the current study and should therefore be included in the definition of the disease. The 
severity scale used in the study with distributions of the lesions is a good guideline for 
further clinical trials when a scale is needed to grade improvement of clinical signs.  
Previously, a connection between FCGS and signalment factors such as age and breed 
have been suggested (Frost and Williams, 1986; Diehl and Rosychuk, 1993; Healey et al., 
2007). In Chapter 3 of this thesis, these possible risk factors were taken into 
consideration. A relatively high percentage (18%) of affected animals were purebred 
cats, compared to what is expected in a normal population (Healey et al., 2007). Since 
the number of cats was relatively low, the signalment was also recorded via a 
questionnaire-based study. No significant differences between 25 healthy and 72 
affected cats were shown for age, breed and sex and no evidence was found for a role 
of any of these factors in the disease aetiopathogenesis. Therefore it seems unlikely 
that a simple genetic factor is involved in the aetiopathogenesis. However, it has been 
suggested that stress may play a role in the aetiopathogenesis of FCGS (Diehl and 
Rosychuk, 1993) and this is where the suggested higher presence of FCGS in purebred 
cats may be of importance - purebred cats are often held indoors and commonly in 
combination with other cats, which could be a reason for a higher prevalence. 
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Figure 9.1: A model for FCGS aetiopathogenesis 
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In the current study it was shown that stress factors may be of importance in the 
development of FCGS. The presence of other cats and the inability to roam outdoors are 
thought to be stress inducers in the cat (Amat et al., 2009; Herron, 2010). Preliminary 
data from the questionnaire designed in the current study shows that a significantly 
higher number of cats with FCGS had no access to outdoors and significantly more cats 
with FCGS were from multi-cat households compared to the healthy group. Although 
this is suggestive of stress-inducing factors playing a role, a large-scale epidemiological 
study is required in order to gain a better insight as to how these factors are possible 
contributors to the development of FCGS (Figure 9.1). A decrease in salivary IgA has 
been shown in cats with FCGS (Harley et al., 2003a). A possible cause for this is cortisol 
increase during stress. Several stress-factors can play a role however, stress caused by 
FCGS itself, should not be overseen. Clinical measurements of cortisol and 
cathecholamine levels in serum, saliva or urine are good parameters for stress, however 
the reason of an increase needs also be investigated. Measuring these clinical 
parameters in healthy cats and diseased cats would ideally be accompanied by 
measurements after changing the possibly stress-factors. 
Viruses that have previously been implicated in the aetiopathogenesis of FCGS (FeLV, 
FIV, FHV-1 and FCV) were assessed in the current study (Chapter 4). Although previous 
studies have investigated the presence of feline viruses in FCGS (White et al., 1992; 
Lommer and Verstraete, 2003; Quimby et al., 2008), conflicting data on the presence of 
viruses in cats with FCGS has been published. Most studies show the prevalence of FCV 
in cats with FCGS to be above 50% but the prevalence of other viruses varied widely 
(Knowles et al., 1989; Bellei et al., 2008). As seen in other studies, the prevalence of 
FCV is significantly higher in cats with FCGS when compared to the healthy group in the 
current study. This concurs with the hypothesis that FCV carriage is associated with 
FCGS (Thompson et al., 1984). The question remains in what way FCV plays a role in 
inducing the lesions typically seen in cats with FCGS. It has been suggested that only 
certain strains of FCV would induce FCGS, this however could not be confirmed when 
SPF cats were infected with FCV strains isolated from cats with FCGS (Knowles et al., 
1991; Reubel et al., 1992). Severe inflammation lateral to the palatoglossal folds could 
be induced but was self-limiting in all cases. FCV shedding and FCGS is well correlated, 
but a number of cats with FCGS lesions did not test positive for FCV in the current 
study. FCV seems not to be the only factor involved in the aetiopathogenesis but must 
be considered as playing a major role. 
The potential effect of viruses on the host immune response to FCGS is discussed in 
Chapter 7. The FCGS group showed a significant increase in the TLR7 mRNA gene 
expression. The immune response is reacting to a viral stimulus since TLR7 recognises 
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single-stranded RNA, which is a common feature of viral genomes. However, when the 
healthy and diseased cats were taken as a total and divided according to the presence 
or absence of FCV, TLR7 gene expression was not significantly increased in the FCV 
group. This could be explained by the possibility of false negative FCV test results in the 
FCGS population. A higher expression of IL-1β, IL-6 and IFN-γ is also seen in the FCV 
positive cats. The ability of FCV to stimulate an immune response could be investigated 
using a cell-culture based in vitro model, although such a model cannot examine the 
complex immune response created by pathogens in vivo. The immune response seems to 
react to the presence of the virus and more research on this subject will possibly help 
to explain how the presence of FCV influences the development of FCGS. 
Bacteriological studies on samples of cats with or without oral diseases have previously 
focussed on standard culture methodology or on the detection of pre-selected bacteria 
(Mallonee et al., 1988; Love et al., 1989; Norris and Love, 1999b; Booij-Vrieling et al., 
2010). In this thesis, culture-independent methods have been used that enable the 
identification of a much wider range of bacteria present in the feline oral cavity. 16S 
rRNA gene sequencing has been used previously to identify bacteria in a variety of 
diseases and is a proven method to identify uncultivable bacteria (Hutter et al., 2003; 
Siqueira and Rocas, 2005; Woo et al., 2008).  
The culture-independent technique used in this study, 16S rRNA gene cloning and 
sequencing, was used in tandem with bacterial culture to optimise bacterial detection. 
The bacteria identified by 16S rRNA gene sequencing were not all identified by culture 
methods. Fastidious species are not able to grow when standard culture methods as 
used in the current study are performed. Conversely, some bacteria isolated by culture 
methods were not detected by 16S rRNA gene sequencing. One possible reason for this 
is primer bias, which can occur if an unequal amplification of PCR product results in a 
higher amplification of some bacterial DNA and under-representation of other species 
(Suzuki and Giovannoni, 1996; Polz and Cavanaugh, 1998). Therefore the combination of 
culture-dependent and culture-independent methods gives the most complete view of 
the bacterial oral flora. 
The obtained 16S rRNA gene sequences were compared to known sequences in the 
online public access database and identified by matching with the database sequence 
that gave the highest percentage identity. In some cases, matches occurred with more 
than one database sequence, which prevented a totally accurate bacterial 
identification. This is one of the few limitations of 16S rRNA gene sequencing, which is 
unable on occasion to distinguish between species with very similar 16S rRNA gene 
sequences (Woo et al., 2009). The percentage identity required with a database 
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sequence for an unknown sequence to be matched and identified as the corresponding 
bacterial species varies, with values between 97% and 99.5% having been used 
(Stackebrandt and Goebel, 1994; Janda and Abbott, 2007) Percentage identity values 
below this cut-off point are highly indicative of potentially novel phylotypes, which can 
be confirmed as such by sequencing of the entire 16S rRNA gene. In the current study, a 
cut-off value of 98% was used. 
On the basis of the results from this study, the most suitable antibiotic therapy would 
be cefavecin. Antibiotic treatment is not the first choice of treatment however 
antibiotics are often useful in cases with periodontal disease before surgical treatment. 
P. multocida is sensitive to cefovecin as well as a wide variety of anaerobes. Another 
reason for cefovecin to be a good choice of treatment is the injectable formula that 
acts up to 14 days, as tablets or capsules often result in reduced owner compliance in 
cats with a painful oral cavity. 
While Sanger 16S rRNA gene sequencing has been a valuable tool in aiding our 
understanding of the bacteria associated with oral diseases, it gives limited coverage of 
the oral microbiome due to the small number of clones (usually 50) sequenced from the 
clone libraries generated for each sample. Recent rapid advances in gene sequencing 
technologies have occurred with the advent of high throughput (next generation) 
sequencing (Pozhitkov et al., 2011). This approach can give millions of gene sequencing 
reads per sample and at a fraction of the cost of Sanger sequencing. Therefore future 
studies on the oral microbiome associated with FCGS and feline oral health should 
utilise high throughput sequencing to obtain the most accurate assessment of the 
bacteria that are important in oral health and disease. Consequently this will provide 
new information on the use of antimicrobial therapy and the possible pathogens that 
play a role in FCGS. 
Since cats with FCGS can initially improve with anti-bacterial treatment (Frost and 
Williams, 1986), the involvement of bacteria in the disease is highly likely. In the 
present study a change was identified in the composition of the phyla between cats 
with FCGS and healthy cats. The microbes in the oral cavity are known to interact with 
each other and form a complex microflora (Kuramitsu et al., 2007). An imbalance of the 
bacterial flora is likely to occur in FCGS. Two of the bacterial species that were often 
identified in cats with FCGS, T. forsythia and P. circumdentaria, also appeared to be 
involved in stimulating a host immune response. In samples in which these bacteria 
were present, a significant increase in mRNA expression of TLR and cytokine genes was 
seen. TLR2 was significantly increased in the cats harbouring T. forsythia or P. 
circumdentaria. Additionally, cats harbouring T. forsythia showed a significant increase 
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in the expression of TLR4, TLR7, TLR9, TNF-α and IL-1β genes when compared to cats 
where this microorganism was not identified. P. multocida species failed to show a 
change in the immune response although they were found in high numbers in cats with 
FCGS. However, these bacteria were also commonly present in the healthy oral cavity. 
There is a strong possibility that lesions initiated by FCV are colonised by bacteria that 
are present in the oral cavity and which will cause further tissue damage. The presence 
of pathogenic bacteria such as T. forsythia and P. circumdentaria is likely when 
concurrent periodontal disease is present, and the current study showed that non-
pathogenic bacteria as well as pathogenic bacteria were able to colonise the lesions. 
In Chapter 6 of this thesis, samples were analysed on a histopathological basis to assess 
cell infiltrate and severity of disease. Two infiltration types could be identified on this 
basis. The first is a plasmacytic and lymphocytic infiltrate and the second is a mainly 
plasmacytic infiltrate. It could be speculated that these represent a different phase of 
development of the disease; however no difference in duration of the disease was seen 
when the two cell infiltrates were compared. This explanation therefore seems unlikely 
but it has to be realised that the time since onset of the disease is not an exact 
measure. This factor is variable and dependent upon the cat owners’ interpretation. 
Often a disease will only be addressed when serious clinical signs occur i.e. when the 
cat stops eating or grooming. However a significant correlation was shown between the 
severity grade of the histopathology and the cell-type infiltrate, which suggests the 
possibility that the cell-type groups represent different phases of FCGS development. 
The more severe cases of FCGS did show a predominantly plasmacytic infiltrate, 
compared to a combined plasmacytic lymphocytic infiltrate in less severe cases. It is not 
certain if the severity reflects the duration of the disease; however if this was the case 
and severe pathology indicated long-standing disease, it is tempting to suggest that the 
bacterial colonisation is indeed secondary since TLR4 mRNA expression, mostly known 
for recognising LPS, was significantly higher in the more severe cases. 
Plasma cell infiltrates are often seen in diseases with an immune-mediated background 
(Perry et al., 1997; Dias Pereira and Faustino, 2003). It has been suggested that the high 
salivary levels of immunoglobulins in cats with FCGS can be caused by the high plasma 
cell concentration within the oral tissues The most predominant plasma cells in cats 
with FCGS are of the IgG type (Harley et al., 2011) The salivary IgG concentration in 
cats with FCGS is much higher than in healthy cats and a moderately higher IgM 
concentration has also been shown (Harley et al., 2003b). However, it is not known how 
these concentrations change according to disease severity.  
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In the current study cytokine and TLR mRNA gene expression levels were investigated 
for each cat with FCGS and compared to a group of healthy cats Previously, only 
cytokine expression in cats with FCGS was assessed by reverse transcriptase PCR (Harley 
et al., 1999); expression of cytokines IL-2, IL-4, IL-6, IL-10, IL-12 and IFN-γ was 
significantly higher in cats with FCGS when compared to a group of healthy cats. TLR 
gene expression has not previously been assessed in cats with FCGS.  
Significantly higher gene expression in FCGS samples was seen for TLR2 and TLR7 and 
for the cytokines TNF-α, IFN-γ, IL-1β and IL-6 in the present study. This suggests an 
immune reaction in the oral mucosa that may be stimulated by a combination of 
bacterial and viral agents. Moreover, in cats harbouring T. forsythia and P. 
circumdentaria gene expression of several TLRs and cytokines was increased suggesting 
that these bacteria are pathogenic, compared to bacteria found extensively in the 
healthy oral cavity such as P. multocida species, that did not show an obvious immune 
response. This strengthens the suggestion that a secondary bacterial colonisation of 
lesions is playing a part in FCGS, and when no pathogenic bacteria are present the 
lesions still persist. To investigate the influence of bacteria and viruses on the feline 
immune response, future studies could use feline cells or cell lines stimulated with 
different pathogens. It would be useful to analyse in particular, gene expression of the 
Th17 family of cytokines, which have been shown to be important in the immune 
response to human oral diseases (Gaffen and Hajishengallis, 2008). However, no gene 
sequences for the feline Th17 cytokine family are currently available. 
So far no treatment method for FCGS has proven successful. In a multi-factorial disease 
it is a challenging task to address different initiating factors in order to successfully 
treat the disease. So far treatments that have given the highest success rate have been 
influencing different factors in addressing bacterial burden by hygienic measures in 
combination with either glucocorticoid administration or treatment against FCV with 
IFN-ω (Hennet et al., 2011). The treatment to reduce the bacterial load in the oral 
cavity shows the importance of the role bacteria play in the disease aetiopathogenesis. 
Periodontal disease was present in all cases of FCGS seen in the current study. 
Periodontal disease provides a source of pathogenic bacteria, which can cause 
secondary infections. Eliminating this source by removing all affected teeth, even those 
with mild gingivitis, has been one of the most successful treatments so far (Hennet, 
1997; Girard and Hennet, 2005; Bellei et al., 2008). In the current study, it was shown 
that the lesions can be colonised by different bacteria, pathogenic and non-pathogenic, 
and the immune reaction reflects the influence of a combination of bacteria and 
viruses. Also, when initiating treatment, it is important to assess environmental factors 
particularly with a view to reducing any possible stress situations. Further investigations 
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into the immune response could lead to the development of immune therapy. It is 
important to assess the possibility of an inappropriate immune response. Immune 
modulating drugs like glucocorticoids, in an anti-inflammatory dosage, give a good 
clinical improvement (Hennet et al., 2011). Other immune modulators could be tried for 
the treatment of FCGS. Recently ciclosporin was registered for cats with atopic 
dermatitis. Ciclosporin has been shown to decrease the expression of IL-2, IL-4, IFN-γ 
and TNF-α in feline mononuclear cells (Kuga et al., 2008). It is of great importance that 
the involvement of pathogenic agents is ruled out or eliminated before the start of any 
immunomodulating therapy. The different factors involved in the aetiopathogenesis 
should be targeted including stress and pathogens. IFN-ω treatment is currently being 
used (Mihaljevic and Klein, 1998; Mihaljevic, 2003; Southerden and Gorrel, 2007; 
Hennet et al., 2011), against FCV infection in FCGS. Targeting specific TLRs with 
agonists or antagonists to activate or partly de-activate the response to certain 
pathogens could be investigated further (O'Neill et al., 2009). More specific research 
into the immune response against the variety of pathogens is needed. Inhibiting or 
activating the immune response could raise potential concerns and targeting one TLR by 
inhibition could influence other TLRs through their pathways. 
The work in this thesis adds valuable information to the current knowledge on the 
aetiopathogenesis of FCGS. It provides information on possible predisposing factors and 
agents that may be of importance and contribute to the development of FCGS. This 
thesis is an important step towards a better understanding of the aetiopathogenesis of 
FCGS and provides a basis for future studies on this important feline disease. 
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